UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-K
(Mark One)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1998
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________ to ____________
COMMISSION FILE NUMBER 1-10451
NORTH AMERICAN VACCINE, INC.
----------------------------
(Exact name of registrant as specified in its charter)
CANADA 98-0121241
------ ----------
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
10150 OLD COLUMBIA ROAD
COLUMBIA, MARYLAND 21046
------------------ -----
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (410) 309-7100
--------------
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Name of each exchange which registered
COMMON STOCK, NO PAR VALUE AMERICAN STOCK EXCHANGE
-------------------------- -----------------------
Securities registered pursuant to Section 12(g) of the Act:
NONE
(Title of class)
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No_
-
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]
State the aggregate market value of the voting and non-voting common equity held
by non-affiliates computed by reference to the price at which the common equity
was sold, or the average bid and asked price of such common equity, as of a
specified date within the past 60 days.
SPECIFIED DATE -- JANUARY 26, 1999; AGGREGATE MARKET VALUE -- $ 121,267,105
Indicate the number of shares outstanding of each of the registrant's classes of
common stock, as of the latest practicable date.
COMMON STOCK, NO PAR VALUE, OUTSTANDING AS OF JANUARY 26, 1999 - 32,216,096
<PAGE>
DOCUMENTS INCORPORATED BY REFERENCE
Part III of this Annual Report on Form 10-K incorporates by reference
certain sections of the registrant's Proxy Statement to be furnished to
shareholders pursuant to the Securities Exchange Act of 1934, as amended, in
connection with the 1999 Annual Meeting of Shareholders of the registrant (the
"1999 Proxy Statement").
TABLE OF CONTENTS
ITEM DESCRIPTION PAGE
- ---- ----------- ----
PART I
1 Business..................................................................3
2 Properties...............................................................31
3 Legal Proceedings........................................................32
4 Submission of Matters to a Vote of Security Holders......................32
PART II
5 Market for Registrant's Common Equity and Related Stockholder Matters....33
6 Selected Financial Data..................................................35
7 Management's Discussion and Analysis of Financial Condition and
Results of Operation.....................................................37
7A Quantitative and Qualitative Disclosures About Market Risk ..............49
8 Financial Statements and Supplementary Data..............................49
9 Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure.....................................................78
PART III
10 Directors and Executive Officers of the Registrant.......................78
11 Executive Compensation...................................................78
12 Security Ownership of Certain Beneficial Owners and Management...........78
13 Certain Relationships and Related Transactions...........................78
PART IV
14 Exhibits, Financial Statement Schedules, and Reports on Form 8-K.........79
Signatures...............................................................82
- 2 -
<PAGE>
PART I
ITEM 1. BUSINESS
--------
THE COMPANY
INTRODUCTION. The Company is engaged in the research, development,
production and sale of vaccines for the prevention of infectious diseases in
children and adults. The Company's first product is a patented, novel
monocomponent acellular pertussis (whooping cough) vaccine that the Company
believes will significantly reduce the incidence of adverse reactions associated
with the whole cell pertussis vaccines that it was designed to replace. The
Company's acellular pertussis ("aP") vaccine has been combined with diphtheria
and tetanus toxoids for use in a combination diphtheria-tetanus-acellular
pertussis ("DTaP") vaccine marketed in the United States under the name Certiva
(TRADEMARK). In July 1998, the Company received regulatory approval from the
U.S. Food and Drug Administration ("FDA") to manufacture and market Certiva
(TRADEMARK) in the United States for immunization of infants and children six
weeks to seven years of age. The product launch for Certiva(TRADEMARK)commenced
during the fourth quarter of 1998.
FDA approval of Certiva(TRADEMARK)follows previous regulatory approvals in
Europe of vaccines using the Company's acellular pertussis vaccine. The aP
vaccine was licensed in Sweden in 1996 as a European formulation of
Certiva(TRADEMARK)("Certiva(TRADEMARK)-EU") in infants and children and in 1997
as a stand-alone aP vaccine for children. Using Certiva(TRADEMARK)-EU as an
"anchor" for combining additional pediatric vaccines, the Company and Statens
Serum Institut of Copenhagen, Denmark ("SSI") have collaborated in the
development of a combined diphtheria, tetanus, pertussis and enhanced,
inactivated polio ("DTaP-IPV") vaccine. This vaccine has been on the market in
Denmark since the first quarter of 1997. The Company has been advised that the
regulatory authorities in Germany, Austria, Sweden and Finland have agreed to
recognize the Danish marketing authorization for the DTaP-IPV vaccine and will
issue national marketing authorizations in one or more of those countries in the
near future. There can be no assurance that these national marketing
authorizations will be issued in a timely fashion as the application process is
principally the responsibility of the Company's European partners, over whom the
Company has no control. In addition to these products, the Company has 14 other
vaccines in various stages of development, including two other combination
vaccines using Certiva(TRADEMARK)as an "anchor", as well as nine conjugate
vaccines for the prevention of various bacterial diseases in children and
adults.
Vaccination against infectious disease is a primary component of
pediatric, and an increasingly important element of adult health-care programs
throughout the world. For example, in the United States, ten pediatric vaccines,
including vaccines for the prevention of diphtheria, tetanus, pertussis and
polio, are generally required by state immunization programs. The Company
estimates that over 22 million doses of combination diphtheria, tetanus and
pertussis vaccines were sold in the United States during 1996. The Company
believes that a market of at least comparable size exists outside the United
States. In the adult market, vaccinations, particularly of older persons, could
lower the number of deaths annually in the United States from influenza,
pneumonia and hepatitis B infections. In 1994, the United States Department of
Health and Human Services estimated that the costs to society of diseases for
which vaccines currently exist exceeded $10 billion each year. As a result,
health-care providers, including managed care organizations, have increasingly
recognized that immunization of adults is a cost effective method for preventing
the incidence of disease and infection.
- 3 -
<PAGE>
CERTIVA(TRADEMARK). In July 1998, the Company received FDA approval to
manufacture and market Certiva(TRADEMARK)in the United States for immunization
of infants and children six weeks to seven years of age. The Company and its
marketing partner, Abbott Laboratories ("Abbott"), commenced the commercial
launch of the product during the fourth quarter of 1998. Abbott is marketing
Certiva(TRADEMARK)to private physicians and managed care markets in the United
States, and the Company is marketing Certiva(TRADEMARK)to government purchasers,
including state governments and the U.S. Centers for Disease Control and
Prevention ("CDC"). See "Risk Factors - No Assurance of Effective Marketing."
Vaccination against diphtheria, tetanus and pertussis is mandated by most
states for all children with a total of five doses administered at two, four,
six and between 15 to 18 months of age and immediately prior to entering grade
school. Prior to 1996, only combined diphtheria, tetanus and "whole cell"
pertussis ("DTP") vaccines were approved for use in the United States for all
recommended pediatric doses; however, within the past two years,
Certiva(TRADEMARK)and three other DTaP vaccines have been licensed by the FDA
for use in the pediatric immunization series. The Company believes that DTaP
vaccines are now replacing the "whole cell" DTP vaccines and are preferred in
the childhood immunization schedule recommended by the Advisory Committee on
Immunization Practices ("ACIP") of the CDC and the American Academy of
Pediatrics ("AAP").
The Company's acellular pertussis vaccine is unique and distinct from all
other pertussis vaccines in that it contains only pertussis "toxoid" (I.E.,
pertussis toxin that has been purified and chemically inactivated by hydrogen
peroxide), instead of the entire BORDETELLA PERTUSSIS bacteria or two or more of
its components. Clinical studies have shown that the Company's toxoid induces
immunity with fewer serious adverse reactions than the "whole cell" pertussis
vaccine.
The Company holds exclusive licenses under United States and foreign
patents on the aP toxoid and the method of its manufacture. Outside of the
United States, Certiva(TRADEMARK)-EU, the European formulation of the DTaP
vaccine, has been approved in Sweden since February 1996 and Denmark since April
1998. The Company also has been advised that the regulatory authorities in
Germany, Austria and Finland have agreed to recognize the Swedish marketing
authorization and will issue authorizations in one or more of those countries in
the near future. There can be no assurance that these national marketing
authorizations will be issued in a timely fashion as the application process is
principally the responsibility of the Company's European partners, over whom the
Company has no control. See "Products Under Development -- Acellular Pertussis
Vaccines"; "Business Relationships."
COMBINATION VACCINES. Using Certiva(TRADEMARK)as an "anchor" for combining
additional pediatric vaccines, the Company is developing combination vaccines
that may be administered in a single injection. The Company believes that, in
many instances, these combination vaccines may replace stand-alone vaccines
because combination vaccines will reduce the number of required injections,
which could lower treatment costs and improve compliance with standard
vaccination schedules.
The Company's first combination vaccine is a DTaP-IPV vaccine developed in
collaboration with SSI, which has been on the market in Denmark since the first
quarter of 1997. The Company has been advised that regulatory authorities in
Germany, Austria, Sweden and Finland agreed, under the European mutual
recognition procedure, to recognize the Danish marketing authorization for the
DTaP-IPV vaccine and the issuance of the national marketing authorizations in
one or more of those countries is expected in the near future. The Company has
appointed Chiron-Behring GmbH & Co. ("Chiron Behring") to market and distribute
the DTaP-IPV product in Germany and Austria, and SSI holds all of the European
- 4 -
<PAGE>
product registrations and will market and distribute the product in the
Scandinavian countries. There can be no assurance that these national marketing
authorizations will be issued in a timely fashion as the application process is
principally the responsibility of the Company's European partners, over whom the
Company has no control.
In the United States, the ACIP and AAP have issued a revised
recommendation related to polio vaccination. A sequential schedule, including
two doses of IPV followed by two doses of oral polio vaccination ("OPV") is now
the preferred recommendation, although a four-dose OPV or four-dose IPV schedule
is acceptable. The Company has filed an investigational new drug application
with the FDA to conduct clinical trials with a Certiva(TRADEMARK)-IPV in the
United States. The Company also is developing a DTaP-HIB vaccine that combines
Certiva(TRADEMARK)with a vaccine against HAEMOPHILUS INFLUENZAE type b ("HIB")
infections, as well as a DTaP-IPV-HIB vaccine. See "Products Under Development
- --Combination Vaccines."
CONJUGATE VACCINES. The Company, using patented and proprietary
technologies, is developing several conjugate vaccines for prevention of
infectious diseases in children and adults. Conjugate vaccines are formed by
chemically linking (I.E., conjugating) polysaccharides to a "carrier" protein.
This procedure has been shown to enhance the immunogenic properties of the
polysaccharides, particularly in infants. Conjugate vaccines may be useful in
preventing several serious diseases, including meningitis, pneumonia and strep
throat in all groups, including infants and children. Vaccines are not currently
available for the prevention of several of these diseases.
In May 1998, the Company announced that in the first of several Phase II
clinical trials currently being conducted in infants and children in the United
Kingdom, the Company's Group C meningococcal conjugate vaccine had been shown to
be safe and immunogenic in infants as measured by immunologic response capable
of inducing bactericidal activity. Previous studies have demonstrated a
correlation between vaccine efficacy and its ability to generate immunologic
response and to stimulate bactericidal activity. See "Products Under Development
- -- Conjugate Vaccines."
COLLABORATIONS. To further develop and expand its technologies in
pediatric and adult vaccines, the Company has established several relationships,
including licenses and collaborations with pharmaceutical companies,
universities and government agencies. Some of these institutions have provided
funding for clinical trials and research, and conducted joint development
projects with the Company. For example, the Company has entered into agreements
with Pasteur Merieux Connaught to jointly develop the Company's new conjugate
vaccine against Group B meningococcal infection for immunization of adults,
adolescents and infants. See "Business Relationships."
Moreover, to maximize market penetration for its first commercial products
within the least amount of time, the Company currently is implementing a
marketing strategy aimed at establishing marketing alliances in the United
States and Europe with well-established local partners on a country-by-country
basis. Toward this end, the Company has entered into marketing alliances for its
DTaP and certain combination vaccines with SSI in Scandinavian, Baltic and
certain other countries comprising its territory, Chiron Behring in Germany and
Austria, and Abbott in the United States. See "Business Relationships."
ORGANIZATION. The Company was incorporated as a Canadian corporation on
August 31, 1989 for the purpose of acquiring American Vaccine Corporation, a
publicly held Delaware corporation ("American Vaccine"), and certain assets of
- 5 -
<PAGE>
BioChem, in a share purchase and merger transaction (collectively described as
the "Merger"). On February 28, 1990, shareholders of American Vaccine approved
the Merger. The Company had no operations prior to the Merger. Pursuant to the
Merger, the shareholders of American Vaccine received 50% ownership in the
Company. Simultaneously, BioChem purchased a 50% interest in the Company in
exchange for cash, shares of BioChem common stock, and the license or assignment
and transfer of certain rights and other intangible assets. See Item 13 -
Certain Relationships and Related Transactions.
The Company maintains its executive offices at 10150 Old Columbia Road,
Columbia, Maryland 21046, and its telephone number is (410) 309-7100. Unless
otherwise indicated or the context otherwise requires, references to the
"Company" or to "North American Vaccine" contained herein are to North American
Vaccine, Inc. and its consolidated subsidiaries.
OVERVIEW OF VACCINE MARKET
PEDIATRIC VACCINES. Due to the potential for epidemic disease, most
countries consider vaccinations to be a matter of national importance. In the
United States, the ten vaccines generally required by state pediatric
vaccination programs are intended to prevent diphtheria, tetanus, pertussis,
measles, mumps, rubella, polio, HIB, hepatitis B and varicella (chicken pox). In
addition to these ten vaccines, the ACIP and AAP periodically review current
immunization practices and issue their recommendations for additional pediatric
vaccinations. In Western Europe, vaccination against diphtheria, tetanus and
pertussis is generally recommended, with each country establishing its own
vaccination schedules and requirements.
Children in the United States receive immunizations from public providers,
such as local health departments, and from private providers. Immunizations
provided by public providers are generally paid for through federal and state
government funding under public health programs. These programs are intended to
reduce barriers to immunization and to improve immunization rates by providing
free vaccine to qualifying infants and children. Government purchases
historically have been at prices substantially below those offered to the
private sector and presently account for a substantial proportion of the vaccine
doses distributed in the United States.
In addition, the government promotes the availability of an adequate
supply of necessary pediatric vaccines for United States public health programs.
In order to achieve this objective, the National Childhood Vaccine Injury Act of
1986 ("NCVI Act") created a no-fault insurance program designed to compensate
those who suffer specified vaccine-related injuries associated with the
administration of one or more of the vaccines generally required by state
pediatric vaccination programs. This insurance program is funded through the
levy of an excise tax paid by the manufacturers on the sale of certain pediatric
vaccines, including combined diphtheria-tetanus-pertussis vaccines.
ADULT VACCINES. Adults, especially older persons who are at greater risk
of contracting and succumbing to disease and infection, can benefit greatly from
immunizations. In 1994, the United States Department of Health and Human
Services estimated that the costs to society of diseases for which vaccines
currently exist exceeded $10 billion each year. In addition, vaccines have been
widely recognized as highly cost-effective in preventing the incidence of
disease and infection. For example, a 1995 study published in THE NEW ENGLAND
JOURNAL OF MEDICINE indicates that annual immunizations with influenza vaccine,
which costs approximately $10 per dose, reduce the medical costs and sick days
by more than $46 per patient immunized. Moreover, it is becoming widely
recognized that many childhood vaccine-preventable infections and diseases, such
as pertussis, are also found among younger adults, who serve as reservoirs for,
and source of pediatric exposure to, these infections and diseases. While the
- 6 -
<PAGE>
size of the target populations for adult vaccines may vary and adult vaccination
rates tend to be low, some of these markets are much larger than the target
population for pediatric vaccines. The Company believes that the market for
adult vaccines will expand as health-care providers increasingly recognize
vaccines as a cost-effective method for preventing the incidence of disease and
infection.
PRODUCTS UNDER DEVELOPMENT
The Company is focusing its research and development efforts on the
vaccines set forth in Table 1 below. The Company spent $18.0 million, $19.9
million and $11.6 million on research and development of its products for 1998,
1997 and 1996, respectively. See Item 7 - Management's Discussion and Analysis
of Financial Condition and Results of Operation. The summary information
included in Table 1 is provided solely for convenience of reference and is
qualified in its entirety by the detailed discussion of each of the Company's
products that follows. There can be no assurance that any of these vaccines will
be developed successfully by the Company or licensed by the FDA or any other
regulatory authority for commercial sale. See "Risk Factors-Need for Regulatory
Approvals" and "Risk Factors-Uncertainties Related to Clinical Trials."
- 7 -
<PAGE>
<TABLE>
<CAPTION>
PRODUCTS UNDER DEVELOPMENT
PRODUCTS DISEASE STATUS (1)
-------- ------- ----------
ACELLULAR PERTUSSIS VACCINES
<S> <C> <C>
Certiva(TRADEMARK) Diphtheria, tetanus and Licensed in United States;
pertussis (whooping cough) Certiva(TRADEMARK) - EU licensed in
Sweden and Denmark, and national
marketing authorization pending in
several European countries
aP....................... ..... Pertussis Licensed in Sweden for children and
young adolescents
Amvax(REGISTERED)........ ..... Tetanus, diphtheria and Safety and immunogenicity clinical trial
pertussis (adolescent/adult being planned
booster)
COMBINATION VACCINES
DTaP-IPV ................ ..... Diphtheria, tetanus, pertussis Licensed in Denmark; National marketing
and polio authorization pending in several
European countries; IND filed for U.S.
clinical trials
DTaP-HIB................. ..... Diphtheria, tetanus, pertussis Preclinical; U.S. clinical trial being
and meningitis planned
DTaP-IPV-HIB............. ..... Diphtheria, tetanus, pertussis, U.S. clinical trial being planned
polio and meningitis
CONJUGATE VACCINES
Group B Streptococcal.... ..... Neonatal sepsis and meningitis U.S. Phase II clinical trials(2)
Group B Meningococcal.... ..... Meningitis U.S. clinical trial being planned
Group C Meningococcal.... ..... Meningitis Phase II clinical trials in U.K.
commenced in infants and children and
pending for adolescents; U.S. Phase I
clinical trial being planned
Group A/C Meningococcal.. ..... Meningitis Preclinical
Group A/B/C
Meningococcal............ ..... Meningitis Preclinical
HAEMOPHILUS INFLUENZAE
type b.................. ..... Meningitis Preclinical; U.S. clinical trial being
planned
Group A Streptococcal.... ..... Streptococcal pharyngitis (strep Preclinical
throat), skin infections, etc.
Pneumococcal (otitis media).... Otitis media (middle ear infection) Preclinical
Pneumococcal (pneumonia)....... Pneumococcal pneumonia Preclinical
- ----------------------------------------------
(1) Preclinical development denotes work to refine product performance characteristics and to conduct
studies relating to product composition, stability, scale-up, toxicity and efficacy in order to create a
prototype formulation in preparation for the filing of an investigational new drug application or IND with the
FDA for authority to commence testing in clinical trials. Phase I-III clinical trials denote safety and efficacy
tests in human patients in accordance with FDA guidelines as follows:
Phase I: Safety, immunogenicity, and optimal dosage studies.
Phase II: Detailed evaluations of safety, immunogenicity and optimal dosage in limited number
of subjects in target population.
Phase III: Evaluation of safety and efficacy in expanded target population. See "Government Regulation."
(2) Proof-of-principle clinical trials for monovalent vaccine manufactured by a third party utilizing
technology licensed to the Company.
</TABLE>
- 8 -
<PAGE>
ACELLULAR PERTUSSIS VACCINES
BACKGROUND. Immunization against diphtheria, tetanus and pertussis using a
combined vaccine during infancy and childhood is a routine practice in the
United States, and the vaccination program is considered to be a major factor in
reducing the incidence of, and number of deaths associated with, each of these
diseases. Vaccination for the prevention of diphtheria, tetanus and pertussis
currently is required in the majority of states within the United States and is
scheduled to be administered to children at the ages of two, four, six, 15 to 18
months, and 4 to 6 years of age. In addition, immunization against diphtheria,
tetanus and pertussis is also required in many countries outside of the United
States.
Since the late 1940s, the widespread use of "whole cell" DTP vaccines led
to a rapid decline in disease-related morbidity and mortality, especially in
children. These "whole cell" DTP vaccines include the entire BORDETELLA
PERTUSSIS bacterium that has been inactivated in the production process by heat
or chemicals, and it is generally believed that the use of the "whole cell"
BORDETELLA PERTUSSIS bacterium has been a leading cause of the adverse reactions
associated with the existing "whole cell" DTP vaccines. These adverse reactions
range from minor local reactions to more serious systemic reactions. Clinical
trials have established that acellular pertussis vaccines should offer
advantages over licensed "whole cell" pertussis vaccines with respect to
improved tolerability and fewer serious adverse reactions. The Company believes
that DTaP vaccines are now replacing the "whole cell" DTP vaccines and are
preferred for all doses in the immunization schedule recommended by the ACIP and
AAP. Currently, four DTaP vaccines, including Certiva(TRADEMARK), have been
licensed by the FDA for use in the United States. In addition, one other firm
has filed for regulatory approval in the U.S. for its DTaP vaccine. See
"Products Under Development - Acellular Pertussis Vaccines - Certiva(TRADEMARK)"
and "Competition."
CERTIVA(TRADEMARK). In July 1998, the Company received FDA approval to
manufacture and market Certiva(TRADEMARK) in the United States for use in
infants and children six weeks to seven years of age. Abbott is marketing
Certiva(TRADEMARK) in the United States to private physicians and managed care
markets, and the Company is marketing Certiva(TRADEMARK) to government
purchasers, including state governments and the CDC. The product launch of
Certiva(TRADEMARK) by Abbott commenced during the fourth quarter 1998. See "Risk
Factors - No Assurance of Effective Marketing."
Certiva(TRADEMARK) combines the Company's proprietary monocomponent
acellular pertussis vaccine with diphtheria and tetanus toxoids, for use as a
combined DTaP vaccine in childhood immunization programs. The Company's
acellular pertussis vaccine is unique and distinct from all other pertussis
vaccines in that it contains only pertussis toxoid (I.E., pertussis toxin that
has been purified and chemically inactivated by hydrogen peroxide), instead of
the entire BORDETELLA PERTUSSIS bacterium or two or more of its components. In
clinical trials, this single toxoid has been shown to induce immunity with fewer
serious adverse reactions than the "whole cell" pertussis vaccine. The method of
manufacture for this pertussis toxoid are the subject of United States and
foreign patents licensed exclusively to the Company. See "Business
Relationships."
FDA approval followed prior European approvals of Certiva(TRADEMARK)-EU.
In February 1996, a license was granted to the Company's European partner, SSI,
to market in Sweden Certiva(TRADEMARK)-EU for all recommended doses for infants
and children. Subsequently, regulatory applications were filed under the
European mutual recognition procedures in other selected European countries
based on the Swedish approval. In April 1998, Certiva(TRADEMARK)-EU was licensed
in Denmark. The Company has been advised that the regulatory authorities in
Germany, Austria and Finland have agreed to recognize the Swedish marketing
authorization for Certiva(TRADEMARK)-EU and will issue national marketing
- 9 -
<PAGE>
authorizations in one or more of these countries in the near future. The Company
has appointed Chiron Behring to market Certiva(TRADEMARK)-EU in Germany and
Austria. SSI holds the European registrations, and holds the product and
marketing rights in SSI's Territory. There can be no assurance that these
national marketing authorizations will be issued in a timely fashion as the
application process is principally the responsibility of the Company's European
partners, over whom the Company has no control. See "Marketing of Vaccines" and
"Business Relationships."
AP VACCINE. In April 1997, the Company's stand-alone aP vaccine received
regulatory and marketing authorization in Sweden. This approval expanded the
indication in Sweden for the Company's aP vaccine to children previously
vaccinated against diphtheria and tetanus, but who are still at risk for
pertussis, and is intended to permit physicians to vaccinate older children and
young adolescents against pertussis. The Company, directly or through one or
more distributors, may seek regulatory approval for sale of the stand-alone aP
vaccine for use in other European countries, although there can be no assurance
that any additional such approval will be granted.
The Company also believes that sale of a stand-alone acellular pertussis
vaccine may be appropriate for adult booster immunizations. Adults are exposed
to and may contract pertussis infections. They also are considered a significant
reservoir of, and source of pediatric exposure to, pertussis. The Company
participated in a safety and immunogenicity clinical trial at Baylor College of
Medicine, which was completed in 1995, for the purpose of establishing the
safety and immunogenicity of the aP vaccine as a booster in adults. This
clinical trial was sponsored by the National Institute of Allergy and Infectious
Diseases ("NIAID") of the National Institutes of Health, and the results of this
study reveal that the Company's aP vaccine is highly immunogenic in adults with
no vaccine associated severe adverse reactions. During 1997, the Vaccine and
Related Biologics Advisory Committee to the FDA recommended that safety and
immunogenicity trials alone would be adequate to support expanded indication of
aP vaccines for adolescent and adult booster doses. The Company developed
Amvax(REGISTERED), a combination of its adult formulation of a
tetanus-diphtheria-acellular pertussis ("TdaP") vaccine for adults. The Company
is presently considering sponsoring safety and immunogenicity adult clinical
trials in the United States and Europe using Amvax(REGISTERED).
COMBINATION VACCINES
The Company is developing three combination vaccines using
Certiva(TRADEMARK) as an "anchor." Additional vaccines would be added to
Certiva(TRADEMARK) to form the combination vaccine. The Company anticipates that
these combination vaccines will become generally acceptable because the ACIP/AAP
recommended schedule for immunization against diphtheria, tetanus, pertussis,
polio and HIB are compatible. Combination vaccines have a number of benefits,
including fewer injections, lower anxiety for the parents and potential
reduction of the number of required visits to the physician, thereby lowering
costs and facilitating compliance with recommended and mandated immunization
programs. The Company's combination vaccines under development are described
below.
DTAP-IPV VACCINE. The Company believes that a single vaccination program
for diphtheria, tetanus, pertussis and polio can be established by combining an
enhanced, injectable IPV with Certiva(TRADEMARK). The Company anticipates that a
DTaP-IPV vaccine can become a generally accepted multivalent vaccine because the
polio vaccination schedule is compatible with the DTaP vaccination schedule, and
because a polio vaccination program that includes IPV has been accepted as both
safe and efficacious. In the United States, the ACIP and AAP have issued a
revised recommendation related to polio vaccination. A sequential schedule,
- 10 -
<PAGE>
including two doses of IPV followed by two doses of oral polio vaccination
("OPV"), is now the preferred recommendation. A four dose OPV or four dose IPV
schedule also is acceptable.
In September 1996, the Danish National Board of Health granted SSI
regulatory approval to market a combined DTaP-IPV vaccine, which incorporates
the Company's acellular pertussis toxoid, for all primary and booster doses in
infants and children. This combination vaccine, was developed jointly by SSI and
the Company, and has been on the market in Denmark since the first quarter of
1997. The Company has been advised that the regulatory authorities in Germany,
Austria, Sweden and Finland, under the European mutual recognition procedures,
have agreed to recognize the Danish marketing authorization for the DTaP-IPV
vaccine and the Company presently anticipates that national marketing
authorizations in one or more of these countries may be issued in the near
future. The Company has appointed Chiron Behring to market the DTaP-IPV product
in Germany and Austria. SSI holds the product registrations, and SSI will market
the product, in SSI's Territory. There can be no assurance that these national
marketing authorizations will be issued in a timely fashion as this application
process is principally the responsibility of the Company's European partners,
over whom the Company has no control. See "Marketing of Vaccines" and "Business
Relationships."
In addition, the Company in collaboration with Abbott has filed an
investigational new drug application with the FDA to conduct Phase II clinical
trials in the United States with a DTaP-IPV vaccine. There can be no assurance
that the clinical trial will commence, that data from the clinical trials will
support a regulatory filing or that any regulatory filings for the
Certiva(TRADEMARK)-IPV will be accepted, or receive regulatory approval in a
timely fashion or at all, by the FDA or other regulatory agencies. See
"Government Regulation" and "Risk Factors - Need for Regulatory Approvals." See
also "Business Relationships."
DTAP-HIB VACCINE. The Company is developing a combined single injectable
DTaP-HIB vaccine in stable liquid form for the prevention of diphtheria,
tetanus, pertussis and infection caused by HAEMOPHILUS INFLUENZAE type b.
Preclinical test results of the Company's DTaP-HIB vaccine demonstrated high
immune responses for each of the components in the combined vaccine and showed
no immunologic interference among the different components of the vaccine. The
Company believes that the development of a safe and immunogenic DTaP-HIB vaccine
is technologically feasible, and that a program utilizing that vaccine can
become generally accepted for a number of the doses in the vaccination schedule
because the vaccination schedules for diphtheria, tetanus, pertussis, and HIB
are compatible. The Company is presently planning clinical trials for a
Certiva(TRADEMARK)-HIB vaccine in the United States. See "Products Under
Development - Conjugate Vaccines - HAEMOPHILUS INFLUENZAE Type b Vaccine" for a
description of the Company's HIB vaccine. See also "Competition." The Company is
collaborating with Abbott in the development of this vaccine. See "Business
Relationships."
DTAP-IPV-HIB VACCINE. The Company is also developing a combined single
injectable DTaP- IPV-HIB vaccine in stable liquid form for the prevention of
diphtheria, tetanus, pertussis, polio and infection caused by HIB. Preclinical
test results of this vaccine demonstrated high immune responses for each of the
components in the combined vaccine and showed no interference among the
different components of the vaccine. The Company believes that the development
of a DTaP-IPV-HIB vaccine is technologically feasible, and that a program
utilizing that vaccine can become generally accepted for a number of the doses
in the vaccination schedule because the vaccination schedules for diphtheria,
tetanus, pertussis, polio and HIB are compatible. The Company is presently
planning clinical trials of the Certiva(TRADEMARK)-IPV-HIB vaccine. See
"Products Under Development - Conjugate Vaccines - HAEMOPHILUS INFLUENZAE Type b
- 11 -
<PAGE>
Vaccine" for a description of the Company's HIB vaccine. The Company is
collaborating with Abbott in the development of this vaccine. See "Business
Relationships."
CONJUGATE VACCINES
In recent decades, vaccines have been developed for certain bacterial
diseases using polysaccharides (long-chained sugars) that coat or encapsulate
certain bacteria's outer membranes. While these polysaccharide vaccines have
generally proven to be safe, many of them do not elicit an adequate immune
response, particularly in infants whose immature immune systems do not recognize
or respond to these polysaccharides. In an attempt to address this problem, the
Company is utilizing proprietary conjugate vaccine technology to link (I.E.,
conjugate) polysaccharides to protein carriers, which serves to enhance the
immunogenic properties of the polysaccharides by effectively carrying or showing
the polysaccharide to the immune system. The Company believes that conjugate
vaccines may prove as safe as and more effective than polysaccharide vaccines.
The Company holds exclusive worldwide rights (excluding Canada) for the
development, production and sale of vaccines against certain bacterial
infections under a license granted by the National Research Council of Canada, a
Canadian federal government agency ("NRC"), for certain conjugate vaccine
technology. United States and, in some cases, foreign patents relating to this
technology have been issued and applied for. The Company also holds, either as
assignee or licensee, several other patents related to the development and
manufacture of conjugate vaccines. The Company is developing conjugate vaccines
for the diseases discussed below and, where appropriate, intends to combine
certain of its conjugate vaccines with Certiva(TRADEMARK) and its DTaP-IPV
vaccines. See "Products Under Development Combination Vaccines" and "Business
Relationships."
GROUP B STREPTOCOCCAL VACCINE. Group B streptococcal ("GBS") infection
affects all age groups in the United States and is the most common cause of
life-threatening infections, including sepsis meningitis in newborns. GBS
infections in infants occur principally during the first three months after
birth and can result in serious complications, including death, pneumonia or
permanent brain damage from meningitis. Disease in newborns during the first
week of life generally is caused by infection of the infant passing through the
mother's colonized birth canal. GBS disease is also a prominent cause of
peripartum maternal infections. Since there is no vaccine for the prevention of
GBS disease in adults or infants, the CDC has issued guidelines for detecting
and treating GBS infections in pregnant women. These guidelines, which have been
adopted by the American Academy of Pediatrics and the American College of
Obstetricians and Gynecologists, include diagnostic testing during the third
trimester and, for those infected, a course of intravenous antibiotics during
and after labor. A primary target market for this vaccine will be women of
child-bearing age. A principal benefit to such an immunization program is that
the vaccine has the potential to generate protective antibodies for both the
mother and the infant.
A vaccine against GBS infection, utilizing patented technologies that the
Company has licensed from the NRC, the Brigham and Women's Hospital, and Harvard
University, has been tested in proof-of-principle Phase I/II clinical trial
conducted under the sponsorship of the NIAID. In that trial, the monovalent
vaccine was well tolerated with minimal reactogenicity and no serious
side-effects in healthy, nonpregnant women subjects. Antibodies elicited by
immunization with different conjugate vaccine serotypes displayed protective
activity IN VITRO and IN VIVO. In addition, the clinical investigators reported
that the delivery of a GBS polysaccharide conjugate vaccine through maternal
immunization may be a realistic approach to the prevention of perinatal GBS
infection and that antibodies transported through the placenta to the fetus may
confer protective immunity even to infants born prematurely between 34 and 37
- 12 -
<PAGE>
weeks of gestation. Trials for monovalent GBS vaccines have been expanded. The
Company is presently planning clinical studies for its multivalent conjugate
vaccine coupled to a new and novel carrier protein in nonpregnant adolescent
girls and women.
MENINGOCOCCAL VACCINES. Meningitis is a serious infection involving the
membranes surrounding the brain and spinal cord, which can lead to significant
central nervous system damage in all age groups. In the United States, those
most often stricken are children and young adults. Serogroups A, B and C of
NEISSERIA MENINGITIDIS (meningococcus) cause a significant number of cases of
meningitidis and systemic meningococcemia. The incidence of meningitis caused by
Group A, B and C meningococcus varies from country to country, with Group B and
C meningococcus accounting for nearly all disease in developed countries.
Currently, a polysaccharide vaccine for the prevention of Group A and C
meningococcal infections is licensed in the United States. This vaccine is
predominantly used in the adult population and, in particular, is routinely
administered to United States military personnel. This vaccine has not been
demonstrated to be protective in children less than two years of age. In
addition, there is currently no licensed conjugate vaccine for the prevention of
Group B meningococcal infection.
Group B meningococcal bacteria have been responsible for most cases of
meningococcal meningitis in developed countries since the late 1940s, and in the
United States account for approximately one-half of the yearly cases of such
meningitis (the other half being attributable principally to Group C
meningococcal bacteria). Epidemic outbreaks occur periodically in the United
States, South America and Europe.
The Company has developed a Group B meningococcal conjugate vaccine
utilizing a unique carrier protein which appears to reduce many of the
previously reported problems associated with the development of an effective
Group B meningococcal polysaccharide vaccine. At the end of 1995, the Company
entered into agreements with Pasteur Merieux Connaught to jointly develop this
conjugate vaccine. The two companies successfully collaborated in 1997 on
preclinical primate studies for this Group B meningococcal conjugate vaccine
that confirmed its safety and immunogenicity. These studies demonstrated that
the conjugate vaccine made using the Company's proprietary technologies elicited
IN VIVO superior bactericidal responses to another Group B meningococcal
conjugate vaccine. In addition, the Company and Pasteur Merieux Connaught
together are planning to file an investigational new drug application with the
FDA to begin a Phase I clinical trial in adults. See "Business Relationships -
Pasteur Merieux Connaught Agreements."
The Company is also developing conjugate vaccines against Group A and C
meningococcal disease and Group A/C and Group A/B/C meningococcal disease for
adults and infants. The Company has completed preclinical development and
testing of its Group A and Group A/C meningococcal conjugate vaccines, as well
as a Phase I clinical trial of its Group C meningococcal conjugate vaccine in
adults. The Company is presently participating in Phase II clinical trials of
the vaccine in infants and children in the United Kingdom to assess the safety
and immunogenicity of the vaccine, and expects to participate in a clinical
study of the vaccine in U.K. adolescents. In May 1998, the Company announced
that in the first of these Phase II trials, its Group C meningococcal vaccine
had been shown to be safe and effective in infants as measured by immunological
response capable of inducing bactericidal activity. Previous studies have
demonstrated a correlation between vaccine efficacy and its ability to generate
immunologic response and to stimulate bactericidal activity. The clinical
development and testing of all of these vaccines are expected to take several
years to complete.
- 13 -
<PAGE>
HAEMOPHILUS INFLUENZAE TYPE B VACCINE. HIB has been a frequent cause of
meningitis and other serious infections in infants and children. The ACIP has
issued a recommendation for universal vaccination of children for protection
against diseases caused by HIB. Vaccination against HIB consists of either a two
or three dose primary regimen (depending on vaccine used), with primary doses
administrated at the ages of two, four and six months and a booster dose
administered at between 12 to 15 months of age. Children infected with HIB
bacteria can develop meningitis, which can lead to blindness, deafness, acquired
mental retardation or death. The peak incidence of HIB infection in the United
States occurs in children between six and 18 months of age.
The Company has developed a conjugate vaccine against HIB for use in
infants and children and for possible use in the Company's combination vaccines.
See "Products Under Development - Combination Vaccines." The Company has
completed its preclinical development of this vaccine. Three manufacturers are
currently licensed by the FDA to sell HIB conjugate vaccines for use in all
primary and booster doses. See "Competition."
GROUP A STREPTOCOCCAL VACCINE. Group A streptococcal disease occurs in all
age groups with a predominance in school-age children. Group A streptococcus
causes infections ranging from severe sore throat and sinus infection to
pneumonia and toxic streptococcal syndrome. Sequelae of Group A streptococcal
infections include rheumatic fever and glomerulonephritis. Currently, there is
no vaccine licensed by the FDA to prevent Group A streptococcal infection. The
Company is engaged in the research and development of a conjugate vaccine to
prevent this infection. Activities on this vaccine are in the preclinical stage.
PNEUMOCOCCAL (OTITIS MEDIA) VACCINE. Otitis media, or middle ear
infection, is a common illness in the United States afflicting children under
five years of age. The majority of bacterial cases are attributable to
pneumococcal organisms. Chronic otitis media can lead to hearing defects and
associated learning and language disabilities. There is no vaccine licensed by
the FDA that prevents otitis media caused by pneumococcal bacteria. The Company
is pursuing efforts to develop a conjugate vaccine to prevent pneumococcal
otitis media. This vaccine is currently in the preclinical stage of development.
PNEUMOCOCCAL (PNEUMONIA) VACCINE. There are in excess of 20 serotypes of
pneumococcal bacteria that cause pneumonia, a respiratory infection that affects
individuals of all ages, as well as other infections. The present pneumococcal
vaccine is a multivalent polysaccharide vaccine recommended for adults,
particularly elderly and other patients with a high risk of contracting
pneumonia. The Company is currently in the preclinical stage of the development
of a multivalent conjugate vaccine against pneumococcus.
OTHER VACCINES
The Company, utilizing patented and proprietary technologies, is
performing research on and developing other adult and pediatric vaccines, which
it selects for development based on the anticipated need for a particular
product, the nature of the competition, and the ability of the Company to
develop the product, among other factors. The Company's research and development
efforts are being conducted independently and in conjunction or in collaboration
with governmental agencies and universities. There are no assurances that any of
these vaccines will enter clinical trials or successfully be developed or
licensed by the FDA or any other regulatory authority for commercial sale.
- 14 -
<PAGE>
MARKETING OF VACCINES
An objective of the Company is to become a leader in the development,
production and marketing of state-of-the-art vaccines for the prevention of
human infectious diseases. In pursuing this objective, the Company considers,
among other things, collaborations with pharmaceutical and other vaccine
manufacturers where appropriate to maximize the value of the Company's products
and technologies.
To maximize market penetration for its first commercial products within
the least amount of time, the Company currently is implementing a marketing
strategy aimed at establishing marketing alliances in the United States, Europe
and other territories with well-established local partners on a
country-by-country basis. Thereafter, the Company intends to develop, where
appropriate and feasible, an internal sales force to succeed these alliances
following expiration of the respective agreements. Toward this end, the Company
has entered into marketing alliances for certain products in the United States
and selected countries within Europe. The Company will continue to seek
distribution, marketing, joint venture and similar arrangements with third
parties in other territories and for other products where, in the judgment of
the Company, such arrangements would be beneficial to the successful
commercialization of its products. See "Business Relationships."
In addition to establishing these commercial alliances, the Company has
developed an internal marketing and sales organization, which commenced the
product launch of Certiva(TRADEMARK) in the United States during the fourth
quarter of 1998. In the United States, federal and state governments currently
purchase a substantial portion of pediatric vaccines sold. The Company is
marketing Certiva(TRADEMARK) directly to federal and state governments through
established purchasing programs. In the fourth quarter of 1998, the Company
began participating in the U.S. government's multiple contract awards for the
purchase of its annual requirements of DTaP vaccine. Under these contracts, the
Company and the other vaccine suppliers effectively are not guaranteed any
minimum purchase requirements, but they are provided the opportunity to revise
their contract proposals on a quarterly basis. The Company also is competing to
supply Certiva(TRADEMARK) to state government programs. The foregoing are
forward looking statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward looking statements
inherently involve risks and uncertainties that may affect the Company's
business and prospects, including without limitation the effectiveness of
product launch, nature of competition, effective marketing, and uncertainties
relating to government purchasing policies, all as discussed under the heading
"Risk Factors", below. See "Risk Factors - No Assurance of Effective Marketing"
and "Risk Factors - Changes in Government Purchasing Policies."
For financial information regarding the segments in which the Company
operates, see Note 3 of the Notes to the Consolidated Financial Statements in
Item 8 - Financial Statements and Supplementary Data. All of the Company's sales
are made in U.S. dollars. The backlog of orders believed to be firm for the
Company's products was approximately $3.2 million and $1 million as of December
31, 1998 and 1997, respectively. The Company does not consider orders for any of
the Company's products to be firm until such time as regulatory approval is
obtained for each product.
To successfully commercialize Certiva(TRADEMARK) in the United States, the
Company will be required, among other things, to participate successfully in
established purchasing programs of Federal and state governments, to establish
an identity and reputation for the Company and its products, to create an
awareness among pediatricians of the safety and efficacy of the vaccine, to
distinguish the Company's products from those of its competitors, to establish
the Company as an effective and reliable supplier of vaccines, to establish
efficient and consistent production of sufficient quantities of vaccine and to
- 15 -
<PAGE>
establish effective distribution channels. There can be no assurance that the
Company will be able to successfully market its vaccine products, that its
existing business relationships will prove to be commercially successful, or
that it will successfully negotiate and execute any additional commercial
arrangements with third parties. See "Business Relationships," "Competition" and
"Risk Factors - No Assurance of Effective Marketing."
BUSINESS RELATIONSHIPS
PERTUSSIS LICENSE AGREEMENT. The process by which the Company's pertussis
toxin is inactivated is the subject of a United States patent held by the United
States Government, which has been licensed exclusively to the Company. The
Company has exclusive rights for a term which, presently, is through the
expiration date of the patent. The patent is scheduled to expire on August 9,
2005. The Company is required to pay the United States Government a royalty
based on net sales of a vaccine that utilizes the patented technology. Foreign
patent applications covering this technology have been filed and fourteen
unexpired foreign patents are issued with expiration dates ranging from 2002 to
2009. The Company has acquired a royalty-bearing exclusive license for the use
of the patented technology in all such foreign jurisdictions for the full term
of the patents. See "Products Under Development - Acellular Pertussis Vaccines."
CANADIAN GOVERNMENT LICENSE AGREEMENTS. The Company is the assignee under
two license agreements between BioChem and the Canadian Government covering the
conjugate technology being developed by the Company. These license agreements
currently cover a total of thirty-three issued patents with expiration dates
ranging from 2005 to 2016, and the Company and the Canadian Government have
applied for additional patents, which, if issued, would be licensed to the
Company under these agreements. The Company is required to pay the Canadian
Government royalties on the sale of licensed vaccines. In the event of a change
in control of the Company, the Canadian Government retains the right to
terminate both agreements if it believes such change in control is detrimental
to the Canadian Government. The Canadian Government also can terminate the
license agreements if all reasonable efforts are not being used to exploit the
technology commercially with due diligence. Under one license agreement, the
Company has the exclusive worldwide rights (excluding Canada) for the
development, production and sale of vaccines produced in accordance with the
conjugate vaccine technology covered by the license. The vaccines covered
include, among others, those against meningococcal, HAEMOPHILUS INFLUENZAE type
b, Group B streptococcal and pneumococcal infections. The term of the license is
co-extensive with the term of the patents. Currently, the last-to-expire patent
licensed under this agreement is scheduled to expire in 2016. Under the second
license agreement, the Company has the exclusive worldwide rights (excluding
Canada) for the development, production and sale of a vaccine against Group B
meningococcal disease produced in accordance with the licensed technology. The
term of the license is co-extensive with the terms of the patents. Currently,
the last-to-expire patent licensed under this agreement is scheduled to expire
in 2016. See also "Products Under Development Conjugate Vaccines."
STATENS SERUM INSTITUT SUPPLY AGREEMENTS. In 1991, the Company and SSI
executed a supply agreement under which SSI is required to supply the Company
with its requirements of diphtheria and tetanus toxoids to be used by the
Company for developing, producing and selling the DTaP vaccine, either alone or
as a combination vaccine. The Company has been using these diphtheria and
tetanus toxoids in producing its DTaP vaccine. In the event SSI fails to
continue to supply the Company with these components, the Company has a
royalty-bearing license to produce the diphtheria and tetanus toxoids. The
Company's right to purchase diphtheria and tetanus toxoids for sale of such
products is exclusive in certain designated countries and nonexclusive in the
rest of the world with the exception of SSI's Territory. The contract has a term
of 20 years. The Company and SSI also have entered into another supply agreement
- 16 -
<PAGE>
pursuant to which the Company has agreed, on an exclusive basis, to supply SSI
with the pertussis toxoid for combination with diphtheria and tetanus toxoids
either alone or together with other antigens for sale in SSI's Territory.
In February 1992, the Company signed two additional supply agreements with
SSI. Under the first supply agreement, SSI has agreed, to provide the Company
with diphtheria and tetanus toxoids for use as carrier proteins in the
development and manufacture of the Company's conjugate vaccines. If SSI fails to
continue to supply the Company with these components, the Company has a
royalty-bearing license to produce diphtheria and tetanus toxoids for this
purpose. Under the second supply agreement, the Company has agreed, to supply
SSI with its conjugate vaccines that utilize SSI's diphtheria or tetanus toxoids
as a carrier protein, solely for use by SSI in combination with DTaP and
DTaP-IPV vaccines in SSI's Territory. SSI's right to market and sell these
products is exclusive in SSI's Territory. These agreements have a term of 20
years.
STATENS SERUM INSTITUT RESEARCH AND DEVELOPMENT AGREEMENT. In 1991, the
Company entered into a research and development agreement with SSI under which
the parties agreed to collaborate on the development of a DTaP-IPV vaccine. See
"Products Under Development - Combination Vaccines." The agreement permits
either party to add other antigens to the DTaP-IPV product. Once the Company
obtains regulatory approval, and commences sales of the DTaP-IPV product, it
will be required to make royalty payments to SSI. SSI is required to sell to the
Company all of its requirements of IPV for the purpose of developing, producing
and selling the DTaP-IPV product, either alone or together with other antigens.
The contract has a term of 20 years.
STATENS SERUM INSTITUT DISTRIBUTION AGREEMENTS. The Company has been
designated the exclusive distributor in North America and the United Kingdom for
SSI's diphtheria, tetanus and IPV vaccines. Additionally, SSI will be the
exclusive distributor in various countries for the conjugate vaccines
manufactured using the components supplied to the Company by SSI. These
agreements were executed in February 1992, and each agreement has a term of 10
years.
TECHNOLOGY TRANSFER AGREEMENT WITH BIOCHEM. In 1990, in addition to the
conjugate vaccine technologies described above, BioChem transferred to the
Company all rights to certain vaccine technologies and granted to the Company a
paid-up exclusive right (excluding Canada) and license to other technologies for
vaccine applications, including those relating to monoclonal antibodies,
synthetic peptides and adjuvants. The licenses granted under this agreement
generally will not terminate until the expiration of the last valid patent or
copyright anywhere in the world for the licensed technologies or until the last
portion of the technologies protected by trade secrecy enters the public domain
everywhere in the world, whichever occurs last. Currently, this agreement covers
one U.S. patent that expires in 2015 and two European patents which expire in
2011.
PASTEUR MERIEUX CONNAUGHT AGREEMENTS. At the end of 1995, the Company
entered into a clinical development agreement and a license agreement with
Pasteur Merieux Connaught under which both parties will jointly develop the
Company's new conjugate vaccine against Group B meningococcus for both adult and
pediatric indications. Total fees and payments to the Company under these
agreements would amount to $52 million upon achievement of all clinical and
regulatory milestones. In addition, Pasteur Merieux Connaught will be
responsible for all costs associated with the clinical development of the
vaccine through the completion of Phase II clinical trials. See "Products Under
Development - Conjugate Vaccines - Meningococcal Vaccines."
- 17 -
<PAGE>
Through December 31, 1998, the Company has received payments from Pasteur
Merieux Connaught in connection with this project in the amount of $13 million.
Further fees and funding will be made upon achievement of development, clinical
and regulatory milestones. Total remaining fees and payments to the Company,
upon achievement of all clinical and regulatory milestones, amount to $39
million. See Item 7 - Management's Discussion and Analysis of Financial
Condition and Results of Operation.
Under the terms of the license agreement, Pasteur Merieux Connaught will
hold co-exclusive world-wide rights to manufacture and sell the Group B
meningococcal vaccine both as a stand-alone product and in combination with
other vaccines. The Company will retain co-exclusive world-wide rights to
manufacture and sell the Group B meningococcal vaccine both as a stand-alone
product and in combination with other vaccines. With limited exceptions, neither
party may grant sublicenses under the technology. Following first product
approval, the Company will receive annual minimum royalties and running
royalties on product sales by Pasteur Merieux Connaught. Pasteur Merieux
Connaught is subject to diligence obligations in the development and
commercialization of the vaccine. The obligations of Pasteur Merieux Connaught
will be reduced in the event of a change of control of the Company involving
certain specified corporations. Pasteur Merieux Connaught may terminate the
agreement at any time with advance notice. The Company may terminate the license
agreement upon Pasteur Merieux Connaught's default or its failure to meet its
obligations under the clinical development agreement.
Under the terms of the clinical development agreement, the parties will
jointly develop the vaccine through Phase II clinical trials, and each party
will have access to and the right to use the clinical trial results. Pasteur
Merieux Connaught will be responsible for all costs associated with the clinical
development of the Group B meningococcal vaccine through the completion of Phase
II clinical trials. Pasteur Merieux Connaught's obligations will terminate upon
a change of control of the Company involving certain specified corporations.
Pasteur Merieux Connaught is subject to specific diligence obligations in the
development and commercialization of the vaccine. Pasteur Merieux Connaught may
terminate the agreement at any time with advance notice.
ABBOTT LABORATORIES AGREEMENT. In October 1996, the Company and Abbott
signed a definitive agreement under which Abbott would market Certiva(TRADEMARK)
following FDA approval. The marketing agreement also will allow Abbott to market
the Company's DTaP-IPV vaccine, and DTaP-HIB and DTaP-IPV-HIB combination
vaccines under development.
Abbott will market Certiva(TRADEMARK) and combination vaccines to private
physicians and managed care markets in the United States for immunization of
infants and children. The Company will market Certiva(TRADEMARK) and the
combination vaccines to government purchasers, including state governments and
the CDC.
On execution of the agreement with Abbott, the Company received $13
million of which $6.3 million represented payment for 350,000 shares of the
Company's Common Stock, and the balance represented a marketing fee and a
clinical development payment. The Company and Abbott will collaborate in the
clinical development of the combination vaccines, and Abbott has provided the
Company with clinical development funding. The Company will receive payments
upon achievement of prescribed milestones. The Company recognized $5.2 million
of revenues under this contract in 1998, including a milestone payment
associated with the FDA approval of Certiva(TRADEMARK). The agreement, as
amended, provides for total payments of up to $40 million by Abbott, of which
the Company has received $18 million through December 31, 1998. In addition, the
Company has received revenues from Abbott as it purchases Certiva(TRADEMARK) and
- 18 -
<PAGE>
will receive additional revenues as Abbott purchases combination vaccine
products for resale to the private pediatric market. Each party is subject to
prescribed diligence obligations. The agreement will expire on the expiration of
the patents covering the products to be marketed. In addition, Abbott may
terminate the agreement at any time with advance notice. See Item 7 -
Management's Discussion and Analysis of Financial Condition and Results of
Operation.
OTHER RELATIONSHIPS. The Company holds licenses and other rights to
additional technologies that the Company is researching and/or developing
jointly with various research institutions. In addition, the Company is in
various stages of discussions with third parties, including multinational
pharmaceutical companies, regarding various business arrangements, including
acquisitions, licensing, research and development, distribution, marketing,
joint venture and other business agreements. There are no assurances that the
Company will successfully negotiate and sign any such agreement or that, if
executed, the financial terms of any such agreement will be significant.
COMPETITION
Competition in the vaccine industry is intense. The Company faces
competition from many companies, including a number of large companies and
specialized firms in the United States and abroad that are engaged in the
development and production of vaccines, and major universities and research
institutions. Many of the Company's competitors have substantially greater
financial and other resources, more extensive experience in conducting clinical
testing and obtaining regulatory approvals for their products, greater operating
experience, larger research and development and marketing staffs, and greater
production capabilities than those of the Company. The Company believes that the
principal competitive factors in the vaccine industry are product quality,
measured by the safety and efficacy of a vaccine product, ease of administration
(represented by combination vaccines and vaccines that are stable in liquid
form) and price. See "Marketing of Vaccines."
The Company believes that its principal competitors in the United States
are Wyeth-Lederle (a subsidiary of American Home Products), Merck & Co.,
SmithKline Beecham plc, and Pasteur Merieux Connaught, most of which are active
in the development of acellular pertussis, combination and conjugate vaccines.
For example, over the past three years, three companies announced that they had
received FDA approval for their DTaP vaccine for infants and children. In
addition, to the extent that these competitors are successful in developing and
marketing combination vaccines that include DTaP vaccines, these combination
vaccines may gain market share at the expense of stand-alone DTaP vaccines,
including Certiva(TRADEMARK). One of these competitors has announced that the
FDA licensed a vaccine that combines by reconstitution that company's HIB
vaccine with its DTaP vaccine for administration at 15-18 months of age and that
it continues to seek FDA approval for administration of this combination vaccine
at two, four and six months of age. Another competitor has reported that it is
in clinical trials for a DTaP-Hib combination vaccine. In addition, several
competing DTaP vaccines and certain combination vaccines incorporating DTaP, IPV
and/or HIB vaccines have been licensed for sale outside of the United States.
See "Risk Factors Competition and Technological Change."
- 19 -
<PAGE>
PATENTS AND PROPRIETARY INFORMATION
The Company actively pursues a strategy of seeking patent protection for
valuable patentable subject matter. The Company believes that patent and trade
secret protection is an important element of its business and that its success
will depend in part on its ability to obtain strong patents, to maintain trade
secret protection, and to operate without infringing the proprietary rights of
third parties. The Company holds as assignee and licensee a number of patents
and patent applications. See "Business Relationships" and "Risk Factors - Patent
Protection and Proprietary Information."
The Company also relies upon trade secrets, know-how and continuing
technological advancement to develop and maintain its competitive position.
Disclosure and use of the Company's know-how is generally controlled under
agreements with the parties involved. In addition, the Company has
confidentiality agreements with its employees, consultants and officers. There
can be no assurance that disclosure of the Company's trade secrets will not
occur, or that others will not independently develop and patent equivalent
technology.
GOVERNMENT REGULATION
The Company and its products are subject to comprehensive regulation by
the FDA in the United States and by comparable authorities in other countries.
These national agencies and other federal, state, and local authorities
regulate, among other things, the preclinical and clinical testing, safety,
effectiveness, approval, manufacturing, labeling, advertising, promotion,
export, and marketing of the Company's products. In the United States, FDA
regulates human vaccine products under the Federal Food, Drug, and Cosmetic Act,
the Public Health Service Act, and other laws.
The steps required before a human vaccine product may be approved for
marketing in the United States generally include: (i) preclinical laboratory and
animal testing; (ii) submission to the FDA of an IND for human clinical testing,
which must become effective before human clinical trials may commence; (iii)
human clinical trials and other studies to establish the safety and efficacy of
the product; (iv) the submission to the FDA of license applications; (v) FDA
review of the license applications; and (vi) satisfactory completion of an FDA
inspection of the manufacturing facility or facilities at which the product is
made to assess compliance with Good Manufacturing Practices ("GMP"). The testing
and approval process requires substantial time, effort and financial resources,
and there can be no assurance that any approval will be granted on a timely
basis, if at all. See "Risk Factors -- Government Regulation; Regulatory
Approvals."
Preclinical tests include laboratory evaluation of the product, as well as
animal studies to assess its safety, immunogenicity, and potential efficacy. The
results of preclinical tests, together with the manufacturing information and
analytical data, are submitted to the FDA as part of an IND, which must become
effective before human clinical trials may begin. An IND will automatically
become effective 30 days after receipt by the FDA, unless before that time the
FDA raises concerns or questions. If it does, the FDA's concerns and questions
must be resolved before clinical trials can proceed.
Clinical trials involve the administration of the investigational new
vaccine to healthy volunteers or to patients, under the supervision of a
qualified investigator. Clinical trials are conducted under protocols that
detail the objectives of the study and the parameters to be used to monitor
efficacy and safety. Each clinical study must be reviewed by an independent
Institutional Review Board ("IRB"), and the IRB must approve the study before it
begins. In its review, the IRB will consider, among other things, ethical
factors and the safety of human subjects.
- 20 -
<PAGE>
Clinical trials are typically conducted in three sequential phases, but
the phases may overlap. In Phase I, the initial introduction of the vaccine into
human subjects (usually healthy volunteers), the vaccine is tested for safety
(adverse effects), optimal dosage, and its ability to induce an immune response
(immunogenicity). Phase II involves studies in limited target patient
populations to further evaluate immunogenicity and optimal dosage, and to
identify possible adverse effects and safety risks. Phase III clinical trials
are undertaken to evaluate clinical efficacy or some measure thereof and to
further test for safety within an expanded target patient population, usually at
geographically dispersed clinical study sites. There can be no assurance that
Phase I, Phase II or Phase III testing of any of the Company's products will be
successfully completed within any specific time period, if at all, or, that if
they are completed, that the results of the trial will be sufficient to serve as
the basis of a license application submission to the FDA. Furthermore, FDA may
suspend clinical trials at any time on various grounds, including a finding that
the subjects in the trial are being exposed to an unacceptable health risk. See
"Risk Factors -- Uncertainties Related to Clinical Trials."
The results of preclinical testing and clinical trials, together with
detailed information on the manufacture and composition of a product, are
submitted to the FDA in the form of both a Product License Application ("PLA")
and Establishment License Application ("ELA") requesting approval to market the
product. Pursuant to the Food and Drug Modernization Act, FDA has proposed to
combine the PLA and ELA into a Biologics License Application ("BLA"). Until that
proposal is made final, companies will continue to submit a PLA/ELA. The PLA
describes the results of clinical and pre-clinical studies; the ELA describes
the facilities, equipment, and personnel involved in the manufacturing process.
The FDA may deny a BLA or PLA/ELA if applicable regulatory criteria are not met,
require additional testing or information, and/or require post-marketing testing
and surveillance to monitor the safety or efficacy of a product. Before
approving a BLA or PLA/ELA, FDA will inspect the facilities at which a product
is manufactured, and will not approve the product unless GMP compliance is
satisfactory.
Both before and after approval is obtained, violations of regulatory
requirements, including the preclinical and clinical testing process, the BLA or
PLA/ELA review process, or thereafter (including after approval), may result in
various adverse consequences, including the FDA's delay in approving or refusal
to approve a product, withdrawal of an approved product from the market,
seizure, injunction, and/or the imposition of criminal penalties against the
license holder. For example, each holder of an IND or FDA license is required to
report certain adverse reactions to the FDA, and to comply with certain
requirements concerning advertising and promotional labeling for their products.
Also, quality control and manufacturing procedures must continue to conform to
GMP regulations after approval, and the FDA periodically inspects manufacturing
facilities to assess compliance with GMP. Accordingly, manufacturers must
continue to expend time, moneys, and effort in the area of production and
quality control to maintain GMP compliance. In addition, discovery of problems
may result in restrictions on a product, including withdrawal of the product
from the market. Also, new government requirements may be established that could
delay or prevent regulatory approval of the Company's products under
development.
The Company will also be subject to a variety of foreign regulations
governing clinical trials and sales of its products. Whether or not FDA approval
has been obtained, approval of a product by the comparable regulatory
authorities of foreign countries must be obtained prior to the commencement of
marketing of the product in those countries. The approval process varies from
country to country and the time may be longer or shorter than that required for
FDA approval.
- 21 -
<PAGE>
Requirements similar to FDA's are also in effect in the European Union and
other foreign countries where the Company has applied or may apply for
regulatory approval for clinical studies and/or marketing of its vaccines. The
Company's research and operations also are subject to regulation by the
Occupational Safety and Health Agency, the Environmental Protection Agency, the
Department of Agriculture, and the Department of Transportation. The Company
also is subject to regulation under the Toxic Substances Control Act, the
Resource Conservation and Recovery Act, and other regulatory statutes, and may
in the future be subject to other federal, state, local or foreign regulations.
The Company's compliance with laws that regulate the discharge of materials into
the environment or otherwise relate to the protection of the environment, does
not have a material effect on the ongoing operations of the Company. The Company
has not made any material expenditures for environmental control facilities, nor
does it anticipate any such expenditures during the current fiscal year.
RAW MATERIALS
Laboratory supplies utilized in the Company's research, development
generally are available from several commercial suppliers under standard terms
and conditions. Most raw materials necessary for process development, scale-up
and commercial manufacturing are generally available from multiple commercial
suppliers. However, certain processes require raw materials from sole sources or
materials that are difficult for suppliers to produce and certify to the
Company's specifications. In addition, the Company may experience temporary or
permanent shortages of critical raw materials necessary for continued production
of its vaccines. Accordingly, given the specific nature of, and critical need
for, certain raw materials, there is a risk that material shortages could delay
production efforts, adversely impact production costs and yields, and even
necessitate the use of substitute materials. Any of these events could have a
significant adverse impact on the Company's operations. See also "Risk Factors -
Dependence on Suppliers."
PRODUCT LIABILITY
The testing and marketing of vaccines entail an inherent risk of product
liability attributable to unwanted and potentially serious health effects. The
extent of this risk was sufficiently great in the United States that, by the
mid-1980s, many manufacturers ceased production of pediatric vaccines because of
liability exposure.
In response to these withdrawals from the vaccine market, Congress enacted
the NCVI Act to ensure the availability of government mandated pediatric
vaccines by addressing the liability of manufacturers for immunization-related
injuries. Among other things, the NCVI Act created a trust fund, supported by an
excise tax on each dose of vaccine sold, to compensate eligible injured parties.
Compensation awards are statutorily established and are generally limited to
actual and projected unreimbursed medical, rehabilitative and custodial
expenses, lost earnings, and pain and suffering, together with reasonable
attorneys' fees. Injured parties are not allowed to bring a lawsuit against the
manufacturer unless they have filed a claim with the program, received a final
determination and rejected it in favor of litigation. The NCVI Act may not,
however, protect vaccine manufacturers against liability if the conditions of
the NCVI Act are not satisfied, or against suits by family members of an injured
party.
As the vaccines covered by the NCVI Act include vaccines for the
prevention of diphtheria, tetanus, pertussis, polio and HIB, the Company's DTaP,
IPV and HIB vaccines have certain protection from liability claims. While none
of the Company's other products are presently covered by the NCVI Act, from time
to time there are legislative and regulatory proposals to expand the list of
- 22 -
<PAGE>
vaccines covered by, and to reduce the excise taxes that fund, the program. The
Company is unable to predict whether any other legislative or regulatory
proposal will ultimately be enacted or the effect any of these proposals may
ultimately have on the Company's business or results of future operations.
The testing and marketing of vaccine products involve an inherent risk of
product liability. The Company has limited product liability insurance coverage.
There can be no assurance that adequate additional insurance coverage will be
available at acceptable cost, if at all, or that a product liability claim would
not materially adversely affect the Company's business or financial condition.
If not covered by insurance, the Company faces potential liability that could be
substantial in the event of claims.
EMPLOYEES
As of December 31, 1998, the Company had 308 full-time employees of whom
35 have Ph.D. degrees and two have M.D. degrees. Of these employees, 191 were
engaged in research, development and production activities, 38 were engaged in
administration, and 79 were engaged in quality/regulatory and related aspects of
the Company's operations. The Company considers its relationship with employees
to be satisfactory.
RISK FACTORS
IN ADDITION TO THE OTHER INFORMATION INCLUDED IN THIS ANNUAL REPORT ON
FORM 10-K, READERS SHOULD CONSIDER THE FOLLOWING RISK FACTORS. THIS ANNUAL
REPORT ON FORM 10-K CONTAINS FORWARD LOOKING STATEMENTS COVERED BY THE SAFE
HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. THESE
STATEMENTS INVOLVE RISKS AND UNCERTAINTIES THAT MAY AFFECT THE COMPANY'S
BUSINESS AND PROSPECTS. THE COMPANY'S ACTUAL RESULTS MAY DIFFER SIGNIFICANTLY
FROM THE RESULTS DISCUSSED IN THE FORWARD LOOKING STATEMENTS. FACTORS THAT MIGHT
CAUSE SUCH A DIFFERENCE INCLUDE, BUT ARE NOT LIMITED TO, THOSE DISCUSSED IN THIS
SECTION.
LACK OF PROFITABILITY. The Company has operated at a loss since its
inception and its net loss for the year ended December 31, 1998 was
approximately $56.6 million. The Company expects additional losses during 1999,
and there can be no assurance that the Company will become profitable
thereafter. To become profitable, the Company must:
. timely and efficiently expand production capacity and output for
its acellular pertussis vaccine products,
. increase commercial sales of Certiva(TRADEMARK) and products
licensed in Europe,
. obtain regulatory approvals for new products and produce and
market those products efficiently, successfully and in sufficient
quantities, and
. obtain milestone and other payments under existing and new
collaborative agreements.
See "Risk Factors - No Assurance of Effective Marketing," "Risk Factors Risks
Associated with Limited Production Capacity" and Item 7 - Management's
Discussion and Analysis of Financial Condition and Results of Operation.
RISK ASSOCIATED WITH LACK OF AVAILABILITY OF CAPITAL. To maintain the
Company's production, research, development and growth at current levels,
present cash and cash equivalents, expected product sales of Certiva(TRADEMARK)
and the Company's other products, and revenues from existing collaborative
agreements are not expected to provide sufficient cash to fund the Company's
- 23 -
<PAGE>
operations, debt service payments and capital expenditures in 1999 and into
2000. As a result, the Company intends to: enter into new license, marketing,
distribution and/or development agreements that are currently under active
discussion; liquidate its investment securities; enter into a sale and
lease-back of the Company's one owned facility; and obtain one or more lines of
credit, which may be secured by accounts receivable, inventory or other assets
of the Company. The Company believes that it may meet 1999 cash requirements for
operations through these efforts, although there are no assurances in this
regard. This is a forward looking statement and the factors that will determine
whether the Company will require additional funding include, without limitation,
the amount and timing of product sales, the amount and timing of payments under
existing and new collaborative agreements and the amount of any proceeds from
other previously identified funding sources.
If the Company is unable to complete one or more of these transactions
and/or proceeds from the transactions are inadequate, the Company would be
required to obtain additional funding through the sale of debt and/or equity
securities. The Company has no current plans, agreements, commitments,
arrangements, or understandings relating to the placement or issuance of any
securities. During the course of the year, the Company will evaluate its need
for additional debt or equity financing to meet its cash requirements for 1999
and 2000. If the Company determines that such additional financing is required
but is not available, then the Company would have to reduce its cash
requirements through significant reductions in operating levels. There can be no
assurances that the Company will be able to obtain debt or equity financing on
favorable terms or in amounts required to meet future cash requirements, or that
the Company, if necessary, would be successful in reducing operating levels, or
that if operating levels are reduced, the Company would be able to maintain
operations for any extended period of time. See Item 6 - Selected Financial Data
and Item 7 - Management's Discussion and Analysis of Financial Condition and
Results of Operation.
NO ASSURANCE OF EFFECTIVE MARKETING. The Company is now implementing its
initial marketing and sales plan for Certiva(TRADEMARK) in the United States.
The Company markets Certiva(TRADEMARK) to government purchasers and, through a
distribution agreement with Abbott, markets Certiva(TRADEMARK) to private
physicians and managed care organizations. There can be no assurance that the
Company or Abbott will successfully implement their respective sales and
marketing strategies.
Factors affecting successful commercial launch of the Company's vaccines
in the United States include:
. establishing an identity and reputation for the Company and its
products,
. increasing awareness among pediatricians of the safety and efficacy
of the Company's vaccines,
. distinguishing the Company's products from those of its competitors,
. establishing the Company as an effective and reliable supplier of
vaccines,
. establishing efficient and consistent production of sufficient
quantities of vaccine, and
. establishing effective distribution channels.
In addition, the Company has entered into supply, marketing and
distribution agreements with third parties under which these parties have agreed
to market certain of the Company's products, such as Certiva(TRADEMARK)-EU and
the DTaP-IPV vaccine, in designated territories. As a result of this
arrangement, the Company's revenues from product sales in Europe and other
territories depend upon the timing, implementation and effectiveness of the
sales, marketing and distribution efforts of others. In addition, the Company
may not be successful in negotiating and executing marketing and/or distribution
agreements with any other third parties and these other third parties may be
unable to market the Company's products successfully. See "Business -- Business
Relationships."
- 24 -
<PAGE>
RISKS ASSOCIATED WITH LIMITED PRODUCTION CAPACITY. The Company's
manufacturing facility has limited production capacity based on the present
size, configuration, equipment, processes and methods used to produce its
products. In addition, production expenses are mainly fixed and consist
primarily of expenses relating to the operation of its production facilities and
maintaining a ready work force. Further, from time to time, the Company
experiences disruptions and production failures. These disruptions and failures
increase unit production costs as units are lost in the production process.
These factors have contributed to higher production costs for the Company's
acellular pertussis products, which costs currently exceed their respective net
selling prices. See Item 7 - Management's Discussion and Analysis of Financial
Condition and Results of Operation.
The Company is addressing this issue by modifying its existing facilities
and operations in a manner intended to significantly expand production capacity
and efficiency. These enhancements are presently scheduled to be completed in
the latter half of 1999, although there are no assurances in this regard.
Following completion of these enhancements, the Company believes that the
manufacturing facility will have substantially increased production capacity and
output, that unit production costs will be reduced significantly and that
Certiva(TRADEMARK) will be produced in sufficient quantities and efficiencies to
generate a gross profit based on current known pricing arrangements, current
competitive environment and projected mix of customer purchases.
The previous paragraph includes forward looking statements and, the
Company's ability to timely and efficiently expand its production capacity
depends, in large part, upon the following:
. adequacy of engineering designs,
. availability of needed equipment,
. manufacturing experience with these enhancements,
. timeliness of regulatory review of modifications, and
. acceptability of the modifications to applicable regulatory
authorities.
The Company's plans to increase production capacity and output could be
ineffective or may not result in production efficiencies that cover future
production costs. Failure to increase production capacity and output could limit
the Company's ability to meet market demand or achieve profitability. See Item 7
- - Management's Discussion and Analysis of Financial Condition and Results of
Operation.
RISKS ASSOCIATED WITH MANUFACTURING AND SCALE-UP. The production of
vaccines is a highly complex, biological process involving many steps from seed
culture through final production. Thus, the Company's production process could
fail or become subject to substantial disruptions that impede its ability to
meet production requirements.
From time to time, the Company experiences disruptions and production
failures. There is no assurance that the Company can adequately address such
failures or that production failures will not continue in the future. These
disruptions and failures:
. limit the Company's production capacity,
. increase its production costs, which would affect the Company's
prospects for profitability, and
. could have a negative impact on the Company's existing licenses for
its products and delay or inhibit its ability to obtain additional
regulatory approvals for its products.
- 25 -
<PAGE>
In addition, the Company may not consistently produce its vaccines in quantity
and quality sufficient to achieve competitive commercial sales or profitability.
The Company's manufacturing operations for Certiva(TRADEMARK) and its
acellular pertussis vaccine are located principally in one facility. Any
condition or event that adversely affects the operation of this facility would
have a material adverse effect on the Company's financial condition and future
results of operations. See Item 7 - Management's Discussion and Analysis of
Financial Condition and Results of Operation.
RISK RELATED TO SIGNIFICANT LEVEL OF INDEBTEDNESS. The Company currently
has a significant level of indebtedness. As of December 31, 1998, the Company's
consolidated indebtedness and capitalized lease obligations were approximately
$112.8 million, including $83.7 million of 6.5% Convertible Subordinated Notes
("6.5% Notes") and $25 million of 4.5% Convertible Secured Notes ("4.5% Notes").
This level of indebtedness could have material consequences for the
Company such as:
. impairing the Company's ability to obtain additional financing for
working capital, capital expenditures, and general corporate or
other purposes, and
. limiting the availability of a substantial portion of the Company's
cash flow from operations, as it will be dedicated to the payment of
the principal and interest on its indebtedness.
The Company's ability to service its indebtedness will depend upon its
future operating performance and the availability of capital. The Company may
not generate sufficient increases in cash flow from operations to service its
indebtedness. In that case, the Company could attempt to refinance such
indebtedness. There can be no assurance, however, that any refinancing would be
available to the Company. See Item 7 - Management's Discussion and Analysis of
Financial Condition and Results of Operations.
RISK OF FORECLOSURE OF COLLATERAL FOR 4.5% NOTES. The 4.5% Notes are
secured by a pledge of collateral, which includes certain of the Company's
equipment and other assets at the Company's principal manufacturing facility and
the Company's ownership rights in U.S. Patent No. 5,425,946, entitled "Vaccines
Against Group C NEISSERIA MENINGITIDIS" (the "Patent"). If the Company defaulted
on its obligations under the 4.5% Notes and the holders of these notes
foreclosed on the collateral, the Company's ability to operate its business may
be substantially impaired.
DEPENDENCE ON SUPPLIERS. While the Company produces the pertussis
component of Certiva(TRADEMARK), it has purchased, and intends to continue to
purchase, required diphtheria and tetanus toxoids from SSI and enhanced IPV from
SSI and another supplier. These suppliers may not fulfill the Company's
requirements, their components may not be supplied on commercially reasonable
terms, or they may experience difficulties in obtaining necessary regulatory
approvals or disruptions in their production of diphtheria and tetanus toxoids
or IPV. Any of the foregoing could significantly affect the Company's
operations.
Certain of the Company's production processes require raw materials from
sole sources or materials that are difficult for suppliers to produce and
certify to the Company's specifications. The Company also may experience
temporary or permanent shortages of critical raw materials necessary for
continued production of its vaccines. Any shortage of these materials could
delay production efforts, adversely impact production costs and yields, or
necessitate the use of substitute materials, any of which could have a
significant adverse impact on the Company's operations.
- 26 -
<PAGE>
In addition, the Company has contracted with third parties for certain
product testing and for the sterile fill, labeling and packaging of its vaccine
products. Failure of any such contractor to meet the Company's requirements
could have a material adverse effect on the Company, may involve costly delays
and significant expense, and would require additional regulatory approval as the
Company seeks alternative arrangements.
COMPETITION AND TECHNOLOGICAL CHANGE. Competition in the vaccine industry
is intense. Competitors of the Company both in the United States and
internationally include major pharmaceutical and chemical companies, specialized
biotechnology firms, universities and other research institutions. Many of these
competitors are actively developing competing vaccines.
Three competitors have received FDA approval for their DTaP vaccine for
use in infants and children. If these competitors are successful in developing
and marketing combination vaccines that include DTaP vaccines, then these
combination vaccines may gain market share at the expense of stand-alone DTaP
vaccines, including Certiva(TRADEMARK). One of those competitors has announced
that the FDA licensed a vaccine for administration at 15-18 months of age that
combines that company's HIB vaccine with its DTaP vaccine by reconstitution.
This same competitor is also seeking FDA approval for administration at two,
four and six months of age. Another competitor has reported that it is in
clinical trials for a DTaP-HIB combination vaccine. In addition, several DTaP
vaccines and DTaP combination vaccines are licensed for sale outside of the
United States.
Many of these competitors have substantially greater resources, more
extensive experience in conducting clinical testing and obtaining regulatory
approvals for their products, greater operating experience, larger research and
development and marketing staffs, and greater production capabilities than the
Company. These factors may be particularly advantageous because the vaccine
industry is subject to significant technological change.
The Company's competitors could also gain a competitive advantage by
designing around the Company's patents, and developing technologies and products
that are as or more effective than any that have been or are being developed by
the Company. They could also develop technologies and products that would render
the Company's technology and products obsolete and noncompetitive.
CHANGES IN GOVERNMENT PURCHASING POLICIES. Children in the United States
receive immunizations from private providers and public providers, such as local
health departments. Immunizations provided by public providers are generally
funded through federal and state government public health programs. Government
purchases historically have been at prices substantially below those offered to
the private sector and presently account for a substantial portion of the
vaccine doses distributed in the United States. In the United States, federal
and state governments historically have purchased DTaP and other vaccines from
multiple suppliers. There can be no assurances that this practice will continue.
From time to time, legislative and regulatory initiatives are proposed
that, if adopted, could significantly modify government vaccine programs. These
initiatives could materially affect the federal government's purchasing
authority, the contract award process, or the funding available for government
vaccine purchases. The Company is unable to predict which legislative
initiative, if any, will ultimately be enacted or the effect any such initiative
may ultimately have on the Company's business or results of future operations.
In addition, proposals for health-care, insurance and tax reform may be
considered in the future by federal and state governments and some of these
proposals, if adopted, may limit government or third-party, private
- 27 -
<PAGE>
reimbursement policies, or prices charged by pharmaceutical and vaccine
manufacturers for their products.
GOVERNMENT REGULATION; REGULATORY APPROVALS. The Company's vaccine
products, product development activities and manufacturing facilities and
processes are subject to extensive and rigorous regulation by the FDA. FDA
regulation includes preclinical and clinical testing requirements and inspection
and approval processes. To date, the Company has received FDA approval for only
one product.
Approval of the Company's products for commercial introduction in the
United States currently requires both a license for each product and a license
for each production facility. Obtaining licenses can be costly and time
consuming. There can be no assurance that the licenses will be granted, or that
FDA review will not involve delays that would adversely affect the Company's
ability to market products. There also can be no assurance that any products
under development by the Company will demonstrate the safety or efficacy
profiles necessary for regulatory approval, or that the Company's products under
development or its production facilities will receive the requisite regulatory
approvals and licenses in a timely fashion or at all.
Moreover, FDA-granted licenses may impose limitations that affect the
commercialization of the product, including limitations on product use and
requirements for post-licensure testing. The FDA can withdraw approvals at any
time by following appropriate regulatory procedures. The FDA can also limit or
prevent the manufacture or distribution of the Company's products both in the
United States and abroad and can require recalls of products. FDA regulations
depend heavily on administrative and scientific interpretation and advisory
committee determinations. Such interpretations, with possible prospective and
retroactive effect, could adversely affect the Company.
In addition, the FDA and various state agencies inspect the Company and
its facilities from time to time to determine whether the Company is in
compliance with regulations, including manufacturing, testing, recordkeeping,
quality control and labeling practices. If such entities find that the Company
is in material violation of these regulations, the Company could be subject to,
among other things, product recalls, suspensions or withdrawals of licenses,
revocation or suspension of export authorizations, and denials of any pending
applications.
UNCERTAINTIES RELATED TO CLINICAL TRIALS. Before obtaining regulatory
approval for the commercial sale of any products under development, the Company
must demonstrate through pre-clinical studies and clinical trials that these
products are safe and effective. The results from pre-clinical studies and early
clinical trials may not be predictive of results obtained in large-scale
clinical trials. There can be no assurance that large-scale clinical trials for
any of the Company's products will demonstrate safety and efficacy, be
sufficient to support application for regulatory approval, or lead to marketable
products. A number of companies in the biotechnology industry have suffered
significant setbacks in advanced clinical trials even after achieving promising
results in earlier trials.
PATENT PROTECTION AND PROPRIETARY INFORMATION. Traditionally, the vaccine
industry has placed importance on obtaining and maintaining patent and trade
secret protection for significant new technologies, products and processes. The
Company believes that this protection will be an important factor in its success
and may require the expenditure of substantial resources.
Many companies, universities and research institutions have applied for
and/or obtained patents for vaccine products and technologies that may be
- 28 -
<PAGE>
competitive or inconsistent with those held by or licensed to the Company. No
assurances can be given that the degree and range of protection of any patents
will be sufficient, that additional patents will be issued to the Company, or
that the Company will not infringe upon patents granted to others. Further,
others have or may independently develop or otherwise properly gain access to
technology or information that is substantially similar to that which is
unpatented yet considered proprietary by the Company.
The Company also may desire or be required to obtain licenses from others
to effectively develop, produce and market commercially viable products. Failure
to obtain those licenses could have a significant adverse effect on the
Company's ability to commercialize its vaccine products. There can be no
assurance that the Company can obtain these licenses on commercially reasonable
terms, if at all, that the patents underlying these licenses will be valid and
enforceable or that the proprietary nature of the unpatented technology
underlying these licenses will remain proprietary.
There has been, and the Company believes that there may be in the future,
significant litigation in the industry regarding patent and other intellectual
property rights. If the Company becomes involved in this type of litigation, it
could consume substantial resources.
RISK OF PRODUCT LIABILITY AND LIMITED INSURANCE. The testing and marketing
of vaccine products involve an inherent risk of product liability. The Company
has limited product liability insurance coverage. There can be no assurance that
adequate additional insurance coverage will be available at acceptable cost, if
at all, or that a product liability claim would not materially adversely affect
the Company's business or financial condition. If not covered by insurance, the
Company faces potential liability that could be substantial in the event of
claims.
DEPENDENCE ON ATTRACTING AND RETAINING QUALIFIED PERSONNEL. The Company's
success in developing marketable products and achieving a competitive position
will depend, in part, on its ability to attract and retain qualified personnel.
Competition for such personnel is intense. No assurance can be given that the
Company will continue to attract or retain such personnel. The loss of key
personnel could adversely affect the Company.
DIVIDENDS AND TAXATION. The Company has never paid cash dividends on its
Common Stock. The Company intends to retain earnings, if any, to finance the
growth and development of its business and does not anticipate paying cash
dividends in the foreseeable future. Moreover, any profits earned by the
Company's U.S. subsidiary will be declared and paid as a dividend to the
Company, and the Company will in turn declare and pay a dividend to its
shareholders. Each such dividend would be subject to a withholding tax. See Item
5 - Market for Registrant's Common Equity and Related Stockholder Matters, and
Item 7 - Management's Discussion and Analysis of Financial Condition and Results
of Operation.
IMPACT OF BECOMING A PASSIVE FOREIGN INVESTMENT COMPANY. If more than a
certain percentage of the Company's assets or income becomes passive, the
Company would be classified as a passive foreign investment company ("PFIC") for
U.S. federal income tax purposes. As a result, U.S. taxpayers who receive
certain dividends from the Company or who sell shares of the Company's Common
Stock would be subject to additional federal income tax. There are no assurances
that the Company will continue to be successful in avoiding PFIC classification.
See Item 5 - Market for Registrant's Common Equity and Related Stockholder
Matters, and Item 7 - Management's Discussion and Analysis of Financial
Condition and Results of Operation.
- 29 -
<PAGE>
VOTING CONTROL BY PRINCIPAL SHAREHOLDERS. The principal shareholders of
the Company, BioChem and Dr. Phillip Frost, either directly or through
affiliates, are parties to a Shareholders' Agreement requiring, among other
things, that the Company's Common Stock covered by the agreement be voted
together for the election of directors. As of December 31, 1998, these principal
shareholders beneficially owned approximately 20.7 million shares of the
Company's outstanding Common Stock, which represented approximately 54.6% of the
then outstanding shares of the Company's Common Stock. See Item 13 - Certain
Relationships and Related Transactions.
VOLATILITY OF STOCK PRICE. The market prices for securities of many
biotechnology and pharmaceutical companies, including the Company, have been
highly volatile. Many factors have historically had, and are expected to
continue to have, a significant impact on the Company's business and on the
market price of the Company's securities, including:
. financial results,
. announcements by the Company and others regarding the results of
regulatory approval filings, clinical trials or other testing,
. technological innovations or new commercial products by the Company
or its competitors,
. government regulations,
. developments concerning proprietary rights,
. public concern as to safety of vaccine and pharmaceutical products,
and
. economic or other external factors.
SHARES ELIGIBLE FOR FUTURE SALE. Sales of substantial amounts of the
Company's Common Stock in the public market following the exercise of options or
the conversion of convertible securities could have an adverse effect on the
price of the Company's securities. If either of the two principal shareholder
groups decides to sell a substantial number of shares of the Company's Common
Stock, these sales could significantly increase the volatility of the market
price of the Company's issued and outstanding securities. In addition, one of
the principal shareholders has registration rights for the shares of the
Company's Common Stock that it owns.
YEAR 2000 ISSUES. The Year 2000 Issue is the result of computer programs
being written using two digits rather than four to define the applicable year.
Management has initiated a Company-wide program to prepare the Company's
computer systems and programs for the Year 2000. The Company could be required
to expend additional funds to achieve Year 2000 qualification. These
expenditures could have a material adverse effect on the future results of
operations or financial condition of the Company. Additionally, the failure of
suppliers and other companies doing business with the Company to achieve Year
2000 qualification in a manner compatible with the Company's systems could also
have a material adverse effect on the Company. See Item 7 - Management's
Discussion and Analysis of Financial Condition and Results of Operation.
- 30 -
<PAGE>
ITEM 2. PROPERTIES
The production of vaccines is a highly complex, biological process
involving many steps, commencing from seed culture through final production. The
Company's vaccine production processes involve the use of patented technologies
and proprietary rights and trade secrets at the Company's facilities. The
Company's facilities are briefly described below:
Square
Facility/Function Location Feet Own/Lease
--------------------------------------------------------------------------
Production Facility Beltsville, MD 26,000 Leased until February 2009
(ten-year renewal option)
Production Facility Beltsville, MD 35,000 Leased until February 2001
(two five-year renewal
options)
Warehouse and Support Beltsville, MD 31,000 Owned
Services for Production
Facility
Support Services Offices Beltsville, MD 25,600 Leased until December 2000
and Warehouse Facility (remaining three-year
renewal option)
Executive Offices and Columbia, MD 75,500 Leased until March 2008
Research and Development (with two five-year
Laboratory Facility renewal options)
The Company's production facilities have been designed and built to
produce vaccines for large scale clinical trials and commercial sales after
product licensing. The Company has modified and continues to modify its 26,000
square foot production facility to expand production capacity for
Certiva(TRADEMARK). The lease on this facility expires in February 2009, subject
to a ten-year renewal option. See Item 1 - Business - "Risk Factors-
Manufacturing and Scale-Up."
In 1996, the Company acquired a 35,000 square foot production facility in
Beltsville, Maryland. The acquisition included the purchase and lease of
equipment and leasehold improvements and the assumption of real estate leases
underlying the facility, which are scheduled to expire in 2001, subject to two
five-year extensions. The facility is dedicated to the production of vaccines
for clinical trials and commercial sale.
The Company owns a building located adjacent to its current production
facility. This building has been modified to house the service and warehouse
departments that support the Company's production facility.
In March of 1998, the Company leased an approximately 75,500 square foot
facility for a period of ten years, with two five-year renewal options. At the
- 31 -
<PAGE>
end of the fifth year of the initial term, the Company has the right to
terminate the lease for a specified fee. In addition, the Company has an option
to purchase the facility during specified periods of the lease term. The Company
has consolidated the research and development groups and most general and
administrative functions in this facility. See Item 7 Management's Discussion
and Analysis of Financial Condition and Results of Operation.
ITEM 3. LEGAL PROCEEDINGS
-----------------
On November 2, 1998, Sharon Mates, Ph.D., a director of the Company and
the Company's former president, initiated litigation in United States District
Court, District of Maryland (Civil Action No. AW 98-3678) (the "Complaint")
against the Company, two of its directors and BioChem. The claims against the
Company seek principally the following: declaratory relief against the Company
regarding the approval and consummation of the private placement of the 4.5%
Convertible Secured Notes due November 13, 2003 (the "4.5% Notes"); injunctive
relief seeking to prevent the Company from consummating the private placement of
the 4.5% Notes (which closed on November 12, 1998); injunctive relief against
the Company relating to Dr. Mates' access to Company books and record and to her
continued service as a director; declaratory relief regarding the termination of
employment and removal as president of the Company; and claims against the
Company alleging abusive discharge and defamation. The Complaint also seeks
actual and punitive damages against the Company in an unspecified amount. In
addition, the Complaint seeks declaratory and injunctive relief against Dr.
Phillip Frost and BioChem arising out of alleged violations of the reporting
requirements of Sections 13(d) and Rule 13d-1(a) of the 1934 Act and unspecified
damages from BioChem and Drs. Frost and Francesco Bellini (chief executive
officer of BioChem) for tortious interference with Dr. Mates' business relations
with the Company. See Item 13 - Certain Relationships and Related Transactions.
In December 1998, the Company filed a motion to dismiss the Complaint in
its totality. BioChem and Drs. Frost and Bellini have also filed motions to
dismiss Dr. Mates' claims. The Company intends to continue to vigorously contest
and defend against the claims in this litigation. The Company believes that the
claims against it are without merit, that the Company has meritorious defenses
available to it, and that certain claims may be covered by insurance. Under the
terms of the Company's By-laws and indemnification agreements with directors,
the Company is obligated to indemnify directors against certain claims. The
Company is presently evaluating the extent of its indemnification obligations
and available insurance coverage. In the opinion of management, this lawsuit
will not have a material adverse effect on the Company. If, however, litigation
costs, including indemnification obligations, and judgments against the
defendants exceed the Company's available insurance coverage, this litigation
could have a material adverse effect on the Company's financial condition and
results of operations.
The Company is, and from time to time becomes, involved in claims and
lawsuits that are incidental to its business. In the opinion of the Company's
management, there are no other material legal proceedings pending against the
Company.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
---------------------------------------------------
None.
- 32 -
<PAGE>
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER
MATTERS
--------------------------------------------------------------------
The Company's Common Stock is listed on the American Stock Exchange
("AMEX") under the symbol "NVX." The table below sets forth the high and low
closing sales prices as reported on the AMEX composite tape for each calendar
quarter of 1997 and 1998:
High Low
---- ---
1997
First Quarter $27 1/2 $19 3/4
Second Quarter 21 17 1/2
Third Quarter 25 1/2 18 5/8
Fourth Quarter 29 3/4 22 7/16
1998
First Quarter 25 16 5/8
Second Quarter 20 1/4 15 1/4
Third Quarter 17 7/16 6 5/8
Fourth Quarter 15 7/8 7 3/8
On January 20, 1999, the last reported sales price of the Company's Common
Stock on the AMEX was $7.50 per share. The number of record holders of the
Company's Common Stock as of January 20, 1999 was approximately 266.
The transfer agent and registrar for the Company's Common Stock is
American Stock Transfer and Trust Company, which is located at 40 Wall Street,
New York, New York 10005.
The Company has never paid cash dividends on its Common Stock and
anticipates that its earnings, if any, will be retained for development of the
Company's business. Therefore, it is not anticipated that any cash dividends on
its Common Stock will be declared in the foreseeable future. The payment of any
future dividends will be at the discretion of the Company's Board of Directors
and will depend upon, among other things, future earnings, operations, capital
requirements, the general financial condition of the Company, general business
conditions and tax considerations.
Any profits earned by its U.S. subsidiary will not be distributable
directly to shareholders. Instead, for those profits to be distributed to
shareholders, the subsidiary must declare a dividend to the Company, and the
Company in turn must declare a dividend to its shareholders. Because the Company
is a Canadian corporation, this will subject each dividend to a withholding tax.
First, the dividend from the subsidiary to the Company will be subject to a 5%
withholding tax imposed by the United States on the gross amount of the
dividend. Pursuant to the Canada-United States Income Tax Convention (1980) (the
"Treaty"), the subsequent dividend paid by the Company to a shareholder resident
in the United States will be subject to Canadian withholding tax at the rate of
15% on the gross amount of the dividend. The rate of withholding tax will be
reduced to 5% in respect of dividends paid to a company that is a resident of
the United States for purposes of the Treaty and owns at least 10% of the voting
stock of the Company. Each shareholder should consult his or her own tax advisor
as to tax consequences associated with dividends received on the Company's
Common Stock.
- 33 -
<PAGE>
If more than a certain percentage of the Company's assets or income is
passive, the Company will be classified for United States tax purposes as a
passive foreign investment company or PFIC, and a United States taxpayer may be
subject to an additional federal income tax on receiving certain dividends from
the Company or selling Common Stock. Certain interest, dividend, capital gain
and royalty income may be considered passive income for PFIC purposes, which, in
the absence of sufficient other income, would result in the Company being
classified as a PFIC.
If the Company becomes a PFIC, a United States taxpayer will be subject to
special rules with respect to transactions involving the Common Stock. Under
these rules, all gains realized on disposition of the United States taxpayer's
Common Stock will be allocated pro rata over the number of years in which the
shareholder held the Common Stock. The gain that is allocated to a prior year
(subsequent to December 31, 1986) in which the Company was a PFIC, or any
subsequent year other than the year of disposition, will be taxed at the highest
marginal rate for that year and such tax will be subject to an interest charge
as if it had originally been due in that year. In addition, gain realized on the
disposition of the United States taxpayer's Common Stock that is allocated to
the current year or to a prior year before the Company was a PFIC will be
treated as ordinary income. Similar rules will apply to distributions made by
the Company. The above rules will not apply if the United States taxpayer elects
to treat the Company as a qualified electing fund and the Company agrees to
provide certain information to the United States Internal Revenue Service. In
such case, the United States taxpayer will include in his or her income each
year his or her pro rata share of the ordinary income and capital gains of the
Company. The Company has not been classified as a PFIC to date, and during 1999,
the Company intends to, and believes that it can, generate sufficient other
income and will hold sufficient non-passive assets to avoid being classified as
a PFIC. This is a forward looking statement, and the factors affecting the
Company's ability to avoid being classified as a PFIC include the nature and
source of its revenues, and classification of its assets. See Item 1 Business
Risk Factors and Item 7 - Management's Discussion and Analysis of Financial
Condition and Results of Operation.
On November 12, 1998, the Company completed a $25 million financing
through the private placement of the 4.5% Notes. The 4.5% Notes were sold at par
by the Company. The 4.5% Notes are convertible, in whole or in part, by the
holder(s) at any time prior to maturity (unless previously redeemed or
repurchased) into shares of the Company's Common Stock at a conversion price of
approximately $8.54 per share.
The net proceeds from the offering of approximately $24.6 million are to
be used for marketing and distribution of first commercial products, research
and development, clinical trials, capital expenditures (including construction
or acquisition of additional facilities and purchase of equipment) protection of
patent rights, and general corporate purposes and working capital. The 4.5%
Notes were issued to certain existing shareholders, affiliates and accredited
investors, including BioChem and Phillip Frost, M.D., which purchased 4.5% Notes
in the aggregate principal amount of $9 million and $4.25 million, respectively.
The 4.5% Notes are not registered under the Securities Act of 1933, as amended
(the "Securities Act"), or any applicable state or foreign securities laws, and
were sold in reliance on prescribed exemptions from registrations under the
Securities Act, including Regulation D, and other applicable state or foreign
securities laws. See Item 7 - Management's Discussion and Analysis of Financial
Condition and Results of Operation and Item 13 - Certain Relationships and
Related Transactions.
- 34 -
<PAGE>
ITEM 6. SELECTED FINANCIAL DATA
-----------------------
Selected consolidated financial data for the Company are set forth below.
The selected financial data as of December 31, 1998 and 1997, and for the years
ended December 31, 1998, 1997 and 1996 have been derived from, and are qualified
by reference to, the audited financial statements included elsewhere in this
Annual Report. The selected financial data as of December 31, 1996, 1995 and
1994 and for the years ended December 31, 1995 and 1994 have been derived from
the audited financial statements of the Company not included in this Annual
Report. The selected consolidated financial data should be read in conjunction
with the financial statements of the Company and other financial information
included in this Annual Report.
- 35 -
<PAGE>
<TABLE>
<CAPTION>
NORTH AMERICAN VACCINE, INC. AND SUBSIDIARIES
SELECTED CONSOLIDATED FINANCIAL DATA
(IN THOUSANDS, EXCEPT PER SHARE DATA)
Fiscal Years Ended December 31,
1998 1997 1996 1995 1994
---- ---- ---- ---- ----
STATEMENT OF OPERATIONS DATA:
Revenues:
<S> <C> <C> <C> <C> <C>
Marketing, research and development agreements $ 6,149 $ 8,001 $ 9,656 $ 3,000 $ -
Product sales
2,230 1,699 892 - -
----------- ----------------- -------------- ------------ -------------
Total revenues 8,379 9,700 10,548 3,000 -
Operating Expenses:
Production 19,196 18,662 14,764 6,317 6,188
Research and development 17,986 19,860 11,594 10,206 5,763
General and administrative 10,800 11,386 6,753 6,696 4,543
----------- ----------------- -------------- ------------ -------------
Total operating expenses 47,982 49,908 33,111 23,219 16,494
----------- ----------------- -------------- ------------ -------------
Operating loss (39,603) (40,208) (22,563) (20,219) (16,494)
Gain on sale of investments in affiliates - - 4,228 14,429 11,929
Interest and dividend income 1,497 3,140 2,934 804 638
Interest expense (18,503) (6,772) (4,088) - -
----------- ----------------- -------------- ------------ -------------
Net loss $(56,609) $ (43,840) $(19,489) $ (4,986) $(3,927)
----------- ----------------- -------------- ------------ -------------
Basic and diluted net loss per share $ (1.76) $ (1.39) $ (0.63) $ (0.17) $(0.14)
=========== ================= ============== ============ =============
Weighted-average number
of common shares outstanding 32,152 31,641 30,764 29,745 28,785
BALANCE SHEET DATA:
Cash and cash equivalents $ 22,953 $ 45,502 $ 70,881 $ 10,443 $20,922
Investment in affiliates, at market 1,554 843 1,281 9,065 17,724
Total assets 64,525 84,508 122,962 41,249 49,580
6.5% Convertible subordinated notes 83,734 83,734 86,250 - -
4.5% Convertible secured notes 25,000 - - - -
Long-term portion of capital lease 2,356 4,110 5,871 - -
Preferred stock 6,538 6,538 6,538 6,538 6,538
Common stock 80,824 78,509 71,357 58,474 56,922
Additional Paid-in capital 11,956 - - - -
Cumulative comprehensive income excluded
from net loss 926 215 653 7,466 14,762
Accumulated deficit (159,218) (102,609) (58,769) (39,280) (34,294)
Dividends - - - - -
</TABLE>
- 36 -
<PAGE>
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATION
--------------------------------------------------------------------
THE FOLLOWING PARAGRAPHS IN THIS ANNUAL REPORT CONTAIN CERTAIN FORWARD
LOOKING STATEMENTS, WHICH ARE WITHIN THE MEANING OF AND MADE PURSUANT TO THE
SAFE HARBOR PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
THESE FORWARD LOOKING STATEMENTS INCLUDE, WITHOUT LIMITATION, THOSE REGARDING
THE PROSPECTS FOR REGULATORY APPROVAL, THE PROSPECTS FOR MARKETING AND
DISTRIBUTION OF VACCINE PRODUCTS, THE PROSPECTS FOR INCREASING PRODUCTION
CAPACITY AND EFFICIENCY, THE PROSPECTS FOR AND FACTORS AFFECTING FUTURE REVENUES
AND PROFITABILITY, LIKELIHOOD OF ADDITIONAL FUNDING UNDER LICENSE, MARKETING,
DISTRIBUTION AND/OR DEVELOPMENT AGREEMENTS OR FROM FURTHER FINANCINGS, PROJECTED
RESULTS FROM OPERATIONS, CASH REQUIREMENTS FOR FUTURE OPERATIONS, AND PROJECTED
CAPITAL EXPENDITURES. READERS ARE CAUTIONED THAT FORWARD LOOKING STATEMENTS
INVOLVE RISKS, UNCERTAINTIES, AND FACTORS THAT MAY AFFECT THE COMPANY'S BUSINESS
AND PROSPECTS, INCLUDING WITHOUT LIMITATION THOSE DESCRIBED BELOW AS WELL AS THE
RISKS ASSOCIATED WITH: OBTAINING REGULATORY APPROVAL OF PRODUCTS BY REGULATORY
AGENCIES INCLUDING THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA); THE
PRODUCTION OF VACCINES; THE NATURE OF COMPETITION; NEED FOR EFFECTIVE MARKETING;
DEPENDENCE ON SUPPLIERS, INCLUDING STATENS SERUM INSTITUT ("SSI"); AND
UNCERTAINTIES RELATING TO CLINICAL TRIALS, ALL AS DISCUSSED IN THIS MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, AND
ELSEWHERE IN THIS ANNUAL REPORT AND THE COMPANY'S FILINGS WITH THE U.S.
SECURITIES AND EXCHANGE COMMISSION ("SEC"), TO WHICH THE READER'S ATTENTION IS
DIRECTED.
BACKGROUND
----------
The Company is engaged in the research, development, production, and sale
of vaccines for the prevention of infectious diseases in children and adults.
In July 1998, the Company received FDA approval to manufacture and market
Certiva(TRADEMARK), its DTaP vaccine, in the United States. Under the FDA
approval, Certiva(TRADEMARK) is indicated for active immunization against
diphtheria, tetanus and pertussis (whooping cough) in infants and children six
weeks to seven years of age. The Company produces the monocomponent acellular
pertussis toxoid and formulates the final product with diphtheria and tetanus
toxoids manufactured and supplied by SSI.
The Company is marketing Certiva(TRADEMARK) and the combination vaccines
to government purchasers, including federal and state government agencies. Under
a marketing agreement between the Company and Abbott Laboratories ("Abbott"),
Abbott markets Certiva(TRADEMARK) to private physicians and managed care
organizations in the United States. Abbott began the launch of
Certiva(TRADEMARK) in October 1998 and the Company began its launch of
Certiva(TRADEMARK) during November 1998. Under the marketing agreement, the
Company will receive revenue from Abbott as it purchases Certiva(TRADEMARK) for
- 37 -
<PAGE>
resale to the private pediatric market in the United States.
The Company and Abbott are collaborating in the clinical development of
the combination vaccines, and the Company will receive payments upon achievement
of prescribed clinical development milestones. Under the agreement, Abbott will
market those combination vaccines following approval to private physicians and
managed care organizations in the United States, and the Company will receive
revenues from Abbott as it purchases the combination vaccine products for
resale.
FDA approval of Certiva(TRADEMARK) followed regulatory approval in various
European countries of vaccines using the Company's acellular pertussis vaccine.
The Swedish Ministry of Health granted regulatory approval in February 1996 to
market a European formulation of Certiva(TRADEMARK). This marketing
authorization was the first regulatory approval for any of the Company's
products. In addition, the Danish National Board of Health granted regulatory
approval in September 1996 of the DTaP vaccine combined with an enhanced
inactivated polio vaccine ("DTaP-IPV") for all primary and booster doses for
infants and children in Denmark. The Company has been advised that the
regulatory authorities in Germany, Austria, Sweden and Finland have agreed to
recognize the Danish marketing authorization for the DTaP-IPV vaccine and will
issue national marketing authorizations in one or more of these countries in the
near future. There can be no assurance that these national marketing
authorizations will be issued in a timely fashion as the application process is
principally the responsibility of the Company's European partners, over whom the
Company has no control. The Company has appointed Chiron Behring to market and
distribute the DTaP-IPV product in Germany and Austria. SSI holds all European
product registrations and is marketing and distributing the products in the
Scandinavian, Baltic and other countries comprising its territory ("SSI's
Territory").
Under supply agreements, the Company manufactures the acellular pertussis
component, and SSI manufactures the diphtheria, tetanus and inactivated polio
vaccine ("IPV") components for the DTaP and DTaP-IPV vaccines. SSI is
responsible for the marketing and distribution of the DTaP and DTaP-IPV products
in SSI's Territory. Accordingly, the Company has been selling its acellular
pertussis toxoid to SSI for formulation into DTaP and DTaP-IPV for sale in SSI's
Territory.
In 1997 and 1996, the Company recognized development revenues pursuant to
agreements with Pasteur Merieux Connaught, under which the Company and Pasteur
Merieux Connaught will jointly develop the Company's Group B meningococcal
vaccine. Additional funding may be provided to the Company by Pasteur Merieux
Connaught under the terms of the license and clinical development agreements.
In May 1996, the Company completed an offering of 6.5% convertible
subordinated notes in the principal amount of $86.25 million due in full on May
1, 2003 ("6.5% Notes"). The 6.5% Notes are convertible into the Company's Common
Stock at an initial conversion price of approximately $24.86 per share,
equivalent to a conversion rate of 40.2293 shares per $1,000 principal amount of
the 6.5% Notes. Interest on the notes is payable semiannually on May 1 and
November 1 each year. In December 1997, approximately $2.5 million of the
- 38 -
<PAGE>
principal amount of the 6.5% Notes was converted into 101,207 shares of the
Company's Common Stock. As of December 31, 1998, the principal amount of the
outstanding notes was $83.7 million.
In November 1998, the Company completed a private placement of $25 million
aggregate principal amount of 4.5% Convertible Secured Notes due November 13,
2003 ("4.5% Notes"). The 4.5% Notes are convertible into the Company's Common
Stock at an initial conversion price of approximately $8.54 per share,
equivalent to a conversion rate of 117.0878 shares per $1,000 principal amount
of the 4.5% Notes. The conversion price was set based on the average closing
price per share of the Company's Common Stock for the twenty (20) trading days
preceding the date of the announcement of the agreement-in-principle. The
measurement period for determining the conversion price began on August 26, 1998
and terminated on September 23, 1998. The closing prices per share of the
Company's Common Stock during that period ranged from a low of $6.875 to a high
of $11.25. The 4.5% Notes are secured by certain assets of the Company, are
otherwise subordinated in right of payment to all existing and future senior
indebtedness of the Company, do not restrict the incurrence of future senior or
other indebtedness of the Company and will be redeemable, in whole or in part,
at the option of the Company on or after November 13, 1999. Upon a change in
control, the Company will be required to offer to purchase all of the 4.5% Notes
then outstanding at a purchase price equal to 100% of the principal amount
thereof, plus interest. The repurchase price will be payable in cash or, at the
option of the Company, in shares of the Company's Common Stock. The 4.5% Notes
were issued to certain existing shareholders, affiliates and accredited
investors, including BioChem Pharma Inc. and Phillip Frost, M.D., which
purchased 4.5% Notes in the principal amount of $9 million and $4.25 million,
respectively. In addition, Societe financiere d'innovation inc. ("Sofinov"), a
high technology investment fund that is a subsidiary of La Caisse de depot et
placement du Quebec, purchased 4.5% Notes in the aggregate principal amount of
$6.25 million. Denis Dionne, a director of the Company, is the President of
Sofinov.
In November 1996, the Company acquired a 35,000 square foot manufacturing
facility in Beltsville, Maryland through the assumption of real estate leases
and the purchase and lease of equipment and leasehold improvements. The total
acquisition cost for the equipment and leasehold improvements was approximately
$24.9 million, which included a cash payment of $17.2 million. The balance of
$7.7 million is represented by an equipment lease obligation accounted for as a
capital lease, which expires in 2000. In April 1998, as permitted by the
equipment lease agreement, the Company posted a letter of credit in the amount
of $5.9 million, thereby suspending the application of all financial covenants
set forth in the equipment lease agreement. The letter of credit decreases on a
monthly basis as the payments on the lease obligation are made and is secured by
a restricted cash deposit of an equal amount. The balance of the letter of
credit and the corresponding restricted cash is $4.9 million at December 31,
1998. The letter of credit will expire by its terms on November 1, 2000. In
addition, the Company has assumed the real estate leases underlying the
facility, which are scheduled to expire in February 2001, but may be extended
through 2011.
In March, 1998, the Company leased an approximately 75,500 square foot
facility to be used for research, development, general and administrative
functions and for future expansion of the Company's operations (the "Research
Facility"). The lease is for an initial term of ten years, with two five year
renewal options. The initial annual base rent under the lease is approximately
$981,000 with minimum annual escalations. At the end of the fifth year of the
initial term, the Company has the right to terminate the lease for a specified
- 39 -
<PAGE>
fee. In addition, the Company has an option to purchase the Research Facility
during specified periods of the lease term. During 1998, the landlord provided
the Company a tenant improvement allowance of $1.4 million, all of which was
utilized during 1998. In addition, the landlord extended a line of credit to the
Company for an additional $1.8 million, if needed, to fund improvement costs in
excess of the tenant improvement allowance. The line of credit will expire in
March 1999. Monthly payments under this line of credit would consist of interest
only accruing at the simple annual rate of 12.75% and the entire unpaid
principal balance would mature in September 2000, unless extended by the Company
to March 2002. The line of credit would be secured by all leasehold improvements
and related facility enhancements purchased with funds provided by the landlord.
No funds have been drawn down under this line of credit.
Research and development expenses were $18.0 million, $19.9 million, and
$11.6 million in 1998, 1997, and 1996, respectively. The Company had 308, 260,
and 206 full-time employees as of December 31, 1998, 1997, and 1996,
respectively.
RESULTS OF OPERATIONS
---------------------
YEARS ENDED DECEMBER 31, 1998 AND 1997
In the fourth quarter of 1998, the Company realized its first sales from
the launch of Certiva(TRADEMARK) in the U.S. to government purchasers and to
Abbott for distribution in the private market. Total product sales in 1998 were
approximately $2.2 million of which approximately $1.2 million were from sales
of Certiva(TRADEMARK) to several government agencies and approximately $1
million were from sales of product to SSI. In addition, during 1998, the Company
recognized $6.1 million consisting primarily of milestone payments and
development funding under the Company's agreement with Abbott and to a lesser
extent milestone payments under a supply and distribution agreement with Chiron
Behring. Revenue in 1997 consisted of $1.7 million from product sales to SSI and
$8.0 million of revenue from collaborative agreements of which $6.0 million was
from an agreement with Pasteur Merieux Connaught.
Production expenses were $19.2 million in 1998 compared to $18.7 million
in 1997. The increase in these expenses in 1998 is primarily attributable to an
increase in the number of production and service-related employees as the
Company prepared for regulatory approval of Certiva(TRADEMARK). The increase was
offset in part by lower depreciation expense related to the use of an
accelerated depreciation method and to the capitalization of Certiva(TRADEMARK)
inventory for sale in the United States following FDA approval. Costs
attributable to Certiva(TRADEMARK) production were expensed until regulatory
approval was obtained in July 1998. Since FDA approval, production costs have
exceeded the net realizable value of inventory produced, which excess has been
recorded as production expenses incurred in 1998.
Research and development expenses were $18.0 million in 1998 compared to
$19.9 million in 1997. The decrease is attributable primarily to lower
depreciation expense related to the use of an accelerated depreciation method,
reduced expenses for clinical trials, and reimbursements for expenses under a
collaborative agreement. These decreases were offset in part by higher labor
expenses as a result of an increase in the number of employees and higher
building costs.
- 40 -
<PAGE>
General and administrative expenses were $10.8 million in 1998 as compared
to $11.4 million in 1997. The decrease is due to the recognition of a non-cash
compensation expense of approximately $1.3 million and a non-recurring royalty
payment both incurred in 1997, offset in part by higher labor expenses as a
result of an increase in the number of employees.
Interest and dividend income decreased to $1.5 million in 1998 from $3.1
million in 1997. This reduction is due primarily to a decrease in the average
cash balance.
Interest expense increased to $18.5 million in 1998 from $6.8 million in
1997. Approximately $12.0 million of this increase is due to a beneficial
conversion feature of the 4.5% Notes resulting in a non-recurring, non-cash
interest expense charge. See "Tax and Other Matters," below. Interest expense
also increased as a result of the accrual of interest on the 4.5% Notes. These
increases were partially offset due to principal payments made on the equipment
lease, as well as to the conversion of $2.5 million principal amount of the 6.5%
Notes into shares of the Company's Common Stock in December 1997.
The factors cited above resulted in a net loss of $56.6 million or $1.76
per share in 1998. Without the effect of the non-recurring non-cash interest
charge of $12.0 million, the loss in 1998 would have been $44.6 million or $1.39
per share. This compares to a net loss of $43.8 million or $1.39 per share in
1997. Without the effect of the $1.3 million non-cash compensation expense, the
loss in 1997 would have been $42.5 million or $1.34 per share. The
weighted-average number of shares of the Company's Common Stock outstanding was
32.2 million for 1998 compared to 31.6 million for 1997. The increase in the
number of weighted-average shares outstanding for 1998 as compared to 1997 is
attributable primarily to the exercise of stock options and the conversion of
$2.5 million principal amount of the 6.5% Notes into 101,207 shares of the
Company's Common Stock in December 1997.
YEARS ENDED DECEMBER 31, 1997 AND 1996
In 1997, the Company recognized $1.7 million in revenue from product sales
to SSI, compared to $892,000 in 1996. In addition, in 1997 the Company
recognized $8.0 million under collaborative agreements, compared to $9.7 million
in 1996. Revenue in 1997 from collaboration agreements consists of a $6 million
milestone payment from Pasteur Merieux Connaught under the license and
development agreements covering the Company's Group B meningococcal vaccine,
with the balance representing revenue attributable to development funding under
the Company's agreement with Abbott. Revenue from collaborative agreements in
1996 were principally with Abbott and Pasteur Merieux Connaught.
Production expenses were $18.7 million in 1997 compared to $14.8 million
in 1996. The increase in these expenses in 1997 is due to increases in
materials, labor, and facilities operating costs as the Company produced its
acellular pertussis vaccine for European distribution and prepared for
regulatory approval of Certiva(TRADEMARK) in the United States. The increase in
labor cost is attributable primarily to an increase in the number of employees.
Production costs attributable to the Company's products are expensed until
regulatory approval is obtained for such product.
- 41 -
<PAGE>
Research and development expenses increased to $19.9 million in 1997 from
$11.6 million in 1996. The increase is attributable primarily to higher
depreciation and operating costs for development work in the manufacturing
facility acquired in November 1996, and to a lesser extent, labor and supplies
as a result of an increase in the number of employees, and costs to prepare and
file product license applications. These increases were offset in part by lower
clinical testing and related expenses.
General and administrative expenses were $11.4 million in 1997 as compared
to $6.8 million in 1996. Approximately $2.0 million of this increase is due to
the combined effect of the recognition of non-cash compensation expense in the
amount of approximately $1.3 million, related to the extension of the term of
one expiring stock option grant, and to a one-time technology license fee
payment. The remaining increase is attributable to higher labor costs as a
result of an increase in salaries and the number of employees, as well as
professional service costs.
In the first quarter of 1996, the Company sold 193,084 shares of its
investment in common stock of IVAX Corporation ("IVAX"), which generated
proceeds of approximately $5.2 million, and a realized gain of $4.2 million.
Interest and dividend income increased to $3.1 million in 1997 from $2.9
million in 1996. This increase is due primarily to higher average cash balances
as a result of the placement of the 6.5% Notes for $86.25 million in May 1996.
Interest expense increased to $6.8 million in 1997 from $4.1 million in
1996 due to the Company's interest obligations under the 6.5% Notes and an
equipment lease accounted for as a capital lease.
The factors cited above resulted in a net loss of $43.8 million or $1.39
per share in 1997 as compared to a net loss of $19.5 million or $0.63 per share
in 1996. Without the effect of the non-cash expense related to the extension of
an expiring stock option, the net loss in 1997 would have been $42.5 million or
$1.34 per share. Without the $4.2 million gain on the sale of investment
securities in 1996, the net loss per share for 1996 would have been $0.77. The
weighted-average number of shares of the Company's Common Stock outstanding was
31.6 million for 1997 compared to 30.8 million for 1996. The increase in the
number of weighted-average shares outstanding for 1997 as compared to 1996 is
attributable primarily to the exercise of stock options, the sale of 350,000
shares of the Company's Common Stock to Abbott in the fourth quarter of 1996,
and the conversion of a portion of the outstanding 6.5% Notes as described
above.
LIQUIDITY AND CAPITAL RESOURCES; OUTLOOK
----------------------------------------
The Company's cash requirement for operations for the fourth quarter and
year-ended December 31, 1998 was $12.6 million and $42.7 million, respectively.
For the quarter and year ended December 31, 1997, cash requirements for
operations were $10.5 million and $37.9 million, respectively. The Company's
cash requirement for operations is the net cash used in operating activities for
the period being reported less amounts received under license, marketing,
- 42 -
<PAGE>
distribution and/or development agreements and further adjusted by the timing of
proceeds from the sale of an investment in an affiliate.
At December 31, 1998, the Company had cash and cash equivalents of
approximately $23.0 million, and investment securities in an affiliate with a
market value of $1.6 million. The investment consisted of 125,000 shares of IVAX
common stock. The fair market value of such stock as of January 18, 1999 was
approximately $1.5 million. This investment is volatile and therefore subject to
significant fluctuations in value. In addition, the Company had $4.9 million of
restricted cash pledged as collateral under the letter of credit agreement,
which will be reduced in amount as payments are made under the equipment lease
described above.
PROJECTED RESULTS FROM OPERATIONS. The Company anticipates that it will
report a net loss of between $8.0 and $9.0 million for each of the first and
second quarters of 1999, and that it will likely continue to incur quarterly net
operating losses during the second half of 1999, although projected to be in
lesser amounts, based upon several factors. The factors contributing to the
projected losses include, among others: limited projected revenues; current
manufacturing limitations; the timing and amount of milestone payments under
existing collaboration agreements; and the timing and amount of up-front and
other payments under anticipated license, distribution, marketing and
collaboration agreements, all as more completely discussed in the following
paragraphs.
As described above, quarterly operating results will be affected by the
revenue associated with the launch of Certiva(TRADEMARK), which began during the
middle of the fourth quarter of 1998. Initial revenues from the sale of
Certiva(TRADEMARK), although encouraging, were limited and the reported net
sales during the fourth quarter of 1998 were approximately $1.2 million,
representing approximately a six percent (6%) market share in the public sector
for that period. The Company anticipates growing but limited revenues during
1999 as Certiva(TRADEMARK) continues to be introduced to U.S. pediatricians and
other vaccine purchasers and as its acellular pertussis toxoid is sold to SSI
for further manufacturing and sale in SSI's Territory. Moreover, the Company's
national marketing authorization for the sale and distribution of its DTaP-IPV
vaccine is pending in Germany and Austria. The Company is presently developing,
with Chiron Behring, a product launch schedule, which should contribute to
further revenues during 1999. For the reasons described below, however, revenues
associated with Certiva(TRADEMARK) sales and further product launches are not
expected to be sufficient to achieve profitability during 1999 and into 2000.
As noted above, quarterly operating results will be affected by various
manufacturing limitations. The Company's manufacturing facility has limited
production capacity based on the present size, configuration, equipment,
processes and methods utilized to produce Certiva(TRADEMARK) and its acellular
pertussis toxoid. In addition, production expenses are mainly fixed and consist
primarily of expenses relating to the operation of its production facility and
maintaining a ready work force. Further, from time to time, the Company
experiences disruptions and production failures. These disruptions and failures
increase unit production costs as units are lost in the production process.
These factors have contributed to higher production costs for the Company's
acellular pertussis products, which costs currently exceed their net realizable
value. These excess costs are expensed in the quarter incurred. Thus, during the
first three quarters of 1999, the Company expects that costs to produce
Certiva(TRADEMARK) and the acellular pertussis toxoid will exceed their
respective net selling prices.
- 43 -
<PAGE>
The Company is modifying its existing facilities and operations in a
manner intended to significantly expand production capacity and efficiency.
These enhancements are presently scheduled to be completed in the latter half of
1999. Following completion of these enhancements, the Company believes that the
manufacturing facility will have substantially increased production capacity and
output, that unit production costs will be reduced significantly and that
Certiva(TRADEMARK) would be produced in sufficient quantities to generate a
gross profit based on current known pricing arrangements, current competitive
environment, and projected mix of customer purchases.
Finally, as noted above, future operating results are dependent upon the
amount and timing of further milestone and other payments under existing and new
license, distribution or development agreements. During 1999, the Company will
be continuing its development efforts for several products, including those
covered by existing marketing, license and research agreements. As noted above,
the Company is entitled under those agreements to milestone payments upon
achievement of prescribed events. In addition, the Company is entitled to be
paid for certain prescribed development costs as incurred. The milestone
payments under the existing agreements are tied to measured progress in the
regulatory process for the Company's combination and Group B meningococcal
vaccines. Although initial clinical development plans have been completed for
these products, and clinical trials are projected to commence during 1999, there
are no assurances that such milestone events will occur during 1999, or at all,
or that any such payments will contribute materially to quarterly net operating
results.
In addition, the Company is considering executing further distribution
agreements for its products in certain markets throughout the world. The Company
also has identified certain vaccines for which it intends to seek collaborative
agreements for the purpose of expediting the further development and
commercialization of the targeted products. The Company has begun this process
with the intention of expeditiously completing these additional collaborative
agreements. The Company is also in various stages of discussions with third
parties regarding various business arrangements. There are no assurances that
the Company will successfully negotiate and sign any such agreements or that, if
executed, the financial terms for any such agreement will be significant.
The foregoing paragraphs include forward looking statements including
statements as to: revenue projections and assessments for further regulatory
approvals; the ability of the Company to timely and efficiently expand its
production capacity and lower unit costs; the ability of the Company to address
production failures; among others. The factors that affect the level of future
revenues from product sales include, among other things, the ability of the
Company and its distribution partners to effectively position the Company's
products against competitive products (including safety, efficacy, and pricing),
the Company's ability to manufacture and deliver products in accordance with
customer orders, the timing and amount of product orders, and the timing of
future product launches. The factors that affect the ability of the Company to
timely and efficiently expand its production capacity include, among others, the
adequacy of engineering designs, the availability of needed equipment, the
manufacturing experience with these enhancements, the timeliness of regulatory
review of modifications, and the acceptability of such modifications to the
applicable regulatory authorities. There can be no assurances that the Company's
plans to increase production capacity and output will be effective or result in
- 44 -
<PAGE>
anticipated production efficiencies and reduced unit cost or will be acceptable
to any regulatory agency. In addition, there are no assurances that the steps
taken by the Company to address production disruption and failures will be
effective or that failures will not continue in the future. Production
disruptions or failures could have a material adverse effect on the Company's
future operating results and could affect the Company's existing licenses as
well as any applications for approval for its products or the timing of such
approval. No assurances can be given that the Company will be successful in
maintaining consistent and continuous commercial production of its products.
Further, because the Company's manufacturing operations are located principally
in one facility, any condition or event that adversely affects the condition or
operation of such facility would have a material adverse affect on the Company's
financial condition and future results of operations.
PROJECTED CASH REQUIREMENTS FOR OPERATIONS. The cash requirements for
operations in the first quarter of 1999 are projected to be between $8.5 and
$9.5 million and between $36.0 and $42.0 million for 1999. The first quarter
cash requirement is anticipated to be lower than that incurred in the fourth
quarter of 1998 due primarily to the semi-annual interest payment of $2.7
million on the 6.5% Notes paid on November 1, 1998. The foregoing is a forward
looking statement and the factors which affect the actual cash required for
operations could include, among other things: the production levels of vaccine
product for commercial sale; the production of vaccine for clinical
investigations; marketing costs associated with the launch of Certiva(TRADEMARK)
in the United States; timing of regulatory authorization to commence clinical
investigations; timing for the commencement of planned clinical trials; and the
level of expenditures for the Company's ongoing research and development
program.
CAPITAL EXPENDITURES. Total capital expenditures for 1998 were $2.3
million, excluding a $1.4 million tenant improvement allowance provided to the
Company under the terms of the Research Facility lease. As noted above, the
Company is expanding its manufacturing capacity and efficiency for its acellular
pertussis toxoid and Certiva(TRADEMARK). Total projected capital expenditures
for 1999 for facilities' modifications, equipment, systems and other capital
additions could range between $3 million to $5 million, with about $1.5 to $2.0
million to be expended in the first quarter of 1999. The foregoing include
forward looking statements. The amount of and timing for capital expenditures
could fluctuate based upon a number of factors including, without limitation:
the equipment purchases required in order to expand the Company's production
capacity and the amount and timing of unanticipated costs to replace or repair
existing equipment and systems in order to keep facilities operational and in
compliance with regulatory requirements.
FUNDING SOURCES. To maintain the Company's production, research,
development and growth at current levels, present cash and cash equivalents,
expected product sales of Certiva(TRADEMARK) and the Company's other products,
and revenues from existing collaborative agreements are not expected to provide
sufficient cash to fund the Company's operations, debt service payments and
capital expenditures in 1999 and into 2000. As a result, the Company intends to:
enter into new license, marketing, distribution and/or development agreements
that are currently under active discussion; liquidate its investment securities;
enter into a sale and lease-back of the Company's one owned facility; and obtain
one or more lines of credit, which may be secured by accounts receivable,
inventory or other assets of the Company. The Company believes that it may meet
1999 cash requirements for operations through these efforts, although there are
- 45 -
<PAGE>
no assurances in this regard. This is a forward looking statement and the
factors that will determine whether the Company will require additional funding
include, without limitation, the amount and timing of product sales, the amount
and timing of payments under existing and new collaborative agreements and the
amount of any proceeds from other previously identified funding sources.
If the Company is unable to complete one or more of these transactions
and/or proceeds from the transactions are inadequate, the Company would be
required to obtain additional funding through the sale of debt and/or equity
securities. The Company has no current plans, agreements, commitments,
arrangements, or understandings relating to the placement or issuance of any
securities. During the course of the year, the Company will evaluate its need
for additional debt or equity financing to meet its cash requirements for 1999
and 2000. If the Company determines that such additional financing is required
but is not available, then the Company would have to reduce its cash
requirements through significant reductions in operating levels. There can be no
assurances that the Company will be able to obtain debt or equity financing on
favorable terms or in amounts required to meet future cash requirements, or that
the Company, if necessary, would be successful in reducing operating levels, or
that if operating levels are reduced, the Company would be able to maintain
operations for any extended period of time.
The foregoing paragraphs contain only a partial description of the factors
affecting the Company's business prospects and risk factors affecting future
operations. Reference is made to the risk factors and other information
described elsewhere in this management's discussion and analysis of financial
condition and results of operations, including in the first paragraph hereof,
and appearing elsewhere in this Annual Report and in the Company's filings with
the SEC, for a more complete description of the risks and uncertainties
affecting the Company and its business.
TAX AND OTHER MATTERS
---------------------
ACCOUNTING AND TAX IMPACT OF CONSUMMATION OF SALE OF THE 4.5% NOTES
("OFFERING"). On November 12, 1998, the date on which the 4.5% Notes were
issued, the closing price of the Company's Common Stock was $12.625. As this
price exceeded the conversion price for the 4.5% Notes, the Company recognized
an approximately $12 million beneficial conversion feature, which was recorded
as paid-in capital in the fourth quarter of 1998. The amount recorded to paid-in
capital was calculated by multiplying the total number of shares then issuable
upon conversion of the 4.5% Notes by the difference between the closing price on
the issuance date and the conversion price. This discount also was deemed to be
an increase in the effective interest rate of the 4.5% Notes to be reflected as
a charge to interest expense and amortized over the period from the issuance
date to the date the 4.5% Notes first become convertible. Given that the 4.5%
Notes are immediately convertible, the Company recognized a corresponding
one-time interest charge of approximately $12 million in the fourth quarter of
1998. This interest expense is not deductible for U.S. or Canadian income tax
purposes.
In addition, with recent amendments to the U.S. tax laws, the 4.5% Notes
may be deemed to be disqualified debt instruments, such that the Company would
not be permitted to deduct the annual $1.1 million interest payments for U.S.
federal tax purposes. Under the new law, if there is a substantial certainty
that the 4.5% Notes would be converted as of the date of issuance, they would be
disqualified for deductibility purposes. In the near term, this would reduce the
- 46 -
<PAGE>
Company's net operating losses to be used to offset any future operating
profits, and, if the Company earns any operating profits while the 4.5% Notes
are outstanding, the non-deductibility of the interest payments would
effectively increase the Company's U.S. federal tax liability.
OTHER TAX ISSUES. At December 31, 1998, the Company and its subsidiaries
had income tax loss carry forwards of approximately $30.0 million to offset
future Canadian source income and approximately $94.7 million to offset future
United States taxable income subject to the alternative minimum tax rules in the
United States.
If more than a certain percentage of the Company's assets or income
becomes passive, the Company will be classified for U.S. tax purposes as a
Passive Foreign Investment Company ("PFIC"), and a U.S. taxpayer may be subject
to an additional Federal income tax on receiving certain dividends from the
Company or selling the Company's common stock. The Company has not been
classified as a PFIC to date, and it intends to, and believes that it can,
generate sufficient other income to avoid being classified as a PFIC. This is a
forward looking statement and the factors affecting this classification include,
among other things, the timing and amount of revenue from product sales; the
timing and amount of license fees, milestone payments and development funding
under license, marketing, distribution and development agreements; the
classification of payments received by the Company as active or passive; and the
classification of the Company's assets as active or passive.
NEW ACCOUNTING PRONOUNCEMENTS. In March 1997, the Financial Accounting
Standards Board ("FASB") issued Statement of Financial Accounting Standards
("SFAS") No. 128, "Earnings Per Share." SFAS No. 128 is effective for financial
statements issued for periods ending after December 15, 1997. The Company
implemented SFAS No. 128 in 1997, retroactive for all periods presented. SFAS
No. 128 requires dual presentation of basic and diluted earnings per share.
Basic loss per share includes no dilution and is computed by dividing net loss
available to common stockholders by the weighted average number of shares of
Common Stock outstanding for the period. Diluted loss per share includes the
potential dilution that could occur if securities or other contracts to issue
Common Stock were exercised or converted into Common Stock. Options, warrants
and convertible securities that were outstanding at December 31, 1998, 1997 and
1996, were not included in the computation of diluted loss per share as their
effect would be anti-dilutive. As a result, the basic and diluted loss per share
amounts are identical.
In June 1997, the FASB issued SFAS No. 130, "Reporting Comprehensive
Income" and No. 131, "Disclosures about Segments of an Enterprise and Related
Information." The Company has implemented SFAS 130 beginning with the first
quarter 1998 financial statements. The implementation of this standard did not
result in a material impact to the Company's financial statements. The Company
implemented SFAS No. 131 for the year ended December 31, 1998 and has determined
that it currently does not have reportable segments. Product sales in the United
States were approximately $1.2 million, $0 and $0 for the years ended December
31, 1998, 1997 and 1996, respectively. Product sales to Europe were
approximately $1.0 million, $1.7 million and $900,000 for the years ended
December 31, 1998, 1997 and 1996, respectively. All products are currently being
manufactured at the Company's one production facility in the United States. The
production process, and ultimately product costing, is primarily the same for
all of the Company's acellular pertussis vaccine products sold in the United
States and Europe. Because of this, and the relative consistency in selling
prices, as well as the nature of the distribution methods utilized by the
- 47 -
<PAGE>
Company, the Company does not differentiate and manage its business along
geographic lines.
IMPACT OF THE YEAR 2000 ISSUE ON THE COMPANY
--------------------------------------------
The Year 2000 issue is the result of some computers, software and other
equipment, including computer code, in which calendar year data is abbreviated
to only two digits. Management has initiated a Company-wide program to prepare
the Company's information systems for the year 2000. Based on an internal
interim assessment, the Company believes that the principal management
information system software that is currently being implemented is designed to
be Year 2000 compliant. However, there can be no assurances in this regard. The
Company intends to test the system for Year 2000 compliance.
The Company also uses various "off the shelf" software applications for
the storage and analysis of various types of data and systems. Management is
dependent on this software for day-to-day operations. The Company is currently
in the inventory and assessment phases in which it is evaluating all such
applications and systems, as well as embedded systems, in order to determine
whether or not modifications or replacement will be necessary to achieve Year
2000 qualification. This is an ongoing process and the Company is unable at this
time to assess the impact, if any, this assessment might ultimately have on the
Company's systems and operations or its future financial position and results of
operations. Upon completion of its assessment, the Company will commence any
required remediation, beginning with its mission critical systems.
The Company has not communicated with all of its significant suppliers to
determine the extent to which the Company is vulnerable to failures by such
third parties to remediate their own Year 2000 issues. The Company has not been
advised by its suppliers that costs to obtain Year 2000 compliance will be
passed on to the Company; however, there can be no assurances that such costs
will not be passed through to the Company either directly or indirectly or, if
passed through to the Company, the magnitude of such charges. The systems of
other companies on which the Company's systems rely may not be timely converted.
Accordingly, there are no assurances that the failure by such other companies'
systems to achieve Year 2000 qualification, or qualify in a manner that is
compatible to Company systems, would not have a material adverse effect on the
Company. Upon completion of the assessment phase, the Company intends to develop
contingency plans for various possible scenarios.
The Company has determined that it has no exposure to contingencies
related to the Year 2000 issue for product it has sold. Based on the preliminary
internal assessment, the Company has not identified any material costs or
expenditures specifically related to modifications of information systems for
Year 2000 compatibility. The costs incurred to date in conducting the internal
assessment have not been material. This internal assessment is a continuing
process, consequently there can be no assurances that the Company will not be
required to expend significant amounts on achieving Year 2000 qualification or
that such expenditures will not have a material adverse affect on future results
of operations or financial condition. The Company has not yet developed any
contingency plans for its operations should any of its systems ultimately prove
not to be Year 2000 compliant.
- 48 -
<PAGE>
The foregoing paragraphs contain forward looking statements and the
factors affecting the impact of Year 2000 on the Company include, among others,
the availability and cost of programming and testing resources, vendors' ability
to modify proprietary software, unanticipated problems identified in the ongoing
compliance assessment, and compliance of material third party suppliers and
vendors.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
----------------------------------------------------------
The Company does not have significant exposure to changing interest rates
on invested cash at December 31, 1998. The Company invests in U.S. Treasury
bills and investment grade commercial paper that have maturities of three months
or less. As a result, the interest rate market risk implicit in these
investments at December 31, 1998, is low, as the investments mature within three
months.
The Company had $25 million of 4.5% Convertible Secured Notes at December
31, 1998, which bear interest at 4.5% per annum and mature in November 2003. The
Company does not have significant exposure to changing interest rates related to
the 4.5% Notes because the interest rate on these notes is fixed.
The Company had $83.7 million of 6.5% Convertible Subordinated Notes at
December 31, 1998, which bear interest at 6.5% per annum and mature in May 2003.
The Company does not have significant exposure to changing interest rates
related to the 6.5% Notes because the interest rate on these notes is fixed.
The Company has not undertaken any actions to cover interest market risk
and is not a party to any interest rate market risk management activities.
A hypothetical ten percent change in the market interest rates over the
next year would not materially impact the Company's earnings or cash flow as the
interest rates on the Company's long-term convertible debt are fixed and its
cash investments are short term. A hypothetical ten percent change in the market
interest rate over the next year, by itself, would not have a material adverse
effect on the fair value of the Company's long-term convertible debt or its
short-term cash investments.
The Company does principally all of its transactions in U.S. dollars and
currently has limited payment obligations in Swedish Krona; however, such
obligations are not material to the Company's operations.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
-------------------------------------------
The Financial Statements and accompanying Notes thereto, the Accountants'
Report, required Supplementary Data, and certain other financial information are
set forth on pages 50 to 77 of this Annual Report immediately following. The
table of contents to the Financial Statements and accompanying Notes appears on
page 79 of this Annual Report.
- 49 -
<PAGE>
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
TO NORTH AMERICAN VACCINE, INC.
AND SUBSIDIARIES:
We have audited the accompanying consolidated balance sheets of North
American Vaccine, Inc. (a Canadian corporation) and Subsidiaries as of December
31, 1998 and 1997, and the related consolidated statements of operations,
shareholders' equity (deficit) and cash flows for each of the three years in the
period ended December 31, 1998. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform an audit to obtain
reasonable assurances about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our
opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of North American Vaccine, Inc.
and Subsidiaries as of December 31, 1998 and 1997, and the results of their
operations and their cash flows for each of the three years in the period ended
December 31, 1998, in conformity with generally accepted accounting principles.
/s/ Arthur Andersen LLP
Arthur Andersen, LLP
Baltimore, Maryland
January 18, 1999
- 50 -
<PAGE>
<TABLE>
<CAPTION>
NORTH AMERICAN VACCINE, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) DECEMBER 31, DECEMBER 31,
1998 1997
----------------- ----------------
<S> <C> <C>
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 22,953 $ 45,502
Accounts receivable 1,625 324
Inventory 4,067 2,730
Prepaid expenses and other current assets 998 615
---------------- ----------------
Total current assets 29,643 49,171
Property, plant and equipment, net 25,315 31,428
Investment in affiliate, at market 1,554 843
Deferred financing costs, net 2,505 2,603
Cash restricted for lease obligation 4,877 -
Other assets 631 463
---------------- ----------------
TOTAL ASSETS $ 64,525 $ 84,508
================ ================
LIABILITIES AND SHAREHOLDERS' DEFICIT
CURRENT LIABILITIES:
Accounts payable $ 3,881 $ 3,343
Deferred revenue 850 3,999
Obligation under capital lease, current portion 1,754 1,593
Other current liabilities 5,848 5,064
---------------- ----------------
Total current liabilities 12,333 13,999
6.5% Convertible subordinated notes, due May 1, 2003 83,734 83,734
4.5% Convertible secured notes, due November 13, 2003 25,000 -
Obligation under capital lease, net of current portion 2,356 4,110
Deferred rent credits, net of current portion 76 12
---------------- ----------------
Total liabilities 123,499 101,855
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' DEFICIT:
Preferred stock, no par value; unlimited shares
authorized- Series A, convertible; issued and outstanding
2,000,000 shares; entitled to Can $2.50 per share (or U.S.
$3.3 million in the aggregate) in liquidation 6,538 6,538
Common stock, no par value; unlimited shares authorized;
issued 32,216,096 shares at December 31, 1998 and
31,936,539 shares at December 31, 1997 80,824 78,509
Additional paid-in capital 11,956 -
Cumulative comprehensive income excluded from net loss 926 215
Accumulated deficit (159,218) (102,609)
---------------- ----------------
Total shareholders' deficit (58,974) (17,347)
---------------- ----------------
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT $ 64,525 $ 84,508
================ ================
</TABLE>
The accompanying notes are an integral part of these consolidated
financial statements.
- 51 -
<PAGE>
<TABLE>
<CAPTION>
NORTH AMERICAN VACCINE, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
YEARS ENDED DECEMBER 31,
1998 1997 1996
------------- -------------- --------------
<S> <C> <C> <C>
REVENUES:
Marketing, research and development agreements $ 6,149 $ 8,001 $ 9,656
Product sales 2,230 1,699 892
------------- -------------- --------------
Total revenues 8,379 9,700 10,548
------------- -------------- --------------
OPERATING EXPENSES:
Production 19,196 18,662 14,764
Research and development 17,986 19,860 11,594
General and administrative 10,800 11,386 6,753
------------- -------------- --------------
Total operating expenses 47,982 49,908 33,111
------------- -------------- --------------
OPERATING LOSS (39,603) (40,208) (22,563)
OTHER INCOME (EXPENSES):
Gain on sale of investment in affiliate - - 4,228
Interest and dividend income 1,497 3,140 2,934
Interest expense (18,503) (6,772) (4,088)
------------- -------------- --------------
NET LOSS $ (56,609) $ (43,840) $ (19,489)
============= ============== ==============
BASIC AND DILUTED NET LOSS PER SHARE $ (1.76) $ (1.39) $ (0.63)
WEIGHTED-AVERAGE NUMBER OF COMMON SHARES
OUTSTANDING 32,152 31,641 30,764
</TABLE>
The accompanying notes are an integral part of these consolidated
financial statements.
- 52 -
<PAGE>
<TABLE>
<CAPTION>
NORTH AMERICAN VACCINE, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' (DEFICIT) EQUITY
(IN THOUSANDS)
CUMULATIVE
SERIES A COMPREHENSIVE TOTAL
CONVERTIBLE INCOME SHARE-
PREFERRED STOCK COMMON STOCK ADDITIONAL EXCLUDED ACCUM- HOLDERS'
------------------- --------------------- PAID-IN FROM ULATED EQUITY
SHARES AMOUNT SHARES AMOUNT CAPITAL NET LOSS DEFICIT (DEFICIT)
-------- ---------- ---------- ---------- ----------- ------------- ---------- ------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Balance,
December 31, 1995 2,000 $ 6,538 30,187 $ 58,474 $ - $ 7,466 $ (39,280) $ 33,198
Net loss - - - - - - (19,489) (19,489)
Realized investment
holding gain - - - - - (4,228) - (4,228)
Decrease in market
value of investment - - - - - (2,585) - (2,585)
------------
Comprehensive loss (26,302)
Exercises of stock
options - - 859 6,356 - - - 6,356
Issuance of common
stock - - 350 6,344 - - - 6,344
Shares issued under
401(k) plan - - 11 183 - - - 183
Balance,
-------- -------- --------- -------- ---------- --------- ----------- ------------
December 31, 1996 2,000 $ 6,538 31,407 $ 71,357 $ - $ 653 $ (58,769) $ 19,779
Net loss - - - - - - (43,840) (43,840)
Decrease in market
value of investment - - - - - (438) - (438)
------------
Comprehensive loss (44,278)
Exercises of stock
options - - 498 5,036 - - - 5,036
Retirement of stock used
to exercise options - - (80) (1,890) - - - (1,890)
Shares issued under
401(k) plan - - 11 238 - - - 238
Stock option
compensation - - - 1,313 - - - 1,313
Conversion of
subordinated convertible
notes into common stock - - 101 2,455 - - - 2,455
Balance,
-------- -------- --------- -------- ---------- --------- ----------- ------------
December 31, 1997 2,000 $ 6,538 31,937 $78,509 $ - $ 215 $ (102,609) $ (17,347)
Net loss - - - - - - (56,609) (56,609)
Increase in market
value of investment - - - - - 711 - 711
------------
Comprehensive loss (55,898)
Exercises of stock
options - - 462 5,452 - - - 5,452
Retirement of stock
used to exercise - - (201) (3,429) - - - (3,429)
Beneficial conversion
feature of 4.5% Notes - - - - 11,956 - - 11,956
Shares issued under
401(k) plan - - 18 292 - - - 292
Balance,
-------- -------- --------- -------- --------- --------- ----------- ------------
December 31, 1998 2,000 $ 6,538 32,216 $80,824 $ 11,956 $ 926 $ (159,218) $ (58,974)
======== ======== ========= ======== ========= ========= =========== ============
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
- 53 -
<PAGE>
<TABLE>
<CAPTION>
NORTH AMERICAN VACCINE, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
YEARS ENDED DECEMBER 31,
1998 1997 1996
----------- ------------ ----------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $ (56,609) $ (43,840) $ (19,489)
Adjustments to reconcile net loss to net cash used in
operating activities:
Gain on sale of investment in affiliate - - (4,228)
Loss (gain) on disposal of equipment 181 131 (12)
Depreciation and amortization 8,177 11,017 6,154
Amortization and reduction of deferred financing costs 498 520 335
Recognition of beneficial conversion feature of 4.5% Notes 11,956 - -
Contribution of common stock to 401(k) plan 292 238 183
Stock option compensation - 1,313 -
(Increase) decrease in other assets (168) 43 47
Decrease in deferred rent (24) (91) (81)
Cash flows (used in) provided by other working capital
items (4,760) 5,756 (1,818)
----------- ------------ ----------
Net cash used in operating activities (40,457) (24,913) (18,909)
----------- ------------ ----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures (2,245) (2,132) (21,012)
Proceeds from sale of investment in affiliate - - 5,199
Proceeds from sale of equipment - 225 27
----------- ------------ ----------
Net cash used in investing activities (2,245) (1,907) (15,786)
----------- ------------ ----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes 25,000 - 86,250
Deferred financing costs of convertible notes (400) - (3,519)
Proceeds from exercises of stock options, net 2,023 3,146 6,356
Loan to a former officer related to the purchase of
common stock (1,228) - -
Repayment of loan from the former officer 1,228 - -
Principal payments on capital lease obligation (1,593) (1,705) (298)
Cash restricted for capital lease obligation (4,877) - -
Proceeds from issuance of common stock - - 6,344
----------- ------------ -----------
Net cash provided by financing activities 20,153 1,441 95,133
----------- ------------ -----------
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (22,549) (25,379) 60,438
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 45,502 70,881 10,443
----------- ----------- ----------
CASH AND CASH EQUIVALENTS, END OF PERIOD $ 22,953 $ 45,502 $ 70,881
=========== =========== ==========
</TABLE>
The accompanying notes are an integral part of these consolidated
financial statements.
- 54 -
<PAGE>
<TABLE>
<CAPTION>
NORTH AMERICAN VACCINE, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(IN THOUSANDS)
YEARS ENDED DECEMBER 31,
1998 1997 1996
------------ ---------- ----------
<S> <C> <C> <C>
CASH FLOWS PROVIDED BY OTHER WORKING CAPITAL ITEMS:
(Increase) decrease in :
Accounts receivable $ (1,301) $ 3,842 $ (2,166)
Inventory (1,337) (948) (1,286)
Prepaid expenses and other current assets (383) (81) 38
Increase (decrease) in :
Accounts payable 538 1,431 (1,638)
Deferred revenue and other current liabilities (2,277) 1,512 3,234
---------- -------- --------
Net cash (used in) provided by other working capital items $ (4,760) $ 5,756 $ (1,818)
========== ======== ========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest $ 5,936 $ 6,249 $ 2,758
========== ======== ========
Equipment acquired through capital lease $ - $ - $ 7,665
========== ======== ========
Conversion of subordinated notes to common stock $ - $ 2,516 $ -
========== ======== ========
Use of stock to exercise stock options $ 3,429 $ 1,890 $ -
========== ======== ========
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
- 55 -
<PAGE>
NORTH AMERICAN VACCINE, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(1) ORGANIZATION
North American Vaccine, Inc. and Subsidiaries (the "Company") is engaged in
the research, development, production, and sale of vaccines for the prevention
of infectious diseases in children and adults.
The Company was incorporated in Canada on August 31, 1989 to consolidate the
assets, liabilities and operations of American Vaccine Corporation ("American
Vaccine"), and certain assets and vaccine-related technologies of BioChem Pharma
Inc. ("BioChem"), in a share purchase and merger transaction (the "Merger"). On
February 28, 1990, the shareholders of American Vaccine approved the Merger.
Prior to February 28, 1990, the Company had no operations.
Pursuant to the Merger, shareholders of American Vaccine exchanged their
shares for 50 percent ownership of the Company. Simultaneously, BioChem
purchased a 50 percent interest in the Company for cash, shares of BioChem
common stock, and certain rights in BioChem's vaccine-related technologies. The
net assets of American Vaccine, common stock of BioChem, and the rights in
vaccine-related technologies transferred by BioChem were carried forward to the
Company at their previously recorded amounts as reflected in the historical
financial statements of BioChem and American Vaccine.
(2) RISK FACTORS
RISK ASSOCIATED WITH LACK OF AVAILABILITY OF CAPITAL. To maintain the
Company's production, research, development and growth at current levels,
present cash and cash equivalents, expected product sales of Certiva(TRADEMARK)
and the Company's other products, and revenues from existing collaborative
agreements are not expected to provide sufficient cash to fund the Company's
operations, debt service payments and capital expenditures in 1999 and into
2000. As a result, the Company intends to: enter into new license, marketing,
distribution and/or development agreements that are currently under active
discussion; liquidate its investment securities; enter into a sale and
lease-back of the Company's one owned facility; and obtain one or more lines of
credit, which may be secured by accounts receivable, inventory or other assets
of the Company.
If the Company is unable to complete one or more of these transactions and/or
proceeds from the transactions are inadequate, the Company would be required to
obtain additional funding through the sale of debt and/or equity securities. The
Company has no current plans, agreements, commitments, arrangements, or
understandings relating to the placement or issuance of any securities. During
the course of the year, the Company will evaluate its need for additional debt
or equity financing to meet its cash requirements for 1999 and 2000. If the
Company determines that such additional financing is required but is not
available, then the Company would have to reduce its cash requirements through
significant reductions in operating levels.
NO ASSURANCE OF EFFECTIVE MARKETING. The Company is now implementing its
initial marketing and sales plan for Certiva(TRADEMARK) in the United States.
The Company markets Certiva(TRADEMARK) to government purchasers and, through a
distribution agreement with Abbott, markets Certiva(TRADEMARK) to private
- 56 -
<PAGE>
physicians and managed care organizations. There can be no assurance that the
Company or Abbott will successfully implement their respective sales and
marketing strategies. Factors affecting successful commercial launch of the
Company's vaccines in the United States include:
establishing an identity and reputation for the Company and its
products,
increasing awareness among pediatricians of the safety and efficacy
of the Company's vaccines,
distinguishing the Company's products from those of its competitors,
establishing the Company as an effective and reliable supplier of
vaccines,
establishing efficient and consistent production of sufficient
quantities of vaccine, and
establishing effective distribution channels.
In addition, the Company has entered into supply, marketing and distribution
agreements with third parties under which these parties have agreed to market
certain of the Company's products, such as Certiva(TRADEMARK)-EU and the
DTaP-IPV vaccine, in designated territories. As a result of this arrangement,
the Company's revenues from product sales in Europe and other territories depend
upon the timing, implementation and effectiveness of the sales, marketing and
distribution efforts of others. In addition, the Company may not be successful
in negotiating and executing marketing and/or distribution agreements with any
other third parties and these other third parties may be unable to market the
Company's products successfully.
RISKS ASSOCIATED WITH LIMITED PRODUCTION CAPACITY. The Company's
manufacturing facility has limited production capacity based on the present
size, configuration, equipment, processes and methods used to produce its
products. In addition, production expenses are mainly fixed and consist
primarily of expenses relative to the operation of its production facilities and
maintaining a ready work force. Further, from time to time, the Company
experiences disruptions and production failures. These disruption failures
increase unit production costs as units are lost in the production process.
These factors have contributed to higher production costs for the Company's
acellular pertussis products, which costs currently exceed their respective net
selling prices.
The Company is addressing this issue by modifying its existing facilities and
operations in a manner intended to significantly expand production capacity and
efficiency.
In addition, the Company's ability to timely and efficiently expand its
production capacity depends, in large part, upon the following:
adequacy of engineering designs,
availability of needed equipment,
manufacturing experience with these enhancements,
timeliness of regulatory review of modifications, and
acceptability of the modifications to applicable regulatory
authorities.
The Company's plans to increase production capacity and output could be
ineffective or may not result in production efficiencies that cover future
production costs. Failure to increase production capacity and output could limit
the Company's ability to meet market demand or achieve profitability.
RISKS ASSOCIATED WITH MANUFACTURING AND SCALE-UP. The production of vaccines
is a highly complex, biological process involving many steps from seed culture
through final production. Thus, the Company's production process could fail or
become subject to substantial disruptions that impede its ability to meet
production requirements.
- 57 -
<PAGE>
From time to time, the Company experiences disruptions and production
failures. There is no assurance that the Company can adequately address such
failures or that production failures will not continue in the future. These
disruptions and failures:
limit the Company's production capacity,
increase its production costs, which would affect the Company's
prospects for profitability, and
could have a negative impact on the Company's existing licenses for
its products and delay or inhibit its ability to obtain additional
regulatory approvals for its products.
In addition, the Company may not consistently produce its vaccines in quantity
and quality sufficient to achieve competitive commercial sales or profitability.
The Company's manufacturing operations for Certiva(TRADEMARK) and its
acellular pertussis vaccine are located principally in one facility. Any
condition or event that adversely affects the operation of this facility would
have a material adverse effect on the Company's financial condition and future
results of operations.
RISK OF FORECLOSURE OF COLLATERAL FOR 4.5% NOTES. The 4.5% Notes are secured
by a pledge of collateral, which includes certain of the Company's equipment and
other assets at the Company's principal manufacturing facility and the Company's
ownership rights in U.S. Patent No. 5,425,946, entitled "Vaccines Against Group
C NEISSERIA MENINGITIDIS" (the "Patent"). If the Company defaulted on its
obligations under the 4.5% Notes and the holders of these notes foreclosed on
the collateral, the Company's ability to operate its business may be
substantially impaired.
DEPENDENCE ON SUPPLIERS. While the Company produces the pertussis component
of Certiva(TRADEMARK), it has purchased, and intends to continue to purchase,
required diphtheria and tetanus toxoids from SSI and enhanced IPV from SSI and
another supplier. These suppliers may not fulfill the Company's requirements,
their components may not be supplied on commercially reasonable terms, or they
may experience difficulties in obtaining necessary regulatory approvals or
disruptions in their production of diphtheria and tetanus toxoids or IPV. Any of
the foregoing could significantly affect the Company's operations.
Certain of the Company's production processes require raw materials from sole
sources or materials that are difficult for suppliers to produce and certify to
the Company's specifications. The Company also may experience temporary or
permanent shortages of critical raw materials necessary for continued production
of its vaccines. Any shortage of these materials could delay production efforts,
adversely impact production costs and yields, or necessitate the use of
substitute materials, any of which could have a significant adverse impact on
the Company's operations.
In addition, the Company has contracted with third parties for certain
product testing and for the sterile fill, labeling and packaging of its vaccine
products. Failure of any such contractor to meet the Company's requirements
could have a material adverse effect on the Company, may involve costly delays
and significant expense, and would require additional regulatory approval as the
Company seeks alternative arrangements.
COMPETITION AND TECHNOLOGICAL CHANGE. Competition in the vaccine industry is
intense. Competitors of the Company both in the United States and
internationally include major pharmaceutical and chemical companies, specialized
biotechnology firms, universities and other research institutions. Many of these
- 58 -
<PAGE>
competitors are actively developing competing vaccines.
Three competitors have received FDA approval for their DTaP vaccine for use
in infants and children. If these competitors are successful in developing and
marketing combination vaccines that include DTaP vaccines, then these
combination vaccines may gain market share at the expense of stand-alone DTaP
vaccines, including Certiva(TRADEMARK). One of those competitors has announced
that the FDA licensed a vaccine for administration at 15-18 months of age that
combines that company's HIB vaccine with its DTaP vaccine by reconstitution.
This same competitor is also seeking FDA approval for administration at two,
four and six months of age. Another competitor has reported that it is in
clinical trials for a DTaP-HIB combination vaccine. In addition, several DTaP
vaccines and DTaP combination vaccines are licensed for sale outside of the
United States.
Many of these competitors have substantially greater resources, more
extensive experience in conducting clinical testing and obtaining regulatory
approvals for their products, greater operating experience, larger research and
development and marketing staffs, and greater production capabilities than the
Company. These factors may be particularly advantageous because the vaccine
industry is subject to significant technological change.
The Company's competitors could also gain a competitive advantage by
designing around the Company's patents and developing technologies and products
that are as or more effective than any that have been or are being developed by
the Company. They could also develop technologies and products that would render
the Company's technology and products obsolete and noncompetitive.
CHANGES IN GOVERNMENT PURCHASING POLICIES. Children in the United States
receive immunizations from private providers and public providers, such as local
health departments. Immunizations provided by public providers are generally
funded through federal and state government public health programs. Government
purchases historically have been at prices substantially below those offered to
the private sector and presently account for a substantial portion of the
vaccine doses distributed in the United States. In the United States, federal
and state governments historically have purchased DTaP and other vaccines from
multiple suppliers. There can be no assurances that this practice will continue.
From time to time, legislative and regulatory initiatives are proposed that,
if adopted, could significantly modify government vaccine programs. These
initiatives could materially affect the federal government's purchasing
authority, the contract award process, or the funding available for government
vaccine purchases. The Company is unable to predict which legislative
initiative, if any, will ultimately be enacted or the effect any such initiative
may ultimately have on the Company's business or results of future operations.
In addition, proposals for health-care, insurance and tax reform may be
considered in the future by federal and state governments and some of these
proposals, if adopted, may limit government or third-party, private
reimbursement policies, or prices charged by pharmaceutical and vaccine
manufacturers for their products.
GOVERNMENT REGULATION; REGULATORY APPROVALS. The Company's vaccine products,
product development activities and manufacturing facilities and processes are
subject to extensive and rigorous regulation by the FDA. FDA regulation includes
preclinical and clinical testing requirements and inspection and approval
processes. To date, the Company has received FDA approval for only one product.
Approval of the Company's products for commercial introduction in the United
States currently requires both a license for each product and a license for each
production facility. Obtaining licenses can be costly and time consuming. There
- 59 -
<PAGE>
can be no assurance that the licenses will be granted, or that FDA review will
not involve delays that would adversely affect the Company's ability to market
products. There also can be no assurance that any products under development by
the Company will demonstrate the safety or efficacy profiles necessary for
regulatory approval, or that the Company's products under development or its
production facilities will receive the requisite regulatory approvals and
licenses in a timely fashion or at all.
Moreover, FDA-granted licenses may impose limitations that affect the
commercialization of the product, including limitations on product use and
requirements for post-licensure testing. The FDA can withdraw approvals at any
time by following appropriate regulatory procedures. The FDA can also limit or
prevent the manufacture or distribution of the Company's products both in the
United States and abroad and can require recalls of products. FDA regulations
depend heavily on administrative and scientific interpretation and advisory
committee determinations. Such interpretations, with possible prospective and
retroactive effect, could adversely affect the Company.
In addition, the FDA and various state agencies inspect the Company and its
facilities from time to time to determine whether the Company is in compliance
with regulations, including manufacturing, testing, recordkeeping, quality
control and labeling practices. If such entities find that the Company is in
material violation of these regulations, the Company could be subject to, among
other things, product recalls, suspensions or withdrawals of licenses,
revocation or suspension of export authorizations, and denials of any pending
applications.
UNCERTAINTIES RELATED TO CLINICAL TRIALS. Before obtaining regulatory
approval for the commercial sale of any products under development, the Company
must demonstrate through pre-clinical studies and clinical trials that these
products are safe and effective. The results from pre-clinical studies and early
clinical trials may not be predictive of results obtained in large-scale
clinical trials. There can be no assurance that large-scale clinical trials for
any of the Company's products will demonstrate safety and efficacy, be
sufficient to support application for regulatory approval, or lead to marketable
products. A number of companies in the biotechnology industry have suffered
significant setbacks in advanced clinical trials even after achieving promising
results in earlier trials.
PATENT PROTECTION AND PROPRIETARY INFORMATION. Traditionally, the vaccine
industry has placed importance on obtaining and maintaining patent and trade
secret protection for significant new technologies, products and processes. The
Company believes that this protection will be an important factor in its success
and may require the expenditure of substantial resources.
Many companies, universities and research institutions have applied for
and/or obtained patents for vaccine products and technologies that may be
competitive or inconsistent with those held by or licensed to the Company. No
assurances can be given that the degree and range of protection of any patents
will be sufficient, that additional patents will be issued to the Company, or
that the Company will not infringe upon patents granted to others. Further,
others have or may independently develop or otherwise properly gain access to
technology or information that is substantially similar to that which is
unpatented yet considered proprietary by the Company.
The Company also may desire or be required to obtain licenses from others to
effectively develop, produce and market commercially viable products. Failure to
obtain those licenses could have a significant adverse effect on the Company's
ability to commercialize its vaccine products. There can be no assurance that
the Company can obtain these licenses on commercially reasonable terms, if at
all, that the patents underlying these licenses will be valid and enforceable or
that the proprietary nature of the unpatented technology underlying these
licenses will remain proprietary.
- 60 -
<PAGE>
There has been, and the Company believes that there may be in the future,
significant litigation in the industry regarding patent and other intellectual
property rights. If the Company becomes involved in this type of litigation, it
could consume substantial resources.
RISK OF PRODUCT LIABILITY AND LIMITED INSURANCE. The testing and marketing of
vaccine products involve an inherent risk of product liability. The Company has
limited product liability insurance coverage. There can be no assurance that
adequate additional insurance coverage will be available at acceptable cost, if
at all, or that a product liability claim would not materially adversely affect
the Company's business or financial condition. If not covered by insurance, the
Company faces potential liability that could be substantial in the event of
claims.
DEPENDENCE ON ATTRACTING AND RETAINING QUALIFIED PERSONNEL. The Company's
success in developing marketable products and achieving a competitive position
will depend, in part, on its ability to attract and retain qualified personnel.
Competition for such personnel is intense. No assurance can be given that the
Company will continue to attract or retain such personnel. The loss of key
personnel could adversely affect the Company.
(3) SIGNIFICANT ACCOUNTING POLICIES
(a) BASIS OF ACCOUNTING AND CURRENCY. The accompanying consolidated financial
statements have been prepared in conformity with generally accepted accounting
principles ("GAAP") in the United States ("U.S.") and are denominated in U.S.
dollars, because the Company conducts the majority of its transactions in this
currency. The application of Canadian GAAP would not result in material
adjustments to the accompanying financial statements, except for the impact of
the adoption of Statement of Financial Accounting Standards ("SFAS") No. 115, as
discussed in Note 6 and the interest charge of $12.0 million related to the
issuance of the 4.5% Notes as discussed in Note 10. Under Canadian GAAP, the
beneficial conversion feature of the 4.5% Notes would be assigned a value and
reported as additional equity to be amortized to retained earnings ratably over
the term of the 4.5% Notes rather than being charged to interest in the current
period. The effect of foreign currency translation has been immaterial.
(b) PRINCIPLES OF CONSOLIDATION. The consolidated financial statements
include the accounts of North American Vaccine, Inc. and its subsidiaries. All
significant intercompany transactions have been eliminated in consolidation.
(c) PERVASIVENESS OF ESTIMATES. The preparation of financial statements in
conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from estimates.
(d) CASH AND CASH EQUIVALENTS. The Company considers all highly liquid
investments with an original maturity of three months or less to be cash
equivalents. Cash and cash equivalents consist primarily of commercial paper and
U.S. Treasury Bills.
(e) INVENTORIES. Inventories are stated at the lower of cost (first-in,
first-out) or market. Components of inventory cost include materials, labor, and
manufacturing overhead. Production costs attributable to a product are expensed
until regulatory approval is obtained for such product. Beginning in the third
quarter of 1998, costs to produce Certiva(TRADEMARK) for sale in the United
States were capitalized. Any production costs incurred in excess of net
realizable value are expensed in the quarter in which they are incurred.
Inventories consist of the following:
- 61 -
<PAGE>
1998 1997
----------------
(in thousands)
Raw Materials $2,509 $2,584
Work-in-process 1,024 0
Finished goods 534 146
------ ------
$4,067 $2,730
====== ======
(f) REVENUE RECOGNITION. Nonrefundable fees or milestone payments in
connection with research and development or collaborative agreements are
recognized when they are earned in accordance with the applicable performance
requirements and contract terms. Revenue from product sales is recognized when
all significant risks of ownership have been transferred, the amount of the
selling price is fixed and determinable, all significant related acts of
performance have been completed, and no other significant uncertainties exist.
In most cases, these criteria are met when the goods are shipped.
In July 1998, the Company received FDA approval to manufacture and market
Certiva(TRADEMARK) in the United States. Under the FDA approval,
Certiva(TRADEMARK) is indicated for active immunization against diphtheria,
tetanus and pertussis (whooping cough) in infants and children six weeks to
seven years of age. The Company produces the monocomponent acellular pertussis
toxoid and formulates the final product with diphtheria and tetanus toxoids
manufactured and supplied by SSI.
In 1998, the Company has recognized revenues of approximately $1.0 million
from sales of its acellular pertussis vaccine to SSI in Denmark and
approximately $1.2 million from sales of Certiva(TRADEMARK), primarily under a
contract with the U.S. Centers for Disease Control and Prevention.
(g) RESEARCH AND DEVELOPMENT COSTS. The Company expenses all research and
development costs as incurred. Under Canadian GAAP, certain development costs
should be deferred to future periods if certain criteria are met. No costs have
been capitalized for Canadian GAAP purposes because the Company believes that
the applicable deferral criteria have not been met.
(h) DEPRECIATION AND AMORTIZATION. Prior to 1998, depreciation of property,
plant and equipment, with the exception of leasehold improvements and an owned
facility, was provided using an accelerated method over the estimated useful
lives of the assets. The estimated useful lives are generally from five to seven
years for machinery, equipment, and furniture. Leasehold improvements are
amortized over the term of the lease. The Company's owned facility is
depreciated on a straight-line basis over twenty years. For property, plant and
equipment purchased after 1997, depreciation is provided using the straight-line
method over the estimated useful lives. The effect of this change in accounting
principle is insignificant.
(i) DEFERRED FINANCING COSTS. Deferred financing costs represent fees and
other costs incurred in connection with the issuance of the 4.5% Notes and the
6.5% Notes. These costs are amortized over the term of the related debt using
the effective interest rate method. Total accumulated amortization through
December 31, 1998 and 1997 was $1,335,000 and $838,000, respectively.
- 62 -
<PAGE>
(j) INCOME TAXES. The Company computes deferred tax assets or liabilities based
on the difference between the financial statement and income tax basis of assets
and liabilities using the enacted tax rate.
(k) BASIC AND DILUTED NET LOSS PER COMMON SHARE. In March 1997, the Financial
Accounting Standards Board ("FASB") issued SFAS No. 128, "Earnings Per Share."
SFAS No. 128 is effective for financial statements issued for periods ending
after December 15, 1997. The Company implemented SFAS No. 128 in 1997,
retroactive for all periods presented. SFAS No. 128 requires dual presentation
of basic and diluted earnings per share. Basic loss per share includes no
dilution and is computed by dividing net loss by the weighted average number of
common shares outstanding for the period. Diluted loss per share includes the
potential dilution that could occur if securities or other contracts to issue
common stock were exercised or converted into common stock. Options, warrants
and convertible securities that were outstanding at December 31, 1998, 1997 and
1996, were not included in the computation of diluted loss per share as their
effect would have been anti-dilutive. As a result, the basic and diluted loss
per share amounts are identical for all periods presented.
(l) COMPREHENSIVE INCOME. In 1997, the Financial Accounting Standards Board
issued SFAS No. 130, "Reporting Comprehensive Income." The Company has
implemented SFAS No. 130 beginning with the first quarter 1998 financial
statements. The implementation of this standard did not result in a material
impact to the Company's financial statements. The Company presents its
comprehensive income in the statement of shareholders' equity.
(m) SEGMENT REPORTING. In 1997, the Financial Accounting Standards Board
issued SFAS No. 131, "Disclosures about Segments of an Enterprise and Related
Information." The Company implemented SFAS No. 131 for the year ended December
31, 1998 and has determined that it currently does not have reportable segments.
Product sales in the United States were approximately $1.2 million, $0 and $0
for the years ended December 31, 1998, 1997 and 1996, respectively. Product
sales to Europe were approximately $1.0 million, $1.7 million and $900,000 for
the years ended December 31, 1998, 1997 and 1996, respectively. All products are
currently being manufactured at the Company's one production facility in the
United States. The production process, and ultimately product costing, is
primarily the same for all of the Company's acellular pertussis vaccine products
sold in the United States and Europe. Because of this, and the relative
consistency in selling prices, as well as, the nature of the distribution
methods utilized by the Company, the Company does not differentiate and manage
its business along geographic lines.
(4) PRODUCTION, DEVELOPMENT, AND MARKETING CONTRACTS
(a) AGREEMENTS WITH PASTEUR MERIEUX CONNAUGHT. In the December 1995 clinical
development agreement and license agreements with Pasteur Merieux Connaught, the
parties agreed to jointly develop the Company's new conjugate vaccine against
Group B meningococcus for both adult and pediatric indications. The Company
recognized $4 and $6 million of research and development revenue for
non-refundable payments made by Pasteur Merieux Connaught in 1996 and 1997;
respectively. No revenue was recognized in 1998 in connection with the clinical
development agreement. Further fees and funding will be made upon achievement of
development, clinical and regulatory milestones and as development funding is
incurred. In addition, the Company will receive royalties on any product sales
by Pasteur Merieux Connaught.
Under the clinical development agreement, the parties will jointly develop
the vaccine through Phase II clinical trials, and each party will have access to
- 63 -
<PAGE>
and the right to use the clinical trial results. Pasteur Merieux Connaught will
be responsible for all costs associated with the clinical development of the
Group B meningococcal vaccine through the completion of Phase II clinical
trials. The Company has incurred approximately $4.6 million of cost under the
contract with Pasteur Merieux Connaught. The Company has entered into
discussions with Pasteur Merieux Connaught regarding the reimbursement of those
costs. No amounts have been recorded. The Company will retain co-exclusive
world-wide rights to manufacture and sell the Group B meningococcal vaccine both
as a stand-alone product and in combination with other vaccines. Pasteur Merieux
Connaught may elect to terminate the agreements at any time.
(b) AGREEMENT WITH ABBOTT LABORATORIES. In 1996, the Company and Abbott
signed an agreement under which Abbott would market Certiva(TRADEMARK), the
Company's DTaP vaccine, when approved by the FDA. With FDA approval of
Certiva(TRADEMARK) in July 1998, Abbott is marketing Certiva(TRADEMARK) to
private physicians and managed care markets in the United States for
immunization of infants and children. The Company is marketing to government
purchasers, including state governments and the Centers for Disease Control and
Prevention. The marketing agreement also will allow Abbott to market the
Company's DTaP-HIB, DTaP-IPV and DTaP-IPV-HIB combination vaccines which are
under development.
On execution of the agreement, the Company received $13 million of which
approximately $6.3 million represented payment for 350,000 shares of the
Company's common stock, and the balance represented a marketing fee and clinical
development funding. The Company and Abbott will collaborate in the clinical
development of the combination vaccines and Abbott has provided the Company with
clinical development funding. Amounts received for clinical development to be
expended in the future by the Company have been recorded as deferred revenue.
The Company received $3 million in 1997 for clinical development funding. In
addition, the Company will receive payments upon achievement of prescribed
milestones. The Company recognized $5.2 million of revenues under this contract
in 1998, including a milestone payment associated with the FDA approval of
Certiva(TRADEMARK) in 1998. Under the agreement, the Company paid $750,000 to
support and enhance Abbott's promotional and advertising program in 1998. The
agreement, as amended, provides for total payments of up to $40 million by
Abbott, including the $18 million received through December 31, 1998. The
Company has received revenues from Abbott for purchases of Certiva(TRADEMARK)
and will receive revenues as Abbott purchases combination vaccine products for
resale to the private pediatric market. Abbott may terminate this arrangement at
any time with advance notice.
- 64 -
<PAGE>
(5) PROPERTY, PLANT, AND EQUIPMENT
Property, plant and equipment were recorded at cost and consisted of the
following components:
AS OF DECEMBER 31,
------------------
1998 1997
--------------
(in thousands)
Property, plant and equipment:
Land $ 498 $ 498
Building and improvements 2,443 2,421
Machinery, equipment and laboratory fixtures 43,806 42,380
Leasehold improvements 8,293 8,587
Office furniture, equipment and software 4,915 4,398
------- -------
59,955 58,284
------- -------
Accumulated depreciation and amortization:
Building and improvements 372 250
Machinery, equipment and laboratory fixtures 26,382 19,885
Leasehold improvements 4,899 4,423
Office furniture, equipment and software 2,987 2,298
------- -------
34,640 26,856
------- -------
Property, plant and equipment, net $25,315 $31,428
======= =======
In 1996, the Company entered into an agreement which included the assumption
of an operating lease of a 35,000 square foot manufacturing facility and the
purchase and capital lease of equipment and leasehold improvements. See Note 9
for further description of the transaction.
(6) INVESTMENT IN AFFILIATE
In accordance with SFAS No. 115, "Accounting for Certain Investments in Debt
and Equity Securities," equity securities classified as available-for-sale are
reported at fair value, with unrealized gains and losses reported as a separate
component of shareholders' equity. As a result, the Company's investments in its
affiliates are reflected at their current market value as of December 31, 1998
and 1997, of $1.6 million and $843,000, respectively (original cost of
$629,000).
In 1996, the Company sold 193,084 shares of its investment in IVAX stock. The
gross proceeds and the realized gain from the sales were $5.2 and $4.2 million,
respectively. The historical cost of the remaining 125,000 shares of IVAX common
stock remains at $629,000 or $5.03 per share at December 31, 1998.
The market values of these securities as of December 31, 1998 and 1997, as
disclosed on the accompanying consolidated balance sheets, have been determined
based on the closing prices for registered securities of IVAX as of those dates.
The aggregate market value of the Company's remaining investment in IVAX common
stock at January 18, 1999, was approximately $1.5 million. These investment
securities are volatile and, therefore, are subject to significant fluctuations
in value.
- 65 -
<PAGE>
(7) OTHER CURRENT LIABILITIES
Other current liabilities consisted of the following components:
AS OF DECEMBER 31,
------------------
1998 1997
----------------
(in thousands)
Payroll and fringe benefits $ 1,702 $ 1,488
Accrued interest 1,103 959
Accrued taxes 1,149 642
Reserve for contract loss 720 720
Accrued consulting and professional fees 353 381
Accrued costs of clinical trials 216 269
Other accrued liabilities 605 605
------- -------
Total other current liabilities $ 5,848 $ 5,064
======= =======
(8) RESTRICTED CASH AND OBLIGATIONS UNDER CAPITAL LEASE
In connection with an operating lease for a 35,000 square foot development
and production facility, the Company entered into an agreement that included the
purchase and lease of equipment and leasehold improvements. As part of the
operating lease, the Company assumed the underlying real estate leases which are
scheduled to expire in February 2001, but may be extended through 2011. Under
the terms of the equipment lease, there are certain financial covenants that
obligate the Company to maintain certain cash and investment balances, a minimum
tangible net worth (defined to include amounts under the outstanding convertible
subordinated notes), and certain other financial ratios. The equipment lease
agreement permits the Company, at its option, to suspend the application of
financial covenants by posting a stand-by letter of credit, which may be revoked
by the Company provided certain conditions are satisfied. In April 1998, as
permitted by the equipment lease agreement, the Company voluntarily posted a
letter of credit in the amount of $5.9 million, thereby suspending the
application of all financial covenants. The letter of credit decreases on a
monthly basis as the payments on the lease obligation are made and is secured by
a restricted cash deposit of an equal amount. The balance of the letter of
credit and the corresponding restricted cash is $4.9 million at December 31,
1998. The letter of credit will expire by its terms on November 1, 2000.
(9) COMMITMENTS AND CONTINGENCIES
(a) OPERATING LEASES. The Company has extended its lease agreement for its
production facility through February 28, 2009. The Company has the option of
further extending this lease for an additional ten years. Under the terms of the
lease of this facility, the lessor reimbursed the Company for $625,000 of
improvements made to the property. This reimbursement has been reflected as a
deferred rent credit, which is being amortized over the initial base term of the
lease which will expire February 28, 1999. The lease provides for minimum annual
escalations of the base rent. These escalations are recorded as expense ratably
over the term of the lease.
The Company has renewed its lease for certain office space through December
31, 2000, and has one three-year renewal option remaining. The Company may
terminate this lease with a six month advance notice.
- 66 -
<PAGE>
As discussed in Note 8, in November 1996, the Company assumed a lease to rent
35,000 square feet of space for a development and production facility through
February 1, 2001, with two five-year renewal options. The lease provides for
minimum annual escalations of the base rent.
In March 1998, the Company leased an approximately 75,500 square foot
facility to be used for research, development, general and administrative
functions and for future expansion of the Company's operations. The lease is for
an initial term of ten years, with two five-year renewal options. The initial
base annual rent under the lease is approximately $981,000 with minimum annual
escalations. At the end of the fifth year of the initial term, the Company has
the right to terminate the lease for a specified fee. In addition, the Company
has an option to purchase the facility during specified periods of the lease
term. The landlord has provided the Company a tenant improvement allowance of
approximately $1.4 million, and will provide an additional $1.8 million to the
Company, if needed, under a line of credit to fund improvement costs in excess
of the tenant improvement allowance. Monthly payments under this line of credit
would consist of interest only accruing at the simple annual rate of 12.75%, and
the entire unpaid principal balance would mature in September 2000, unless
extended by the Company up to March 2002. The line of credit also would be
secured by all leasehold improvements and related facility enhancements
purchased with funds provided by the landlord. No funds have been drawn down
under this line of credit as of December 31, 1998. The line of credit is
available to the Company through March 1999.
Minimum future lease payments under all leases, exclusive of real estate tax
escalations, are as follows:
YEARS ENDING
DECEMBER 31,
------------
(in thousands)
1999 $ 1,956
2000 2,006
2001 1,496
2002 1,463
2003 1,501
Beyond 7,239
-------
Total $15,661
=======
Total rent expense was $1,620,000, $1,232,000, and $898,000 in 1998, 1997,
and 1996, respectively.
(b) CAPITAL LEASE. In connection with the operating lease agreement described
in Note 8 that was entered into in 1996, the Company also entered into an
agreement that included the purchase and lease of equipment and leasehold
improvements. The total acquisition cost was approximately $24.9 million, which
included a cash payment of $17.2 million. The balance of $7.7 million was
financed through an equipment lease obligation which expires in 2000. In 1997,
the Company disposed of approximately $457,000 of this equipment recognizing a
non-cash loss of approximately $97,000. The equipment lease has been accounted
for as a capital lease for financial reporting purposes, with monthly payments
of approximately $174,000. As of December 31, 1998, the total obligation under
this capital lease was $4.1 million. Total depreciation expense associated with
equipment under the capital lease was approximately $2.7 million and $4.1
million for 1998 and 1997, respectively. Under the terms of the equipment lease,
the Company has a buyout option at the end of the third year for a predetermined
amount, and a buyout option at the end of the fourth year at the greater of the
fair market value of the equipment or a predetermined amount. Under the
equipment lease agreement there are financial covenants that obligate the
Company to maintain certain minimum cash and investment balances, a minimum
- 67 -
<PAGE>
tangible net worth and certain other financial ratios. As discussed in Note 8,
in April 1998, as permitted by the equipment lease agreement, the Company
voluntarily posted a letter of credit in the amount of $5.9 million, thereby
suspending the application of all financial covenants. The letter of credit
decreases on a monthly basis as the payments on the lease obligation are made
and is secured by a restricted cash deposit of an equal amount. The balance of
the letter of credit and the corresponding restricted cash is $4.9 million at
December 31, 1998. The letter of credit will expire by its terms on November 1,
2000.
Minimum future lease payments are as follows:
YEARS ENDING
DECEMBER 31,
------------
(in thousands)
1999 (includes interest of $320) $ 2,074
2000 (includes interest of $139) 2,495
--------
Total $ 4,569
Less interest component (459)
--------
Total principal payments $ 4,110
========
(c) CONTINGENCIES. In prior years, the Company was awarded various
cost-plus-fixed-fee contracts by the National Institute of Child Health and
Human Development ("NICHD"). Performance under these contracts was completed in
1993. Provisional payments to the Company under cost-reimbursable contracts are
subject to adjustment upon completion of audits of reimbursable costs by the
NICHD. In the opinion of management, adjustments, if any, resulting from the
audits of the contracts are not expected to have a material adverse impact on
the Company's financial position or future results of operations.
On November 2, 1998, Sharon Mates, Ph.D., a director of the Company and the
Company's former president, initiated litigation in United States District
Court, District of Maryland (Civil Action No. AW 98-3678) (the "Complaint")
against the Company, two of its directors and BioChem. The claims against the
Company seek principally the following: declaratory relief against the Company
regarding the approval and consummation of the private placement of the 4.5%
Notes due November 13, 2003 (See Note 10 below); injunctive relief seeking to
prevent the Company from consummating the private placement of the 4.5% Notes
(which closed on, November 12, 1998, as described in Note 10); injunctive relief
against the Company relating to Dr. Mates' access to Company books and records
and to her continued service as a director; declaratory relief regarding the
termination of employment and removal as president of the Company; and claims
against the Company alleging abusive discharge and defamation. The Complaint
also seeks actual and punitive damages against the Company in an unspecified
amount. In addition, the Complaint seeks declaratory and injunctive relief
against Dr. Phillip Frost and BioChem arising out of alleged violations of the
reporting requirements of Sections 13(d) and Rule 13d-1(a) of the Securities Act
of 1934, as amended, ("1934 Act") and unspecified damages from BioChem and Drs.
Frost and Francesco Bellini (chief executive officer of BioChem) for tortious
interference with Dr. Mates' business relations with the Company.
In December 1998, the Company filed a motion to dismiss the Complaint in its
totality. BioChem and Drs. Frost and Bellini have also filed motions to dismiss
Dr. Mates' claims. The Company intends to continue to vigorously contest and
defend against these claims in this litigation. The Company believes that the
claims against it are without merit, that the Company has meritorious defenses
available to it, and that certain claims may be covered by insurance. Under the
terms of the Company's By-laws and indemnification agreements with directors,
the Company is obligated to indemnify directors against certain claims. The
- 68 -
<PAGE>
Company is presently evaluating the extent of its indemnification obligations
and available insurance coverage. In the opinion of management, this lawsuit
will not have a material adverse effect on the Company. If however, litigation
costs, including indemnification obligations, and judgments against the
defendants exceed the Company's available insurance coverage, this litigation
could have a material adverse effect on the Company's financial condition and
results of operations.
The Company is, and from time to time becomes, involved in various claims and
lawsuits that are incidental to its business. In the opinion of the Company's
management, there are no other material legal proceedings pending against the
Company.
(10) CONVERTIBLE DEBT
In November 1998, the Company completed a $25 million financing through the
private placement of 4.5% Notes. BioChem and Dr. Frost, affiliates of the
Company, purchased 4.5% Notes in the aggregate principal amount of $9 million
and $4.25 million, respectively. In addition, Sofinov purchased 4.5% Notes in
the aggregate principal amount of $6.25 million. Denis Dionne, a director of the
Company, is the President of Sofinov.
The 4.5% Notes were sold at par, mature on November 13, 2003 and provide for
interest payable semi-annually on May 13 and November 13 of each year commencing
on May 13, 1999. The net proceeds from this offering were approximately $24.6
million. The 4.5% Notes are convertible, in whole or in part, by the holder(s)
at any time prior to maturity (unless previously redeemed or repurchased) into
shares of the Company's Common Stock at the conversion price of approximately
$8.54 per share. The conversion price was set based on the average closing price
of the Company's Common Stock for the twenty (20) trading days preceding the
date of the announcement of the agreement-in-principle between the Company and
prospective purchasers. The measurement period for determining the conversion
price began on August 26, 1998 and terminated on September 23, 1998. The closing
prices of the Company's Common Stock during that period ranged from a low of
$6.875 to a high of $11.25. The 4.5% Notes are secured by certain assets of the
Company; are otherwise subordinated in right of payment to all existing and
future senior indebtedness of the Company, do not restrict the incurrence of
future senior or other indebtedness of the Company and are redeemable, in whole
or in part, at the option of the Company on or after one year from the date of
issuance at par, plus accrued interest to the redemption date. Upon a change in
control, the Company is required to offer to purchase all of the 4.5% Notes then
outstanding at a purchase price equal to 100% of the principal amount thereof,
plus interest. The repurchase price will be payable in cash or, at the option of
the Company, in shares of the Company's Common Stock (valued at 95% of the
average closing prices of the Common Stock for a specified period prior to the
repurchase date).
The 4.5% Notes are not registered under the Securities Act of 1933, as
amended, ("1933 Act") or any applicable state or foreign securities laws, and
were sold in reliance on prescribed exemptions from registrations under the 1933
Act and other applicable state or foreign securities laws.
On November 12, 1998, the date on which the 4.5% Notes were issued, the
closing price for the Company's Common Stock was $12.625, which exceeded the
initial conversion price for the 4.5% Notes. The difference between the initial
conversion price and the fair market value per share on the date of issue of the
4.5% Notes, for the number of equivalent shares, has been recognized and
recorded as paid in capital, thus increasing the effective interest rate of the
4.5% Notes. Given that the 4.5% Notes are immediately convertible, the interest
expense of approximately $12.0 million was recognized immediately and is
included in the accompanying Consolidated Statements of Operations. This
interest expense is not deductible for U.S. or Canadian income tax purposes.
- 69 -
<PAGE>
In May 1996, the Company completed an offering of 6.5% Notes in the principal
amount of $86.25 million due May 1, 2003. The net proceeds from this offering
were approximately $82.7 million. Interest on the notes is payable semi-annually
on May 1 and November 1 of each year. The 6.5% Notes are convertible into common
shares of the Company at the conversion price of approximately $24.86 per common
share. The 6.5% Notes are subordinated to present and future senior indebtedness
of the Company and will not restrict the incurrence of future senior or other
indebtedness by the Company. The 6.5% Notes are redeemable, in whole or in part,
at the option of the Company on or after May 1, 1999, at certain pre-established
redemption prices plus accrued interest. Upon a change in control, the Company
is required to offer to purchase all or part of the notes then outstanding at a
purchase price equal to 100% of the principal amount thereof, plus interest. The
repurchase price is payable in cash or, at the option of the Company, in common
shares. In December 1997, the Company issued 101,207 shares of common stock upon
conversion of the $2,516,000 principal amount of notes.
(11) FAIR VALUE OF FINANCIAL INSTRUMENTS
The carrying amounts reported in the Company's consolidated balance sheets at
December 31, 1998 and 1997, for cash and cash equivalents, accounts receivable,
accounts payable and accrued liabilities approximate fair values due to the
short maturity of those instruments. Management believes the carrying value of
the 4.5% Notes and the capital lease obligation approximate fair value. At
December 31, 1998, Management estimates the fair value of the 6.5% Notes at $42
million as determined by a review of a December 31, 1998 trade of the 6.5%
Notes.
(12) INCOME TAXES
The operations of the Company are taxed under Canadian income tax laws and
the operations of its United States branch are taxed under United States income
tax laws subject to applicable treaty provisions for the avoidance of double
taxation. The Company's wholly owned subsidiaries, American Vaccine Corporation
and AMVAX, Inc.("AMVAX"), are both taxed under United States income tax laws.
In 1998, 1997 and 1996, the Company incurred a loss for income tax reporting
purposes in Canada and the United States.
- 70 -
<PAGE>
The components of the net deferred tax assets consisted of:
AS OF DECEMBER 31,
------------------
1998 1997
-------------------
(in thousands)
Deferred tax assets:
Net operating loss carryforwards $48,348 $38,489
Accrued intercompany interest 6,046 4,172
Depreciation and amortization 2,581 1,497
Reserve for contract loss 278 278
Deferred rent 7 46
Other 3,240 2,447
------- -------
Total deferred tax assets 60,500 46,929
------- -------
Deferred tax liabilities:
Historical accrual to cash difference (745) (1,489)
Investments in affiliates (312) (312)
------- -------
Total deferred tax liability (1,057) (1,801)
------- -------
Net deferred tax assets before allowance 59,443 45,128
Less: Valuation allowance (59,443) (45,128)
Net deferred tax assets $ -- $ --
The Company has determined that $59.4 million in 1998 and $45.1 million in
1997 of net deferred tax assets do not satisfy the recognition criteria set
forth in SFAS No. 109. Accordingly, a valuation allowance was recorded against
the applicable net deferred tax assets.
At December 31, 1998, the Company had net operating loss carryforwards of
approximately $124.7 million. Of this consolidated total, approximately $30.0
million of the Company's net operating loss carryforwards are available to
offset future Canadian-sourced taxable income, if any. These loss carryforwards
expire between 1999 and 2005. Of the remaining balance, American Vaccine and
AMVAX had net operating loss carryforwards of approximately $93.8 million and
$911,000, respectively, available to offset future United States taxable income,
if any. These loss carryforwards expire between 2002 and 2018.
The net operating loss carryforwards available to be used in any given year
may be limited due to significant changes in ownership interests resulting from
future stock issuances or other changes in equity interests.
(13) INDEMNIFICATION AGREEMENT
In connection with the Merger described in Note 1, certain shareholders of
American Vaccine with significant ownership interests were required to file gain
recognition agreements with the United States Internal Revenue Service. Under
the terms of the gain recognition agreements, these shareholders have agreed to
amend their income tax returns for 1990 if the Company disposes of substantially
all of the stock or assets of American Vaccine within a ten-year period. With
those amended returns, the shareholders will be required to pay tax based on the
- 71 -
<PAGE>
difference between their basis in American Vaccine stock and the value, at
February 28, 1990, of the Company stock received in the Merger, plus interest
from the time of the Merger to the disposition of American Vaccine stock or
assets by the Company.
In connection with the Merger, the Company entered into an indemnification
agreement with these shareholders of American Vaccine whereby the Company will
(i) lend to the affected shareholders, on an interest-free and after-tax basis,
an amount equal to the taxes to be paid with the amended tax returns; and (ii)
pay to the affected shareholders, on an after-tax basis, any interest and
penalties with respect to the taxes to be paid with the amended tax returns.
Under the terms of the indemnification agreement, repayment of the loans
described above will only be required at the time and to the extent that the
affected shareholders receive benefit from the resulting increase in the tax
basis of their Company stock. There can be no assurance that any such benefit
will be received.
The ultimate amount of this potential liability, if any, is not presently
determinable but will be based on the amount of gain, interest rates in effect
during the period, and the length of time between the consummation of the Merger
and the event triggering the gain recognition. Based on current interest rates,
the Company estimates that, in the event that the gain recognition would have
occurred at December 31, 1998, its obligations to the affected shareholders
could approximate $15.2 million.
(14) LICENSE AGREEMENTS
Certain of the conjugate vaccine-related technologies transferred to the
Company by BioChem in connection with the Merger are licensed under two
agreements with the National Research Council of Canada (the "NRC"), a Canadian
federal governmental agency. Under these license agreements, the Company will be
required to pay royalties to the NRC on all sales of such licensed products and
related services. Certain minimum annual royalties are payable irrespective of
the volume of sales of such products and services. BioChem has agreed to
reimburse the Company for 10 % of these minimum annual royalties. BioChem's
share of minimum annual royalties was less than five thousand dollars in each of
the last three years. The NRC has the right to terminate the license agreements
under certain specified conditions including if it concludes that all reasonable
efforts are not being used to develop and commercialize the technologies.
The Company has a license agreement with the National Technical Information
Service (the "NTIS"), an agency of the United States government, to bring the
method of preparing the acellular pertussis vaccine to the point of practical
application. In return, the NTIS granted the Company an exclusive license to
make, have made, use and sell the vaccine following approval of commercial sale
by the FDA. Under the agreement, the Company pays to the NTIS an annual
maintenance fee and a royalty based on sales or other similar dispositions of
the vaccine. The exclusive rights under this agreement will terminate seven
years from the date of the first commercial sale of the vaccine, which was on
October 29, 1998. The Company has acquired a royalty-bearing exclusive license
for the use of this patented technology in certain foreign jurisdictions for the
full term of the patents.
(15) SHAREHOLDERS' EQUITY
(a) PREFERRED STOCK. Preferred shares are nonvoting (other than as required
by law) and may be issued in one or more series. The Company has issued shares
of Series A preferred stock, which are convertible, at the option of the holder,
- 72 -
<PAGE>
into common stock on the basis of two shares of common stock for each share of
preferred stock held. The preferred stock had a liquidation preference of Can.
$2.50 per share or U.S. $3.3 million in the aggregate at December 31, 1998. The
conversion ratio is subject to adjustment for certain dilutive events.
(b) 1990 SHARE OPTION PLAN. In 1990, the Company adopted the North American
Vaccine, Inc. Share Option Plan (the "1990 Plan"), which, as amended, provided
for the issuance of up to 3,650,000 shares of its common stock to officers,
directors, employees and consultants. The 1990 Plan, which expired in February
1995, provided that options be granted at no less than market value on the date
of grant. In 1996 the Company extended the expiration date for options to
purchase 540,000 shares of common stock previously granted under this plan. The
fair market value of the Company's stock on the new grant date was less than the
exercise price of these options. Therefore no expense was recorded. In 1997, the
Company extended the expiration date for options to purchase 150,000 shares of
common stock previously granted under this plan. The Company recognized
approximately $1.3 million of expense representing the difference between the
fair market value and the exercise price of the options on the date of the
extension in 1997. For accounting purposes, the extensions of these options have
been treated as new grants.
(c) 1995 SHARE OPTION PLAN. In 1995, the Company adopted the North American
Vaccine, Inc. 1995 Share Option Plan (the "1995 Plan"), which provides for the
issuance of up to 1,000,000 shares of its common stock to officers, directors,
employees and consultants. The 1995 Plan, which expires in March 2000, provides
that options be granted at no less than market value on the date of the grant
and may have a term of up to 10 years.
(d) 1997 SHARE OPTION PLAN. In 1997, the Company adopted the North American
Vaccine, Inc. 1997 Share Option Plan (the "1997 Plan"), which provides for the
issuance of up to 5,000,000 shares of its common stock to officers, directors,
employees and consultants. The 1997 Plan, which expires in December 2007,
provides that options be granted at no less than market value on the date of the
grant and may have a term of up to 10 years.
- 73 -
<PAGE>
The following table summarizes option activity outside of any formal stock
option plan and under the 1990 Plan, the 1995 Plan and the 1997 Plan for the
period from December 31, 1995, through December 31, 1998:
<TABLE>
<CAPTION>
Number of Shares
----------------
1990 Plan 1995 Plan 1997 Plan Non-Plan Exercise Wtg.Avg.
Options Options Options Options Price Exer.Price
-----------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Balance at December 31, 1995 1,646,900 505,000 346,876 $ 1.56-14.13 $ 10.34
Granted 540,000 18,500 -- 12.88-21.50 13.16
Exercised (428,231) -- (231,252) 1.56-12.88 7.08
Expired or canceled (558,987) (24,000) -- 9.13-13.88 12.82
--------------------------------------------------------------
Balance at December 31, 1996 1,199,682 499,500 115,624 2.92-21.50 11.59
Granted 150,000 500,500 -- 11.13-24.50 18.69
Exercised (230,964) (19,291) (57,812) 9.00-13.88 9.66
Expired or canceled (153,069) (67,738) -- 9.13-24.50 14.68
--------------------------------------------------------------
Balance at December 31, 1997 965,649 912,971 57,812 2.92-24.50 13.93
Granted -- 60,000 879,700 -- 8.75-19.94 9.96
Exercised (368,938) (3,365) -- -- 9.00-13.88 12.44
Expired or canceled (200,603) (146,207) -- -- 9.00-24.50 14.52
--------------------------------------------------------------
Balance at December 31, 1998 396,108 823,399 879,700 57,812 $ 2.92-24.50 $ 12.37
</TABLE>
At December 31, 1998, under the 1990 Plan, outstanding options to purchase an
aggregate of 396,108 common shares were exercisable at prices ranging from $9.13
to $13.63 per share (weighted average exercise price per share of $11.09), and
no options were available for grant. At December 31, 1998, under the 1995 Plan,
options to purchase an aggregate of 587,174 common shares were exercisable at
prices ranging from $11.25 to $24.50 per share (weighted average exercise price
per share of $15.52), and 153,945 options were available for grant. At December
31, 1998, no options were exercisable under the 1997 Plan.
The weighted-average per share grant date fair value of options granted
during 1997 and 1996 for the 1990 Plan was $13.16 and $5.11, respectively. The
weighted-average per share grant date fair value of options granted during 1998,
1997 and 1996 for the 1995 Plan was $10.62, $12.39 and $10.59, respectively. The
weighted-average per share grant date fair value of options granted during 1998
for the 1997 Plan was $7.59.
(e) 1990 NON-EMPLOYEE DIRECTOR AND SENIOR EXECUTIVE STOCK OPTION PLAN ("1990
SESOP"). In 1990, the Company adopted the 1990 SESOP, which, as amended,
provided for the issuance of up to 1,850,000 shares of its common stock to all
the Company's non-employee directors, and senior executives who are residents of
Canada. Under the 1990 SESOP, which expired in October 1995, options were
granted automatically to each non-employee director annually on January 1. The
1990 SESOP required that the exercise price must not be less than the market
value of the stock at the date of grant. Options issued to non-employee
directors under the 1990 SESOP are exercisable in Canadian currency, vest
ratably over a period of three years and expire five years from the date of
grant. Upon a change of control of the Company, all outstanding stock options
granted under the 1990 SESOP become fully exercisable.
- 74 -
<PAGE>
(f) 1995 NON-EMPLOYEE DIRECTOR AND SENIOR EXECUTIVE STOCK OPTION PLAN ("1995
SESOP"). In 1995, the Company adopted the 1995 SESOP, which provides for the
issuance of up to 500,000 shares of its common stock to all the Company's
non-employee directors, and its senior executives who are residents of Canada.
Under the 1995 SESOP, which expires in March 2000, options are granted
automatically to each non-employee director annually on January 1. The 1995
SESOP requires that the exercise price must not be less than the market value of
the stock at the date of grant. Options issued to non-employee directors vest
ratably over a period of three years and expire ten years from the date of
grant. Upon a change of control of the Company, all outstanding stock options
granted under the 1995 SESOP become fully exercisable.
The following table summarizes option activity under the 1990 SESOP plan and
the 1995 SESOP plan from December 31, 1995 through December 31, 1998:
<TABLE>
<CAPTION>
1990 1995
SESOP SESOP Exercise Price Wtg.Avg.
Plan Options Plan Options Can.$ U.S.$ Exer.Price(U.S.)
----------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Balance at December 31, 1995 700,000 -- $ 1.88-15.10 $ 1.37-11.02 $ 9.56
Granted -- 130,000 -- 14.13 14.13
Exercised (199,999) -- 1.88-15.10 1.37-11.01 8.47
Expired or canceled (10,001) (10,000) 11.75-14.56 8.58-14.13 11.69
---------------------------------------------------------------
Balance at December 31, 1996 490,000 120,000 11.75-15.10 8.58-14.13 10.82
Granted -- 130,000 -- 24.38 24.38
Exercised (190,000) -- 12.88-15.10 9.01-10.56 10.31
Expired or canceled -- -- -- -- --
---------------------------------------------------------------
Balance at December 31, 1997 300,000 250,000 11.75-14.56 8.22-24.38 13.83
Granted -- 130,000 -- 24.94 24.94
Exercised (90,000) -- 12.88-14.56 8.42-9.52 8.54
Expired or canceled -- (20,001) -- 14.13-24.94 22.95
---------------------------------------------------------------
Balance at December 31, 1998 210,000 359,999 $ 11.75-14.56 $ 7.68-24.94 $ 16.57
</TABLE>
At December 31, 1998, under the 1990 SESOP, 210,000 options were
exercisable at prices ranging from Can. $11.75 to Can. $14.56 (U.S. $7.68 to
U.S. $9.52) per share (weighted average U.S. price of $8.55) and no options
were available for grant under the 1990 SESOP. At December 31, 1998, under
the 1995 SESOP, 123,234 options were exercisable at prices ranging from U.S.
$14.13 to U.S. $24.38 per share (weighted average U.S. price of $17.73), and
140,001 options were available for grant. Subsequent to year end, options to
acquire an additional 130,000 shares were granted under this plan at an
exercise price of U.S. $8.88. The weighted-average per share grant date fair
value of options granted during 1998, 1997 and 1996 for the 1995 SESOP plan
was U.S. $16.96, $15.92 and U.S. $10.58, respectively.
(g) STOCK BASED COMPENSATION PLANS. The Company applies the intrinsic value
based method of accounting pursuant to APB Opinion No. 25, "Accounting For Stock
Issued To Employees," and related interpretations for option grants under its
stock based compensation plans. Accordingly, no compensation cost has been
recognized in the accompanying financial statements. Had compensation cost for
- 75 -
<PAGE>
the Company's five stock option plans been determined on the fair value based
method of SFAS No. 123, "Accounting for Stock-Based Compensation," at the grant
dates for awards under these plans, the Company's net loss and loss per share
for 1998, 1997 and 1996 would have been $61.0 million or a loss of $1.90 per
share, $49.3 million or a loss of $1.56 per share, and $23.9 million or a loss
of $0.78 per share, respectively.
The Black-Scholes option valuation model was developed for use in estimating
the fair value of traded options which have no vesting restrictions and are
fully transferable. In addition, option valuation models require the input of
highly subjective assumptions including the expected stock price characteristics
significantly different from those of traded options, and because changes in the
subjective input assumptions can materially affect the fair value estimate, in
management's opinion, the existing models do not necessarily provide a reliable
single measure of the fair value of its employee stock options.
Pursuant to SFAS No. 123, the fair value of each option grant is estimated on
the date of grant using a Black-Scholes option pricing model with the following
weighted average assumptions used for grants in 1998, 1997, and 1996,
respectively: risk-free interest rates of 6.04-6.41 percent for the 1990 Plan
option extensions, 5.64-6.99 percent for the 1995 Plan options, 4.34-4.81
percent for the 1997 Plan options, and 5.21-6.47 percent for the 1995 SESOP
options; no expected dividend yields; expected lives of between 1.5 and 4 years
for the 1990 Plan option extensions, between 4 and 8 years for the 1995 Plan
options, between 5 years and 8 years for the 1997 Plan, and 7-8 years for the
1995 SESOP options; and expected volatilities of 65, 58 and 78 percent. Of the
2,727,018 options outstanding at December 31, 1998, 1,316,606 options have a
weighted average remaining contractual life of approximately 4.5 years. All of
these options are exercisable. The remaining 1,410,412 options have a weighted
average remaining contractual life of approximately 9.0 years.
(16) RETIREMENT AND SAVINGS 401(K) PLAN AND TRUST
The Company's Retirement and Savings 401(k) Plan and Trust (the "Plan")
became effective April 1, 1991. The Plan is a qualified profit-sharing plan with
a cash or deferred compensation arrangement and discretionary matching
contributions. Under the Plan, eligible employees may elect to contribute to the
Plan by salary deferrals up to an annual limit, which is the lesser of 20
percent of a participant's annual compensation or the maximum allowed by law,
and the Company may contribute matching amounts as provided by the Plan. Salary
deferrals and matching contributions are vested immediately. The Company's
matching expense, contributed in the form of the Company's common stock, was
$309,000, $251,000, and $200,000 for 1998, 1997, and 1996, respectively.
The Company may elect to make additional contributions to the Plan, from its
current or accumulated net profits, in the form of a profit sharing
contribution. This discretionary contribution will be made for all eligible
participants regardless of whether such participants make any salary deferrals
for that plan year. Profit sharing contributions are vested ratably over a five
year period. From inception of the Plan, the Company has not made a profit
sharing contribution.
The Plan provides for an overall limitation with respect to the amount of
contributions (including Company match, if any) which can be allocated to any
participant in any plan year. This limitation is the lesser of 25 percent of a
participant's annual compensation or the maximum allowed by law.
- 76 -
<PAGE>
(17) RELATED-PARTY TRANSACTIONS
In the Merger, as discussed in Note 1, the Company and BioChem granted to
each other a one time demand registration right (with expenses to be paid by the
party exercising the registration right) and certain piggy-back registration
rights, through January 17, 1995. In connection with a proposed offering of the
Company's stock in 1994 by both BioChem and the Company, which offering was
later withdrawn at BioChem's request, BioChem's one-time demand registration
right was extended through January 17, 1998. In the first quarter of 1998, this
demand registration was further extended to January 17, 2001.
In April 1998, the Company extended a loan to its then president, related
to the exercise of expiring stock options. The loan was comprised of
approximately $1.0 million for the exercise of the options and $217,000 for
payment of withholding taxes. The loan was made on a full recourse basis, was
for a six month period, was collateralized by approximately 94,000 shares of
common stock of the Company, which at the time of the loan had a fair market
value of 125% of the principal amount of the loan. The loan accrued interest at
a fair market rate, was repaid in full at maturity in October 1998, and the
related collateral has been released.
In November 1998, the Company completed a $25 million financing through the
private placement of an offering of 4.5% Notes. BioChem and Dr. Frost,
affiliates of the Company, purchased 4.5% Notes in the aggregate principal
amount of $9 million and $4.25 million, respectively. In addition, Sofinov
purchased 4.5% Notes in the aggregate principal amount of $6.25 million. Denis
Dionne, a director of the Company, is the President of Sofinov. See Note 10 for
further details.
- 77 -
<PAGE>
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
-----------------------------------------------------------------
None.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
--------------------------------------------------
The information required by this Item 10 is incorporated by reference to
the discussion under the headings "Election of Directors," "Identification of
Senior Management" and "Security Ownership of Certain Beneficial Owners and
Management - Section 16(a) Beneficial Ownership Reporting Compliance" as set
forth in the Company's 1999 Proxy Statement.
ITEM 11. EXECUTIVE COMPENSATION
----------------------
The information required by this Item 11 is incorporated by reference to
the discussion under the heading "Executive Compensation" and "Election of
Directors - Compensation of Directors" set forth in the Company's 1999 Proxy
Statement.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
--------------------------------------------------------------
The information required by this Item 12 is incorporated by reference to
the discussion under the heading "Security Ownership of Certain Beneficial
Owners and Management" set forth in the Company's 1999 Proxy Statement.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
----------------------------------------------
The information required by this Item 13 is incorporated by reference to
the discussion under the heading "Certain Transactions" set forth in the
Company's 1999 Proxy Statement.
- 78 -
<PAGE>
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
----------------------------------------------------------------
A) DOCUMENTS FILED AS PART OF FORM 10-K.
-------------------------------------
The following documents are filed as part of this Annual Report on Form
10-K:
1. Financial Statements: Page
--------------------- ----
Report of Independent Public Accountants 50
Consolidated Balance Sheets as of
December 31, 1998 and 1997 51
Consolidated Statements of Operations for the
Years Ended December 31, 1998, 1997 and 1996 52
Consolidated Statements of Shareholders' Equity (Deficit)
for the Years Ended December 31, 1998,
1997 and 1996 53
Consolidated Statements of Cash Flows for the
Years Ended December 31, 1998, 1997 and 1996 54
Notes to Consolidated Financial Statements 56
2. Financial Statement Schedules:
-----------------------------
Schedule II - Valuation and Qualifying Accounts for the
Years Ended December 31, 1998, 1997 and 1996 81
3. Exhibits: See Exhibit Index on page 83.
--------
B) REPORTS ON FORM 8-K.
--------------------
The following reports on Form 8-K were filed during the three months ended
December 31, 1998:
(1) On November 20, 1998, the Company filed with the Securities and
Exchange Commission a Current Report on Form 8-K under Item 5
reporting the completion of a $25 million financing through the
private placement of 4.5% Convertible Secured Notes due November 13,
2003.
(2) On December 11, 1998, the Company filed with the Securities and
Exchange Commission a Current Report on Form 8-K under Item 5
reporting that the Company's 1999 Annual Meeting of Shareholders
will be held on February 23, 1999 and the record date for the
meeting will be January 15, 1999.
C) FINANCIAL STATEMENT SCHEDULES.
-----------------------------
- 79 -
<PAGE>
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To North American Vaccine, Inc. and Subsidiaries:
We have audited in accordance with generally accepted auditing
standards, the consolidated financial statements of North American Vaccine, Inc.
(a Canadian corporation) and subsidiaries included in this Form 10-K and have
issued our report thereon dated January 18, 1999. Our audit was made for the
purpose of forming an opinion on the basic consolidated financial statements
taken as a whole. The accompanying schedule is presented for purposes of
complying with the Securities and Exchange Commission's rules and is not part of
the basic consolidated financial statements. This schedule has been subjected to
the auditing procedures applied in the audit of the basic consolidated financial
statements and, in our opinion, fairly states in all material respects the
financial data required to be set forth therein in relation to the basic
consolidated financial statements taken as a whole.
Arthur Andersen LLP
/s/ Arthur Andersen LLP
- -----------------------
Baltimore, Maryland
January 18, 1999
- 80 -
<PAGE>
<TABLE>
<CAPTION>
North American Vaccine, Inc. and Subsidiaries
Schedule II - Valuation and Qualifying Accounts
For Years Ended December 31, 1996, 1997 and 1998
(In thousands)
Balances as of Additions Balances as of
Beginning Charges to End of
of Period Expense Deductions Period
---------------- ------------- -------------- ---------------
<S> <C> <C> <C> <C>
PHYSICAL INVENTORY RESERVE
Year Ended December 31, 1996 $ 19 $ 54 $ - $ 74
Year Ended December 31, 1997 $ 74 $ 113 $ - $ 187
Year Ended December 31,1998 $ 187 $ 787 $ - $ 974
TAX VALUATION ALLOWANCE
Year Ended December 31, 1996 $ 18,697 $ 11,786 $ - $ 30,483
Year Ended December 31, 1997 $ 30,483 $ 14,645 $ - $ 45,128
Year Ended December 31,1998 $ 45,128 $ 14,315 $ - $ 59,443
</TABLE>
- 81 -
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, North American Vaccine, Inc. has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.
NORTH AMERICAN VACCINE, INC.
Dated: January 29, 1999 By: /s/ Randal Chase
-----------------------------------
Randal Chase, Ph.D.
President & Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of North
American Vaccine, Inc. in the capacities and on the dates indicated.
PRINCIPAL EXECUTIVE OFFICER:
/s/ Randal Chase January 29, 1999
- ------------------------
Randal Chase, Ph.D.
President & Chief Executive Officer
PRINCIPAL FINANCIAL OFFICER AND
PRINCIPAL ACCOUNTING OFFICER:
/s/ Lawrence J. Hineline January 29, 1999
- ------------------------
Lawrence J. Hineline
Vice President-Finance
A MAJORITY OF THE BOARD OF DIRECTORS:
<TABLE>
<CAPTION>
<S> <C> <C> <C>
/s/ Francesco Bellini January 25, 1999 /s/ Philip Frost January 25, 1999
- ---------------------- -------------------
Francesco Bellini, Ph.D . Philip Frost, M.D.
/s/ Alain Cousineau January 25, 1999 /s/ Lyle Kasprick January 25, 1999
- ---------------------- -------------------
Alain Cousineau Lyle Kasprick
/s/ Jonathan Deitcher January 25, 1999 /s/ Francois Legault January 29, 1999
- ---------------------- -------------------
Jonathan Deitcher Francois Legault
/s/ Denis Dionne January 25, 1999
- ---------------------- --------------------
Denis Dionne Sharon Mates, Ph.D. January ___, 1999
/s/ Gervais Dionne January 25, 1999 /s/ Richard C. Pfenninger, Jr.
- ---------------------- ------------------------------
Gervais Dionne, Ph.D. Richard C. Pfenninger, Jr. January 25, 1999
/s/ Neil W. Flanzraich January 28, 1999
- ----------------------
Neil W. Flanzraich
</TABLE>
- 82 -
<PAGE>
EXHIBIT INDEX
EXHIBIT
NO. DESCRIPTION
- --- -----------
2.1 Master Agreement, dated October 25, 1989, among North American Vaccine,
Inc. ("NAV"), American Vaccine Corporation ("American Vaccine") and IAF
BioChem International, Inc. ("BioChem"). (1)
2.2 Agreement and Plan of Merger, dated as of October 25, 1989, among NAV,
American Vaccine and NAVA Acquiring Corp. (1)
2.3 Share Purchase Agreement, dated January 17, 1990, between NAV and
BioChem. (1)
2.4 Technology Transfer Agreement, dated January 17, 1990, between NAV and
BioChem. (1)
2.5 Amendment to Share Purchase Agreement dated as of January 8, 1998 between
NAV and BioChem. (2)
3.1 Articles of Incorporation of NAV, as amended. (1)(6)
3.2 Restated Bylaws of NAV. (3)
9.1 Shareholders' Agreement, dated January 17, 1990, among BioChem, Phillip
Frost, M.D., IVAX Corporation ("IVAX") and Frost-Nevada, Limited
Partnership ("Frost-Nevada"). (1)
10.1 License Agreement, dated July 27, 1987, between Canadian Patents and
Development Limited ("CPDL") and BioChem [with certain confidential
information deleted therefrom]. (1)
10.2 License Agreement, dated June 27, 1988, between CPDL and BioChem [with
certain confidential information deleted therefrom]. (1)
10.3 Agreement, dated April 6, 1989, between AMVAX, Inc. ("AMVAX") and the
National Institute of Child Health and Human Development ("NICHD"). (1)
10.4 License Agreement, dated March 25, 1988, between National Technical
Information Service ("NTIS") and Selcore Laboratories, Inc., predecessor
to AMVAX ("Selcore") [with certain confidential information deleted
therefrom]. (1)
10.5 Second Amended and Restated Patent License Agreement, dated March 12,
1992, between Ronald D. Sekura, Ph.D., and AMVAX [with certain
confidential information deleted therefrom]. (6)
10.6* North American Vaccine, Inc. Share Option Plan, as amended. (7)
10.9 Form of Indemnification Agreement among NAV, American Vaccine, IVAX,
Frost-Nevada and Ronald D. Sekura, Ph.D. (1)
- 83 -
<PAGE>
EXHIBIT
NO. DESCRIPTION
- --- -----------
10.12 Lease Agreement dated December 31, 1987, as amended, between Selcore and
Indian Creek Holding Associates Limited Partnership. (1)
10.14 Supply Agreement between AMVAX and Statens Seruminstitut dated March 26,
1991 [with certain confidential information deleted therefrom]. (4)
10.16 Supply Agreement between AMVAX and Statens Seruminstitut dated March 26,
1991 [with certain confidential information deleted therefrom]. (4)
10.17 Research, Development and License Agreement between AMVAX and Statens
Seruminstitut dated March 26, 1991 [with certain confidential information
deleted therefrom]. (4)
10.18* Non-Employee Director and Senior Executive Stock Option Plan, as amended.
(7)
10.22 Amended and restated master agreement dated June 20, 1994 among NAV,
BioChem, IVAX, D&N Holding Company, Frost-Nevada and Phillip Frost. (9)
10.23 Share exchange agreement dated April 20, 1994 between NAV and BioChem.
(8)
10.25* North American Vaccine, Inc. 1995 Share Option Plan. (10)
10.26* North American Vaccine, Inc. 1995 Non-Employee Director and Senior
Executive Stock Option Plan. (11)
10.27 Clinical Development Agreement dated December 22, 1995 between NAV and
Pasteur Merieux Serums et Vaccins ("PMSV") [with certain confidential
information deleted therefrom]. (12)
10.28 License Agreement dated December 22, 1995 between NAV and PMSV [with
certain confidential information deleted therefrom]. (12)
10.29 Indenture dated May 7, 1996 between NAV and Marine Midland Bank. (13)
10.30 Registration Rights Agreement dated May 1, 1996 between NAV, Goldman,
Sachs & Co. and UBS Securities LLC. (13)
10.32 Stock Purchase Agreement dated October 11, 1996 between Abbott
Laboratories and NAV. (14)
10.33 Assets Purchase Agreement dated October 17, 1996 among NAV, Cephalon
Property Management, Inc. ("CPMI") and Cephalon, Inc. [with certain
confidential information deleted therefrom]. (14)
10.34 Assignment and Assumption of Leases dated November 12, 1996 between CPMI
and NAV. (15)
10.35 Master Agreement dated November 1, 1996 between NAV and General Electric
Capital Corporation [with certain confidential information deleted
therefrom]. (15)
10.36* North American Vaccine, Inc. 1997 Share Option Plan. (16)
- 84 -
<PAGE>
EXHIBIT
NO. DESCRIPTION
- --- -----------
10.37 Lease Agreement dated as of March 25, 1998 between ARE-10150 Old
Columbia, LLC and the Company [with certain confidential information
deleted therefrom]. (17)
10.38 Indenture dated November 12, 1998 by and between the Company and Bankers
Trust Company, as Trustee. (18)
10.39 Security and Pledge Agreement dated November 12, 1998 by and between the
Company and Bankers Trust Company, as Trustee. (18)
10.40* North American Vaccine, Inc. 1999 Non-Employee Director and Senior
Executive Stock Option Plan.
10.41 First Amendment to the Lease Agreement dated as of January 21, 1999
between Liberty Property Limited Partnership and Amvax, Inc. f/k/a
Selcore Laboratories, Inc.
21 Subsidiaries. (5)
23 Consent of Independent Public Accountants.
27 Financial Data Schedule.
- -----------------------------
* Management contract or compensatory plan or arrangement.
(1) This exhibit is incorporated herein by this reference to the
corresponding exhibit in the Company's Form S-4 Registration Statement
(File No. 33-31512) filed with the SEC and declared effective on January
24, 1990.
(2) This exhibit is incorporated herein by this reference to the
corresponding exhibit in the Company's Current Report on Form 8-K filed
with the SEC on January 29, 1998 (File No. 1-10451).
(3) This exhibit is incorporated herein by this reference to the
corresponding exhibit in the Company's Form 10-Q Quarterly Report for the
Quarter Ended June 30, 1990 (File No. 1-10451).
(4) This exhibit is incorporated herein by this reference to the
corresponding exhibit in the Company's Form 10-K Annual Report for the
Year Ended December 31, 1990 (File No. 1-10451).
(5) This exhibit is incorporated herein by this reference to Exhibit 22 in
the Company's Form 10-K Annual Report for the Year Ended December 31,
1990 (File No. 1-10451).
(6) This exhibit is incorporated herein by this reference to the
corresponding exhibit in the Company's Form 10-K Annual Report for the
Year Ended December 31, 1991 (File No. 1-10451).
(7) This exhibit is incorporated herein by this reference to the
corresponding exhibit in the Company's Form 10-K Annual Report for the
Year Ended December 31, 1992 (File No. 1-10451).
(8) This exhibit is incorporated herein by this reference to the
corresponding exhibit in the Company's Form 10-Q Quarterly Report for the
Quarter Ended March 31, 1994 (File No. 1-10451).
- 85 -
<PAGE>
(9) This exhibit is incorporated herein by this reference to Exhibit 99.1 in
the Company's Registration Statement on Form S-3 (Registration No.
33-78002) filed with the SEC and withdrawn from registration on November
23, 1994.
(10) This exhibit is incorporated herein by this reference to Exhibit 4.1 in
the Company's Registration Statement on Form S-8 (Registration No.
33-80479) filed with the SEC and effective as of December 15, 1995.
(11) This exhibit is incorporated herein by this reference to Exhibit 4.2 in
the Company's Registration Statement on Form S-8 (Registration No.
33-80479) filed with the SEC and effective as of December 15, 1995.
(12) This exhibit is incorporated herein by this reference to the
corresponding exhibit in the Company's Form 10-K Annual Report for the
Year Ended December 31, 1995 (File No. 1-10451).
(13) This exhibit is incorporated herein by this reference to the
corresponding exhibit in the Company's Form 10-Q Quarterly Report for the
Quarter Ended March 31, 1996 (File No. 1-10451).
(14) This exhibit is incorporated herein by this reference to the
corresponding exhibit in the Company's Form 10-Q Quarterly Report for the
Quarter Ended September 30, 1996 (File No. 1-10451).
(15) This exhibit is incorporated herein by this reference to the
corresponding exhibit in the Company's Form 10-K Annual Report for the
Year Ended December 31, 1996 (File No. 1-10451).
(16) This exhibit is incorporated herein by this reference to the
corresponding exhibit in the Company's Form 10-K Annual Report for the
Year Ended December 31, 1997 (File No. 1-10451).
(17) This exhibit is incorporated herein by this reference to the
corresponding exhibit in the Company's Form 10-Q Quarterly Report for the
Quarter Ended March 31, 1998 (File No. 1-10451).
(18) This exhibit is incorporated herein by this reference to the
corresponding exhibit in the Company's Current Report on Form 8-K filed
with the SEC on November 20, 1998 (File No. 1-10451).
- 86 -
EXHIBIT 10.40
NORTH AMERICAN VACCINE, INC.
1999 NON-EMPLOYEE DIRECTOR AND
SENIOR EXECUTIVE STOCK OPTION PLAN
This 1999 Non-Employee Director and Senior Executive Stock Option Plan
(the "Plan") of North American Vaccine, Inc., a Canadian corporation (the
Corporation"), is effective as of January 25, 1999. The purpose of the Plan is
to help attract, keep and motivate the Corporation's Non-Employee Directors and
Senior Executives, as those terms are defined in the Plan.
ARTICLE I
STOCK SUBJECT TO OPTION
-----------------------
The total number of shares which may be issued under stock options
("options") granted pursuant to the Plan is 650,000 shares of the Corporation's
Common Stock, no par value per share ("Common Stock"). The shares issued under
options shall be newly issued or treasury shares of Common Stock. The grant of
an option pursuant to the Plan shall reduce the number of shares of Common Stock
that thereafter may be available for future grants under the Plan; provided,
however, that if an option should expire, terminate or otherwise become
unexercisable for any reason without having been exercised in full, the
unpurchased shares that were subject thereto shall, unless the Plan shall have
been terminated, become available for further grant under the Plan. Exercise of
an option in any manner shall result in a decrease in the number of shares of
Common Stock that thereafter may be available for purchase under the option by
the number of shares of Common Stock as to which the option is exercised.
ARTICLE II
ADMINISTRATION OF PLAN
----------------------
SECTION 2.1 The Plan shall be administered at all times by a committee
appointed by the Corporation's Board of Directors (the "Committee"). The
Committee shall consist of not less than two members of the Board of Directors,
each of whom is a "non-employee director" as defined in Rule 16b-3 promulgated
under the Securities Exchange Act of 1934, as amended (the "1934 Act"), and an
"outside director" as defined for purposes of Section 162(m) of the Internal
Revenue Code of 1986, as amended (the "Code").
SECTION 2.2 Subject to the provisions of the Plan, the Committee is
authorized to interpret the Plan, to prescribe, amend, and rescind rules and
regulations relating to the Plan, and to make all other determinations necessary
or advisable for the administration of the Plan, including, without limitation,
(i) to accelerate the vesting of any option already granted, (ii) to determine
whether the exercise price of or taxes relating to an option may be paid in
already owned shares of Common Stock and/or shares then issuable upon the
exercise of the option, (iii) to determine the terms and provisions of each
option granted under the Plan (which need not be identical), (iv) to waive or
<PAGE>
amend any and all restrictions and conditions of any options, including, without
limitation, extending the term of any option, and (v) to authorize any person to
execute on behalf of the Corporation any instrument required to effectuate the
grant of an option previously granted by the Committee. The Board of Directors
may in its discretion at any time and from time to time alter the membership of
the Committee consistent with the requirements set forth in Section 2.1.
SECTION 2.3 Any interpretation issued by the Committee shall be final,
conclusive and binding on each optionee. No member of the Board of Directors or
the Committee shall be liable for any action or determination made in good faith
with respect to the Plan or any option agreement.
ARTICLE III
AUTOMATIC GRANT OF OPTIONS TO NON-EMPLOYEE DIRECTORS
----------------------------------------------------
SECTION 3.1 Each member of the Board of Directors of the Corporation who
is not an employee of the Corporation or any of its subsidiaries (a
"Non-Employee Director") shall automatically receive options in accordance with
the provisions of Section 3.2 below, without any further action or authorization
required by the Board of Directors or the Committee.
SECTION 3.2 (a) On each January 1, commencing on January 1, 2000, each
Non-Employee Director who holds office as of the relevant January 1, shall
automatically receive an option to acquire:
(i) 20,000 shares of the Corporation's Common Stock if the
Non-Employee Director is the Chairman of the Board or Vice-Chairman of the
Board; or
(ii) 5,000 shares of the Corporation's Common Stock for all
other Non-Employee Directors.
(b) On each January 1, commencing on January 1, 2000, each
Non-Employee Director (other than the Chairman and Vice Chairman of the Board)
of the Corporation who holds office as of the relevant January 1 and who serves
on a committee of the Board of Directors as of the relevant January 1, shall
automatically receive an option, in addition to the grant of the options
prescribed in Section 3.2(a)(ii), above, to acquire 5,000 shares of the
Corporation's Common Stock for each committee of the Board of Directors on which
he or she serves.
SECTION 3.3 Each option automatically granted under this Article III shall
be exercisable in accordance with the following schedule:
(a) each option shall first become exercisable to purchase one-third
of the shares under such option on the first January 1 following the date of
grant of the option;
-2-
<PAGE>
(b) each option shall first become exercisable to purchase an
additional one-third of the shares under such option on the second January 1
following the date of grant of the option; and
(c) each option shall first become exercisable to purchase the
remaining one-third of the shares under such option on the third January 1
following the date of grant of the option.
ARTICLE IV
GRANT OF OPTIONS TO SENIOR EXECUTIVES
-------------------------------------
SECTION 4.1 Subject to the provisions of, and within the parameters
established in, the Plan, the Committee shall have the exclusive power to select
the Senior Executives, as defined in Section 4.2, of the Corporation who will be
granted options, the time or times at which an option may be granted, the number
of shares for which an option is granted, the vesting schedule for the options,
the term of the option, and the exercise price per share of the options to be
granted; provided, however, that subject to the provisions of Article X of the
Plan, the maximum number of shares of Common Stock with respect to which options
may be granted under the Plan to any Senior Executive in any calendar year is
one percent (1%) of the shares of Common Stock issued and outstanding as of the
first day of such calendar year.
SECTION 4.2 All Senior Executives of the Corporation who are residents of
Canada shall be eligible to receive options to purchase stock under the Plan.
The term "Senior Executive" for purposes of the Plan shall mean any person
exercising the function of president, vice-president, secretary, treasurer,
controller or general manager, or similar functions but shall not include any
person who is a director of the Corporation, whether or not such person would
otherwise qualify as a Senior Executive. Senior Executives who are not residents
of Canada are not eligible to receive options to purchase Common Stock under the
Plan.
ARTICLE V
OPTION PRICE
------------
For options granted to Non-Employee Directors, the option price for the
purchase of any Common Stock pursuant to any option granted under Article III
shall be 100% of the fair market value of the Common Stock at the time the
option is granted. For options granted to Senior Executives, the minimum option
price for the purchase of any Common Stock pursuant to any option granted under
Article IV shall be 100% of the fair market value of the Common Stock at the
time the option is granted. The fair market value thereof shall be determined by
the Committee; provided, however, that where there is a public market for the
Common Stock, the fair market value per share shall be the closing sale price of
the Common Stock on the principal securities exchange (or Nasdaq, if applicable)
on which the Common Stock is trading on the date of grant, or if there were no
sales reported as of such date, then the last date preceding such date on which
a sale was reported, or if any such exchange or quotation system is closed on
that date, then on the last preceding date on which the securities exchange (or
Nasdaq, if applicable) was open for trading.
-3-
<PAGE>
ARTICLE VI
TERM OF PLAN; VESTING OF OPTIONS
--------------------------------
SECTION 6.1 The Plan shall be effective as of the date first above written
and shall expire on, and all options authorized under the Plan must be granted
on or before, January 25, 2009.
SECTION 6.2 Each option granted under Article III of the Plan shall
provide that it is to be exercised within a period of ten (10) years after the
date the option is granted and shall be exercisable in accordance with the
vesting schedule set forth in Section 3.3. Each option granted under Article IV
of the Plan shall provide that it is to be exercisable within a period to be
determined by the Compensation Committee, which shall not exceed ten (10) years
after the date the option is granted, and shall be exercisable by the optionee
at such time or times as shall be prescribed and specified in the option
agreement with each such optionee. Options granted under the Plan may be
exercised by the optionee in whole or in part or in installments. Options may
not be exercised for a fraction of a share.
SECTION 6.3 (a) The exercisability of each option granted under Article
III of the Plan shall be automatically accelerated so that each such option
outstanding shall, immediately prior to the specified effective date of any of
the following events, become fully exercisable with respect to the total number
of shares subject to such option and may be exercisable for all or any portion
of such shares, in the event that:
(i) any person (as defined for purposes of Section
13(d) and 14(d) of the 1934 Act, but excluding the Corporation and any of its
wholly-owned subsidiaries) acquires direct or indirect ownership of fifty
percent (50%) or more of the combined voting power of the then outstanding
voting securities of the Corporation as a result of a tender or exchange offer,
open market purchases, privately negotiated purchases or otherwise;
(ii) any election has occurred of persons to the Board
of Directors of the Corporation that causes two-thirds of the Corporation's
Board of Directors to consist of persons other than (A) persons who were members
of the Corporation's Board of Directors on January 1, 1999 and (B) persons who
were nominated by the Corporation's Board of Directors for election as members
of the Corporation's Board of Directors at a time when two-thirds of the
Corporation's Board of Directors consisted of persons who were members of the
Corporation's Board of Directors on January 1, 1999; provided, however, that any
person nominated for election by the Board of Directors of the Corporation at
least two-thirds of whom constituted persons described in clauses (A) and/or (B)
above or by persons who were themselves nominated by such Board shall, for this
purpose, be deemed to have been nominated by a Board composed of persons
described in clause (A) above; or
(iii) the shareholders of the Corporation approve (A)
any statutory consolidation, merger or amalgamation of the Corporation in which
the Corporation is not the surviving corporation (other than a merger or
amalgamation of the Corporation in which the holders of Common Stock immediately
prior to the merger or amalgamation have the same proportionate ownership of the
-4-
<PAGE>
surviving corporation immediately after the merger or amalgamation), or (B) any
sale, lease, exchange or other transfer (in one transaction or a series of
related transactions) of all, or substantially all, of the assets of the
Corporation to an entity that is not a wholly-owned subsidiary of the
Corporation.
(b) If one of the events cited in Section 6.3(a) occurs, any optionee
granted an option pursuant to Article III of the Plan has the right, for a
period of sixty (60) days following the later of (i) the date of such event or
(ii) the expiration of six (6) months from the date of grant of an option under
the Plan, to elect to surrender for cancellation any option to the extent not
exercised and the optionee will be entitled to receive, in the sole discretion
of the Committee, either a cash payment, or Common Shares having a fair market
value, equal to (A) the aggregate fair market value of the unexercised shares
remaining under the option surrendered for cancellation, less (B) the aggregate
exercise price for such optioned shares; provided, however, if, in the opinion
of the Corporation's counsel, such discretion by the Committee would cause the
members of the Committee to cease to be "non-employee directors" as defined in
Rule 16b-3 of the 1934 Act or "outside directors" as defined for purposes of
Section 162(m) of the Code, then such optionee shall receive only Common Stock
upon the surrender for cancellation of such option. For purposes of this Section
6.3(b), fair market value shall be determined pursuant to Article V as of the
date on which an event cited in Section 6.3(a) occurs. Notwithstanding the
foregoing, an optionee shall not be entitled to the benefits of this Section
6.3(b) where such event is solely attributable to the event described in Section
6.3(a)(i) and the optionee is the person (or is a member of a group which
comprises the person) who acquires beneficial ownership of fifty percent (50%)
or more of the combined voting power of the then outstanding securities of the
Corporation.
ARTICLE VII
TERMINATION OF EMPLOYMENT
-------------------------
SECTION 7.1 (a) Except as noted in Section 7.2, upon a Senior Executive's
resignation from or termination of employment with the Corporation for any
reason whatsoever (including, without limitation, death), any option held by
such person shall be exercisable within twelve (12) months after the date of
such resignation or termination (or such shorter or longer period as the
Committee shall determine) to the extent such person was entitled to exercise
such option as of the date of such resignation or termination.
(b) Except as noted in Section 7.2, upon a Non-Employee Director's
resignation or termination from the Corporation's Board of Directors for any
reason whatsoever (including, without limitation, death), any option held by
such person shall be exercisable, to the extent such person was entitled to
exercise such option as of the date of such resignation or termination, at any
time prior to the expiration date of the option.
SECTION 7.2 Notwithstanding the provisions of Section 7.1, if any Senior
Executive or Non-Employee Director is terminated or removed by the Corporation
for willful or gross misconduct, including, without limitation, breach of
fiduciary duty (the Committee's determination in this regard shall be final,
binding and conclusive), any and all options held by such person shall terminate
immediately and automatically at the time of his or her termination, unless the
Committee provides for an earlier or later time for the termination of such
-5-
<PAGE>
option(s), and such option(s) will not be exercisable after such time of
termination unless otherwise determined by the Committee.
SECTION 7.3 Subject to the provisions of the Plan, any option held by an
optionee at the time of his or her death may be exercised subsequently by the
legal representative of such optionee's estate during the remaining term of the
option, but only to the extent such optionee was entitled to exercise such
option as of the date of his or her death, unless the Committee provides
otherwise. In the event of the death of an optionee during the final three (3)
months of the time period specified in Section 7.1(a), the option may be
exercised, at any time within three (3) months following the date of his or her
death, by the optionee's estate or by a person or persons who acquired the right
to exercise the option by bequest or inheritance, but only to the extent the
optionee was entitled to exercise such option as of the date of his or her
death, unless the Committee provides for a longer or shorter period.
SECTION 7.4 None of the events described in this Article VII shall extend
the period of exercisability of an option beyond the expiration date thereof
prescribed under Section 6.2 above, notwithstanding the intervention of a
succeeding vesting date or an event described in Section 6.3(a). To the extent
that an optionee was not entitled to exercise an option on the date of his or
her resignation or termination of employment with the Corporation for any reason
whatsoever (including, without limitation, death), or if the option is not
exercised within the time period specified in this Article VII, the option shall
terminate and become null and void, unless the Committee determines otherwise at
the time of or after the grant of the option. Notwithstanding the provisions of
Sections 7.1 and 7.3 hereof, no options shall be exercisable after an optionee
resigns or terminates his or her employment with the Corporation in the event
the optionee shall have, during the time period in which his or her options are
exercisable, engaged in deliberate action which, as determined by the Committee
in its sole discretion (whose determination shall be final, binding and
conclusive), causes substantial harm to the interests of the Corporation or
constitutes a breach of any obligation of the optionee to the Corporation. In
such event, the optionee shall forfeit all rights to any unexercised option as
of the date of such deliberate action and all such unexercised options shall
terminate immediately and automatically at the time of such deliberate action.
SECTION 7.5 The granting of an option to an optionee does not alter in any
way the Corporation's existing rights to terminate such person's employment or
position with the Corporation at any time for any reason, nor does it confer
upon such person any rights or privileges except as specifically provided for in
the Plan.
-6-
<PAGE>
ARTICLE VIII
NONTRANSFERABILITY
------------------
Options granted under the Plan may not be sold, assigned or transferred,
other than by will or by the laws of descent and distribution or pursuant to a
qualified domestic relations order as defined in the Code or Title I of the
Employee Retirement Income Security Act of 1974, as amended ("ERISA"), or the
rules thereunder, and, except with respect to a qualified domestic relations
order as aforesaid, may be exercised during the lifetime of the optionee, only
by such optionee or his or her legal representative.
ARTICLE IX
METHOD OF EXERCISE
------------------
SECTION 9.1 During the period when an option is exercisable, the option
may be exercised, in whole or in part, by giving written notice of exercise to
the Corporation (in form acceptable to the Corporation) specifying the number of
shares of Common Stock to be purchased. Such notice shall be accompanied by
payment in full of the aggregate exercise price of the shares to be purchased in
cash, check (including, without limitation, payment in accordance with a
cashless exercise program under which, if so instructed by the optionee, Common
Stock may be issued directly to the optionee's broker or dealer upon receipt of
the purchase price in cash from the broker or dealer) or such other form and in
such other manner as the Committee may accept. If and to the extent determined
by the Committee in its sole discretion at or after grant, payment in full or in
part may also be made in the form of Common Stock duly owned by the optionee
(and for which the optionee has good title, free and clear of any liens and
encumbrances) or by reduction in the number of shares of Common Stock issuable
upon such exercise based, in each case, on the fair market value of the Common
Stock on the date the option is exercised. In the event the purchase price of an
option is paid in whole or in part through the delivery of shares of Common
Stock issuable in connection with the exercise of the option, an optionee will
be determined to have exercised the option with respect to those shares. In the
event shares of Common Stock are surrendered to the Corporation, they shall be
canceled by the Corporation. Fair market value of such Common Stock shall be
determined as provided in Article V herein.
SECTION 9.2 An option shall be deemed to be exercised when written notice
of such exercise has been given to the Corporation in accordance with the terms
of the option by the person entitled to exercise the option and full payment for
the shares with respect to which the option is exercised has been received by
the Corporation. Until the issuance (as evidenced by the appropriate entry on
the books of the Corporation or of a duly authorized transfer agent of the
Corporation) of the share certificate evidencing the shares to be issued, no
right to vote or receive dividends or any other rights as a shareholder shall
exist with respect to the optioned shares, notwithstanding the exercise of the
option. No adjustment will be made for a dividend or other right for which the
record date is prior to the date the share certificate is issued, except as
provided in the Plan.
SECTION 9.3 As a condition to the exercise of any portion of an option,
the Corporation may require the person exercising such option to make whatever
provision is required, in the reasonable opinion of the Corporation, to ensure
-7-
<PAGE>
that any withholding or tax obligations required by United States or Canadian
federal, state/provincial, or local law as a result of the granting or exercise
of such option are withheld or paid in accordance with such applicable law.
Provisions for addressing the withholding or tax obligations pursuant to the
preceding sentence may include, but shall not be limited to, (i) full payment of
the withholding or tax obligations by the person exercising such option
simultaneously with exercise of the option, (ii) the payment in shares of Common
Stock already owned by optionee, based on the fair market value (as determined
pursuant to Article V) of such shares on the date that the withholding or tax
obligation is to be determined, to satisfy such withholding or tax requirements,
(iii) the withholding from the option, at the appropriate time, of a number of
shares of Common Stock sufficient, based upon the fair market value (as
determined pursuant to Article V) of such shares on the date that the
withholding or tax obligation is to be determined, to satisfy such withholding
or tax requirements, and (iv) an agreement by the person exercising such option
that such withholding or tax obligations may be withheld in full from any
compensation payable to such person.
SECTION 9.4 (a) Shares shall not be issued pursuant to the exercise of an
option granted under the Plan unless the exercise of such option and the
issuance and delivery of the shares pursuant thereto shall comply with all
relevant provisions of Canadian and Unites States laws, including, without
limitation, Canada Business Corporations Act, the Securities Act (Quebec), the
Securities Act of 1933, as amended, the 1934 Act, the rules and regulations
promulgated thereunder, and the requirements of any securities exchange upon
which the shares may then be listed or Nasdaq, and shall be further subject to
the approval of counsel for the Corporation with respect to such compliance. As
a condition to the exercise of an option, the Corporation may require the person
exercising such option to complete a questionnaire in a form acceptable to the
Corporation and to make certain representations and warranties required or
desirable (in the opinion of the Corporation or its counsel), including, without
limitation, any representations and warranties required by law, in the opinion
of counsel, regarding investment intent. If, in the opinion of counsel for the
Corporation, such a representation is required by any of the aforementioned
relevant provisions of laws, certificates representing shares issued upon
exercise of the option shall bear a legend prohibiting transfer of such shares
unless, in the opinion of such counsel, such transfer is not inconsistent with
any of the requirements of any applicable Canadian and United States securities
laws.
(b) Inability of the Corporation to obtain authority from any
regulatory body having jurisdiction, which authority is deemed by the
Corporation's counsel to be necessary to the lawful issuance and sale of any
shares hereunder, shall relieve the Corporation of any liability in respect of
the failure to issue or sell such shares as to which such requisite authority
shall not have been obtained.
(c) In the event that any option is exercised by the executors,
administrators, legatees or distributees of the estate of a deceased optionee,
the Corporation shall be under no obligation to issue stock thereunder unless
and until the Corporation is satisfied that the person or persons exercising the
option are the duly appointed legal representatives of the deceased optionee's
estate or the proper legatees or distributees thereof.
-8-
<PAGE>
ARTICLE X
ADJUSTMENT OF NUMBER OF SHARES IN CERTAIN EVENTS
------------------------------------------------
SECTION 10.1 Subject to any required action by the shareholders of the
Corporation, each of (i) the number of shares of Common Stock covered by each
outstanding option, (ii) the number of shares of Common Stock that have been
authorized for issuance under the Plan but as to which no options have yet been
granted or that have been returned to the Plan upon cancellation, termination or
expiration of an option, (iii) the exercise price per share covered by each such
outstanding option, (iv) the number of shares of Common Stock set forth in
Section 3.2 and (v) the maximum number of shares with respect to which options
may be granted to any Senior Executive in any calendar year, shall be
proportionately adjusted for any increase or decrease in the number of issued
shares of Common Stock resulting from a stock split or the payment of a stock
dividend with respect to the Common Stock or any other increase or decrease in
the number of issued shares of Common Stock effected without receipt of
consideration by the Corporation; provided, however, that conversion of any
convertible securities of the Corporation shall not be deemed to have been
"effected without receipt of consideration." Such adjustment shall be made by
the Committee, whose determination in that respect shall be final, binding and
conclusive. Except as expressly provided herein, no issuance by the Corporation
of shares of any class, or securities convertible into shares of any class,
shall affect, and no adjustment by reason thereof shall be made with respect to,
the number or exercise price of shares of Common Stock subject to an option.
SECTION 10.2 In the event of a dissolution or liquidation of the
Corporation, all outstanding options will terminate upon the consummation of
such action, unless otherwise provided by the Committee.
SECTION 10.3 In the event of a merger, amalgamation, reorganization,
consolidation, share exchange, transfer of assets or other transaction having
similar effect involving the Corporation in which the Corporation is not the
surviving corporation or pursuant to which a majority of the shares that are of
the same class as the shares that are subject to outstanding options granted
under the Plan are exchanged for, or converted into, or otherwise become
securities of another corporation or entity, or other consideration, the
Committee shall have the sole discretion to determine that (i) the surviving,
continuing, successor or purchasing corporation or other entity, as the case may
be (the "Acquiror"), will either assume the Corporation's rights and obligations
under outstanding options granted under the Plan or substitute options in
respect of the Acquiror's securities for outstanding options granted under the
Plan or (ii) the outstanding options shall be canceled in exchange for such
consideration as the Committee shall approve (based on the value of the
consideration received in the transaction by holders of the same class of shares
that are subject to outstanding options).
SECTION 10.4 Adjustments and determinations under this Article X shall be
made by the Committee, upon the advice of counsel, whose decisions shall be
final, binding and conclusive.
-9-
<PAGE>
ARTICLE XI
AMENDMENT OF PLAN AND OPTIONS
-----------------------------
SECTION 11.1 Subject to the provisions of Sections 11.3 and 11.4, the Plan
may be amended, altered, suspended, discontinued or terminated at any time by
the Committee without the approval of the Corporation's shareholders in such
respects as the Committee may deem advisable so that the Plan and/or the options
granted hereunder may conform to any changes in the law or in any other respect
which the Committee may deem to be in the best interests of the Corporation,
other than any amendments required to be approved by shareholders under the
Canada Business Corporation Act, the Securities Act (Quebec), the rules of the
securities exchange or Nasdaq on which the Common Stock is listed, or in order
to comply with Section 162(m) of the Code, or any other requirement of
applicable law or regulation. No option may be granted during any suspension or
discontinuation of the Plan or after its termination. Amendments to the Plan
also shall be subject to any approvals required under applicable laws or
regulations or under the applicable rules of any stock exchange or Nasdaq on
which the Common Stock is listed.
SECTION 11.2 Subject to the provisions of Sections 11.3 and 11.4, the
Committee may waive any conditions or rights under, or amend, alter, suspend,
discontinue or terminate, any option granted to a Senior Executive under the
Plan and/or any corresponding option agreement; provided, however that the
Committee may amend any option and/or the terms of any corresponding option
agreement only to the extent that the option and/or such option agreement, as
either may be amended, could have been granted pursuant to the Plan with such
amended terms. No amendment of an option shall be deemed to be the grant of a
new option for purposes of the Plan.
SECTION 11.3 No amendment, suspension, discontinuation or termination of
the Plan or any option granted hereunder shall, without an optionee's consent,
impair any of the rights of the optionee under any option theretofore granted to
such optionee under the Plan. The foregoing shall not limit the Committee's
rights to make determinations under Sections 7.2, 7.4 and 10.3 hereof.
SECTION 11.4 Notwithstanding the provisions of Section 11.1 and 11.2,
Section 6.3 shall not be amended or terminated at any time. Further, any
amendment or termination of the Plan prior to a transaction described in Section
6.3 which: (a) was at the request of a third party who has indicated an
intention or taken steps reasonably calculated to effect such transaction; or
(b) otherwise arose in connection with or in anticipation of such transaction,
shall be null and void and shall have no effect whatsoever.
ARTICLE XII
RESERVATION AND ISSUANCE OF SHARES
----------------------------------
The Corporation, during the term of the Plan, will at all times reserve
and keep available such number of shares as shall be sufficient to satisfy the
requirements of the Plan and the options granted hereunder. The issuance of
shares of Common Stock upon the exercise (in accordance with the Plan) of
-10-
<PAGE>
options granted hereunder as fully paid and non-assessable shares is hereby
authorized.
ARTICLE XIII
OPTION AGREEMENT
----------------
Options shall be evidenced by written option agreements in the form or
forms approved by the Committee.
ARTICLE XIV
SHAREHOLDER APPROVAL
--------------------
The effectiveness of the Plan shall be subject to approval by the
shareholders of the Corporation, in a separate vote, within twelve (12) months
after the date the Plan is adopted. Such shareholder approval shall be obtained,
at a duly held shareholders' meeting, by the affirmative vote of a majority of
the votes actually cast, in person or by proxy, at such meeting on a separate
proposal to approve the Plan. All options granted prior to shareholder approval
are granted conditional upon shareholder approval of the Plan.
ARTICLE XV
MISCELLANEOUS PROVISIONS
------------------------
SECTION 15.1 NO RIGHTS AS A SHAREHOLDER. An optionee shall have no rights
as a shareholder with respect to any shares covered by his or her option until
the date of the issuance of a share certificate to him or her for such shares.
SECTION 15.2 NO RIGHT TO OPTION; NO RIGHT TO EMPLOYMENT. No employee or
other person shall have any claim or right to be granted an option. Neither the
Plan nor any action taken hereunder shall be construed as giving any Senior
Executive any right to be retained in the employ of the Corporation or any of
its subsidiaries.
SECTION 15.3 INDEMNIFICATION. In addition to such other rights of
indemnification as they may have as members of the Corporation's Board of
Directors, the members of the Committee shall be indemnified, to the extent
permitted by applicable law, by the Corporation against, and the Corporation
shall advance, the reasonable expenses, including attorneys' fees actually and
necessarily incurred in connection with the defense of any action, suit or
proceeding, or in connection with any appeal therein, to which they or any of
them may be a party by reason of any action taken or failure to act under or in
connection with the Plan or any option granted thereunder, and against all
amounts paid by them in settlement thereof (provided such settlement is approved
to the extent required by and in the manner provided by the Articles of
Incorporation and By-laws of the Corporation), or paid by them in satisfaction
for a judgment in any such action, suit or proceeding, except in relation to
matters as to which it shall be adjudged in such action, suit or proceeding that
such Committee member did not act honestly and in good faith with a view to the
best interests of the Corporation. Within sixty (60) days after institution of
-11-
<PAGE>
any such action, suit or proceeding, a Committee member shall notify the
Corporation of the institution of the suit and grant to the Corporation in
writing the opportunity, at its own expense, to handle and defend the same.
Failure to provide such notice and grant shall, at the option of the
Corporation, relieve the Corporation of the indemnification obligations set
forth in this Section 15.3.
SECTION 15.4 APPLICATION OF FUNDS. The proceeds received by the
Corporation from the sale of Common Stock pursuant to options will be used for
general corporate purposes.
SECTION 15.5 NO OBLIGATION TO EXERCISE OPTION. The granting of an option
shall impose no obligation upon the optionee to exercise such option.
SECTION 15.6 OTHER COMPENSATION PLANS. The adoption of the Plan shall not
affect any other share option or incentive or other compensation plans in effect
for the Corporation or any parent or subsidiary, nor shall the Plan preclude the
Corporation or any parent or subsidiary from establishing any other forms of
incentive or other compensation for employees and directors of the Corporation
or any parent or subsidiary.
SECTION 15.7 OPTIONS NOT INCLUDABLE FOR BENEFIT PURPOSES. Income
recognized by an optionee pursuant to the provisions of the Plan shall not be
included in the determination of benefits under any employee pension benefit
plan (as such term is defined in Section 3(2) of ERISA or the rules thereunder)
or group insurance or other benefit plans applicable to the optionee that are
maintained by the Corporation or any of its subsidiaries, except as may be
provided under the terms of such plans or determined by resolution of the
Corporation's Board of Directors.
SECTION 15.8 SINGULAR, PLURAL, GENDER. Whenever used herein, nouns in the
singular shall include the plural, and the masculine pronoun shall include the
feminine gender.
SECTION 15.9 HEADINGS, ETC., NO PART OF PLAN. Headings of Articles and
Sections hereof are inserted for convenience and reference; they constitute no
part of the Plan.
SECTION 15.10 UNFUNDED PLAN. The Plan shall be unfunded. The Corporation
shall not be required to establish any special or separate fund or to make any
other segregation of assets to assure the issuance of shares or the payment of
monies under the Plan and the issuance of shares and the payment of monies to
optionees under the Plan shall be subordinate to the claims of the Corporation's
general creditors.
SECTION 15.11 ACCEPTANCE OF PLAN. By accepting any option or other benefit
under the Plan, each optionee, for himself and for his or her successors,
assigns, heirs, beneficiaries and personal and legal representatives, shall be
conclusively deemed to have indicated his or her acceptance and ratification of,
and consent to, any action taken under the Plan by the Corporation, the
Committee and the Corporation's Board of Directors.
-12-
<PAGE>
SECTION 15.12 GOVERNING LAW. The Plan and all determinations made and
actions taken pursuant to the Plan shall be governed by the laws of the State of
Delaware, except that the issuance of Shares by the Corporation upon the
exercise of options shall be governed by the Canada Business Corporations Act.
SECTION 15.13 NO STRICT CONSTRUCTION. No rule of strict construction shall
be implied against the Corporation, the Committee, or any other person in the
interpretation of any of the terms of the Plan, any option granted under the
Plan or any rule or procedure established by the Committee.
SECTION 15.14 SEVERABILITY. Whenever possible, each provision in the Plan
and every option at any time granted under the Plan shall be interpreted in such
manner as to be effective and valid under applicable law, but if any provision
of the Plan or any option at any time granted under the Plan shall be held to be
prohibited by or invalid under applicable law, then (a) such provision shall be
deemed amended to accomplish the objectives of the provision as originally
written to the fullest extent permitted by law and (b) all other provisions of
the Plan and every other option at any time granted under the Plan shall remain
in full force and effect.
-13-
EXHIBIT 10.41
FIRST AMENDMENT TO LEASE AGREEMENT
----------------------------------
THIS FIRST AMENDMENT ("Amendment") is made as of the 21st day of
JANUARY, 1999 by and between the LIBERTY PROPERTY LIMITED PARTNERSHIP
("Landlord"), successor in interest to Indian Creek Holding Associates Limited
Partnership, and AMVAX, INC. f/k/a SELCORE LABORATORIES, INC. ("Tenant").
RECITAL A. Landlord leases to Tenant approximately 22,800 rentable
square feet of space in the building located at 12040 Indian Creek Court,
Beltsville, Maryland (the "Building") pursuant to a Lease Agreement dated
December 31, 1987 (the "Lease Agreement"). The Lease Agreement, together with
the Rider to Agreement of Lease (the "Rider") and all other exhibits attached
thereto, are collectively referred to herein as the "Lease".
RECITAL B. Landlord and Tenant have agreed to amend the Lease under the
terms and conditions set forth herein.
NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties hereto agree as
follows:
1. AMENDMENT TO SECTION 2 - TERM. The "Term" of the Lease, defined in
Section 2 of the Lease, is hereby extended for an additional period of 10 years
(the "Extension Period") beyond the Term set forth in the Lease. Likewise, the
"Expiration Date" of the Term of the Lease, also defined in Section 2 of the
Lease, is hereby changed to February 28, 2009. In addition, Sections 2(a) and
(b) of the Lease are hereby deleted and replaced with the following:
If Tenant, or person claiming through Tenant, shall
continue to occupy the Premises after the expiration or
termination of this Lease or any renewal thereof, such
occupancy shall be deemed to be under a month-to-month tenancy
under the same terms and conditions set forth in the Lease,
except that the monthly installment of Minimum Rent during
such continued occupancy shall be double the amount applicable
to the last month of the Term. Anything to the contrary
notwithstanding, any holding over by Tenant without Landlord's
prior written consent shall constitute a default hereunder and
shall be subject to all the remedies available to Landlord.
2. AMENDMENT TO SECTION 5 - MINIMUM RENT. Beginning on March 1, 1999,
and continuing during the Extension Period, the net component of the minimum
annual rent under the Lease, set forth in Section 5 of the Lease, shall be as
follows:
Year of Annual Monthly
Extension Period Amount Installment
---------------- ------ -----------
3/1/99 - 2/29/00 $356,986.00 $29,748.83
3/1/00 - 2/28/01 $367,695.58 $30,641.30
3/1/01 - 2/28/02 $378,726.45 $31,560.54
-1-
<PAGE>
3/1/02 - 2/28/03 $390,088.24 $32,507.35
3/1/03 - 2/29/04 $401,790.89 $33,482.57
3/1/04 - 2/28/05 $413,844.61 $34,487.05
3/1/05 - 2/28/06 $426,259.95 $35,521.66
3/1/06 - 2/28/07 $439,047.75 $36,587.31
3/1/07 - 2/29/08 $452,219.18 $37,684.93
3/1/08 - 2/28/09 $465,785.76 $38,815.48
Such net component of the Minimum Rent and all additional rent and other
charges under the Lease, shall continue to be paid in the manner and at the
times provided in the Lease.
3. Sections 2 and 31(g) of the Rider to the Lease are hereby deleted
from the Rider and replaced with the following provisions:
Tenant shall have an option to renew the Term of the Lease
upon its expiration for an additional period of 10 years (the
"Renewal Term," which shall be deemed part of the Term),
subject to the following terms:
(A) In order to exercise this option to renew the Lease, Tenant
must give Landlord written notice of its election to renew not later
than 365 days before the expiration of the then-current Term. All terms
of the Lease shall remain in full force and effect for the Renewal Term,
except that at Landlord's option, the standard terms of the Lease which
are not specific to the Tenant's occupancy shall be replaced with the
Landlord's then-current lease agreement form (with the understanding
that the new Rider Section 11 set forth in Paragraph 5 of this Amendment
below is not one such clause to be replaced), which Tenant shall execute
within 30 days after receipt thereof, and except that the annual minimum
rent for the Renewal Term shall be as follows:
Year of Annual Monthly
Extension Period Amount Installment
---------------- ------ -----------
3/1/09 - 2/29/10 $489,075.05 $40,756.25
3/1/10 - 2/28/11 $513,528.80 $42,794.07
3/1/11 - 2/28/12 $539,205.24 $44,933.77
3/1/12 - 2/28/13 $566,165.50 $47,180.46
3/1/13 - 2/29/14 $594,473.78 $49,539.48
3/1/14 - 2/28/15 $624,197.47 $52,016.46
3/1/15 - 2/28/16 $655,407.34 $54,617.28
3/1/16 - 2/28/17 $688,177.71 $57,348.14
3/1/17 - 2/29/18 $722,586.59 $60,215.55
3/1/18 - 2/28/19 $758,715.95 $63,226.33
(B) If Tenant fails to give notice exercising the foregoing
option by the date required herein, or if at the time Tenant exercises
-2-
<PAGE>
such option or at commencement of the Renewal Term the Tenant is in
default of any term of this Lease past applicable notice or grace
periods, or if this Lease is assigned by Tenant or the Premises sublet
in whole or in part to any party which is not affiliated with Tenant,
then Tenant's right and option to renew shall be automatically
terminated and of no further force or effect.
4. AMENDMENT TO SECTION 7 - INSURANCE. Section 7(b) of the Lease is
hereby deleted and replaced with the following provision:
Tenant, at its own expense, shall keep in effect
comprehensive general liability insurance with respect to the
Premises and the Property, including contractual liability
insurance, with such limits of liability for bodily injury
(including death) and property damage as reasonably may be
required by Landlord from time-to-time, but not less than a
combined single limit of $1,000,000 per occurrence and a
general aggregate limit of not less than $3,000,000 (which
aggregate limit shall apply separately to each of Tenant's
locations if more than the Premises); however, such limits
shall not limit the liability of Tenant hereunder. The policy
of comprehensive general public liability insurance also shall
name Landlord and Landlord's agent as insured parties with
respect to the Premises, shall be written on an "occurrence"
basis and not on a "claims made" basis, shall provide that it
shall not be cancelable or reduced without at least 30 days
prior written notice to Landlord, and shall be issued in form
satisfactory to Landlord. The insurer shall be a responsible
insurance carrier which is authorized to issue such insurance
and licensed to do business in the state in which the Property
is located and which has at all times during the Term a rating
of no less than A VII in the most current edition of Best's
Insurance Reports. Tenant shall deliver to Landlord on or
before the date on which the Extension Period becomes
effective, and subsequently renewals of, a certificate of
insurance evidencing such coverage and the waiver of
subrogation described herein.
5. AMENDMENT TO RIDER SECTION 11 - ALTERATIONS BY TENANT. Section 11 of
the Rider to the Lease is hereby deleted from the Rider and replaced with the
following:
Notwithstanding anything in Section 11 of the Lease to the
contrary, in those instances where Tenant is required to seek
Landlord's prior written approval for alterations or
improvements to the Premises, Tenant shall deliver to
Landlord, in advance of any proposed construction, plans,
specifications, bid proposals, work contracts and such other
information concerning the nature and cost of the alterations
or improvements as may be reasonably requested by Landlord.
Deliveries to Landlord pursuant to this section shall be
subject to the terms of the written confidentiality agreement
dated December 23, 1997 and previously executed by Landlord
and Tenant if designated for such treatment by Tenant at the
time of delivery to Landlord. Landlord agrees to respond to
Tenant's request for approval within 15 days after receiving
such information. Landlord acknowledges that the conduct of
Tenant's business and the use of the Premises in connection
with Tenant's business are subject to the rules and
regulations of the U.S. Food and Drug Administration and other
governmental agencies, offices, departments, bureaus and
boards. Landlord agrees that it shall not unreasonably
-3-
<PAGE>
withhold or condition its consent for any such approvals to
the extent the same are reasonably necessary to cause Tenant
or the Premises to be in compliance with all laws, rules,
orders, ordinances, directives, regulations, and requirements
of all governmental agencies, offices, departments, bureaus
and boards having jurisdiction over the same ("Legal
Requirement"). Nothing in this Lease shall be construed to
require Tenant to violate any Legal Requirement, and if it is
determined that there are any additional restoration costs
associated with any improvements, alterations or additions
proposed by Tenant as a result of a Legal Requirement or
otherwise, then as a condition of Landlord's approval Tenant
may be required to pay Landlord as an additional security
deposit an amount equal to the incremental demolition costs
(if any) necessary as a result of such improvements,
alterations or additions to restore the Premises to a building
shell condition. In each instance, such incremental demolition
costs shall be determined based on estimates of a third party
contractor mutually acceptable to the parties.
In addition, and notwithstanding anything in the Lease to
the contrary, Tenant shall be obligated, at the Tenant's
expense and prior to the expiration of the last day of the
Term of the Lease, to (i) remove all trade fixtures,
machinery, equipment and personal property installed at the
Premises by Tenant, (ii) restore the Premises to a so-called
"building shell" condition as existing prior to any
alterations or improvements made by Tenant, and (iii) repair
any damage to the Premises or the building or property caused
by such removal and restoration.
6. AMENDMENT TO RIDER SECTION 18 - INDEMNIFICATION. Section 18 of the
Rider to the Lease is hereby deleted from the Rider and replaced with the
following:
(A) Landlord hereby indemnifies and holds harmless the Tenant
from any claims, suits, losses, damages (but not consequential damages)
and expenses, including attorneys' fees and court costs, arising from
any maintenance, repair or other construction work which is performed by
the Landlord at the Premises after the receipt by Landlord from Tenant
of written notice of the need for such work.
(B) Tenant shall be responsible for insuring, at replacement
cost as appropriate, all furniture, equipment, machinery, appliances and
other personal property owned by the Tenant and all alterations,
fixtures and improvements made by Tenant at the Premises.
7. AMENDMENT TO SECTIONS 25 AND 28 - DEFAULTS/REMEDIES. Sections 25 and
28 of the Lease and Section 28 of the Rider to Lease are hereby deleted and
replaced with the following:
(A) An "event of default" shall have occurred under the Lease
upon occurrence of any one of the following: (a) the Tenant fails to pay
any amount of annual minimum or basic rent, additional rent or any other
sum due hereunder, and such delinquency continues for a period of 10
days after written notice from Landlord, or (b) Tenant fails to perform
-4-
<PAGE>
any of its other duties or obligations, and such breach continues for a
period of 30 days after written notice from Landlord or, if such breach
cannot be cured within 30 days, within a reasonable time not to exceed
90 days provided that tenant commences to cure such breach within 30
days after such notice and diligently prosecutes such cure to
completion.
(B) Upon the occurrence of any event of default, the Landlord
may take any or all of the following actions:
(1) Perform on behalf of and at the expense of Tenant any
obligation of Tenant under this Lease which Tenant has failed to perform, the
total cost of which by Landlord, together with interest thereon at the rate of
12% per annum from the date of such expenditure, shall be deemed additional rent
and shall be payable by Tenant to Landlord upon demand.
(2) With or without terminating the Lease, re-enter the Premises
with or without court action or summary proceedings and remove all property and
persons therefrom, all without resort to legal process and without Landlord
being deemed guilty of trespass or becoming liable for any loss or damage
occasioned thereby.
(3) With or without terminating this Lease, and from time to
time, make such improvements, alterations and repairs as may be necessary in
order to relet the Premises, and relet the Premises or any part thereof upon
such term or terms, at such rental or rentals and upon such other terms and
conditions as Landlord in its sole discretion may deem advisable.
(4) Enforce any provision of the Lease or any other agreement
between the parties by injunction, temporary restraining order or other similar
equitable remedy, to which the Tenant hereby expressly consents and agrees.
(5) Exercise any other legal or equitable right or remedy which
it may have by law or otherwise.
(C) Upon any event of default, Tenant shall remain liable to
the Landlord for the following amounts: (i) any rent of any kind
whatsoever which may have become due with respect to the period in the
Term which has already expired, (ii) all rent which becomes due during
the remainder of the Term (except that which is actually collected from
replacement tenants, if any), (iii) all out-of-pocket costs, fees and
expenses incurred by Landlord in leasing the Premises to others from
time to time, including but not limited to leasing commissions,
construction and other build-out costs, design and permitting costs and
the like, and (iv) all out-of-pocket costs, fees and expenses incurred
by Landlord in pursuit of its remedies hereunder, including but not
limited to attorneys' fees and court costs. Furthermore, at Landlord's
option, Tenant shall be obligated to pay, in lieu of item (ii) above in
this paragraph, an amount (the "Substitute Amount") which is equal to
(a) the present value of all rent which would become due during the
remainder of the Term, including all additional rent, with such present
-5-
<PAGE>
value to be determined by discounting at an annual rate of interest
which is equal to the bond-equivalent yield for the most recent auction
of U.S. Treasury Bills with a 1-year maturity (the "Discount Rate"),
minus (b) the fair market rental value of the Premises for the remainder
of the Term, as determined and calculated (i) taking into account
vacancy periods for reletting, build-out costs for new tenants and other
factors, (ii) by discounting to present value at the Discount Rate as
appropriate, and (iii) by an independent real estate professional
selected by Landlord. Tenant and Landlord acknowledge and agree that
payment to Landlord of the foregoing Substitute Amount is a reasonable
forecast of the actual damages which will be suffered by Landlord in
case of an event of default by Tenant, which actual damages are
otherwise difficult or impossible to ascertain, and therefore such
payment and reimbursement together constitute liquidated damages and not
a penalty. All such amounts shall be payable upon demand by Landlord.
(D) All parties hereto, both the Landlord and Tenant as
principals and any guarantors, hereby release and waive any and all
rights provided by law to a trial by jury in any court or other legal
proceeding initiated to enforce the terms of this Lease, involving any
such parties, or connected in any other manner with this Lease.
(E) Any amount of annual minimum or basic rent, additional rent
or other sum or charge which is not paid when due hereunder shall bear
interest at an annual rate of 12% from the date due until paid.
8. AMENDMENT TO SECTION 32 - NOTICES. Section 32 of the Lease is hereby
deleted in its entirety and the following is substituted in lieu thereof:
Any notice, consent, demand, bill, statement or other
communication required or permitted to be given hereunder must
be in writing and may be given by (i) personal delivery, (ii)
overnight courier, (iii) U.S. certified or registered mail
(and, if given by mail, such notice or other communication
shall be deemed given 2 days after being posted), or (iv)
confirmed facsimile transmission, to the parties at the
following addresses:
Landlord:
Liberty Property Limited Partnership
c/o Liberty Property Trust
9145 Guilford Road, Suite 100
Columbia, MD 21046
Tenant:
AMVAX, Inc.
c/o North American Vaccine, Inc.
10150 Old Columbia Road
Columbia, MD 21046
-6-
<PAGE>
Either party may, by notice to the other given pursuant to this Section
32, specify additional or different addresses for notice purposes.
9. AMENDMENT TO SECTION 33 - SECURITY DEPOSIT. Simultaneously with the
execution and delivery of this Amendment by Tenant to Landlord, Tenant shall pay
to Landlord an amount of $154,200.00 by certified check or wire transfer of
funds, to be held by Landlord as additional security deposit money pursuant to
Section 33 of the Lease. The parties hereby agree that such payment, together
with the $60,800.00 previously paid by Tenant as a security deposit under the
Lease (notwithstanding anything to the contrary in the Lease), shall comprise a
total security deposit of $215,000.00, and such amount shall be held, without
interest, for the duration of the Term as security for Tenant's performance of
the Lease.
10. APPROVAL OF IMPROVEMENTS. By its execution of this Amendment,
Landlord approves the alterations to the Premises made by the Tenant as
described in the architectural and engineering plans prepared by Quasar
Engineers, Architects and Constructors (Project # 94-E-101) submitted to
Landlord under transmittals numbered 98-023 (dated 2/13/98), 98-024 (dated
2/20/98) and 98-112 (dated 10/27/98). In addition, Landlord hereby acknowledges
that, to Landlord's knowledge (without independent investigation), provided
Tenant makes the payment required by Section 8 of this Amendment above, (i)
Tenant is not in default under the Lease as of the date of this Amendment, and
(ii) there exists no occurrence or circumstance which, with the giving of notice
and the passing of time, will become an event of default under the Lease.
11. SURVIVAL. The Lease will remain in full force and effect, binding on
the parties and unmodified except as expressly set forth in this Amendment. In
the case of any conflicts between the terms of the Lease and the terms of this
Amendment, the terms of this Amendment shall govern.
IN WITNESS WHEREOF, Landlord and Tenant have executed this Amendment
intending to be legally bound thereby.
Landlord:
LIBERTY PROPERTY LIMITED PARTNERSHIP
By: Liberty Property Trust, Sole General Partner
Date signed: 1-22-98 By: /s/ Michael C. Weitzmann
Name: Michael C. Weitzmann
Title: Sr. Vice President
-7-
<PAGE>
TENANT:
Date signed: January 21, 1999
________________ AMVAX, INC.
Witness/Attest:
/s/ Russell P. Wilson By: /s/ Lawrence J. Hineline
______________________________ ____________________________________________
Name: RUSSELL P. WILSON Name: LAWRENCE J. HINELINE
Title: ASSISTANT SECRETARY Title: VICE PRESIDENT-FINANCE
-8-
EXHIBIT 23
CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS
As independent public accountants, we hereby consent to the incorporation of our
report included in this Annual Report on Form 10-K into the Company's previously
filed Registration Statements on Form S-8, File Nos. 33-37325, 33-39416,
33-48752, 33-48753 and 33-80479.
ARTHUR ANDERSEN LLP
/s/ Arthur Andersen LLP
Washington, D.C.
January 18, 1999
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S ANNUAL REPORT ON FORM 10-K FOR THE TWELVE MONTHS ENDED DECEMBER 31,
1998 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-START> JAN-01-1998
<PERIOD-END> DEC-31-1998
<CASH> 22,953
<SECURITIES> 1,554
<RECEIVABLES> 1,625
<ALLOWANCES> 0
<INVENTORY> 4,067
<CURRENT-ASSETS> 29,643
<PP&E> 59,955
<DEPRECIATION> 34,640
<TOTAL-ASSETS> 64,525
<CURRENT-LIABILITIES> 12,333
<BONDS> 108,734
0
6,538
<COMMON> 80,824
<OTHER-SE> (146,336)
<TOTAL-LIABILITY-AND-EQUITY> 64,525
<SALES> 2,230
<TOTAL-REVENUES> 8,379
<CGS> 0
<TOTAL-COSTS> 47,982
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 18,503
<INCOME-PRETAX> (56,609)
<INCOME-TAX> 0
<INCOME-CONTINUING> (56,609)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (56,609)
<EPS-PRIMARY> (1.76)
<EPS-DILUTED> (1.76)
</TABLE>
